

Quality of Life and Satisfaction with Outcome among Pr

New England Journal of Medicine

358, 1250-1261

DOI: 10.1056/nejmoa074311

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2014, 8, 435.	1.1	10
2	Radical prostatectomy for low risk carcinoma of the prostate. World Journal of Urology, 2008, 26, 443-446.	2.2	6
3	A 43-year-old African American man with low-risk prostate cancer. Current Urology Reports, 2008, 9, 437-440.	2.2	0
5	Defining potency: A comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer, 2008, 113, 2687-2694.	4.1	38
6	Does a nerve-sparing technique or potency affect continence after open radical retropubic prostatectomy?. BJU International, 2008, 102, 1581-1584.	2.5	67
7	Decision-Making in Clinically Localized Prostate Cancer: Evaluating and Communicating Risks. Clinical Genitourinary Cancer, 2008, 6, 63-64.	1.9	4
8	Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. Yearbook of Urology, 2008, 2008, 154-156.	0.1	1
9	Second Malignancies After Radiotherapy for Prostate Cancer: Keeping Perspective. Urology, 2008, 72, 971-973.	1.0	6
12	Quality of Life in Men With Locally Advanced Adenocarcinoma of the Prostate: An Exploratory Analysis Using Data From the CaPSURE Database. Journal of Urology, 2008, 180, 2409-2414.	0.4	23
13	Diet and Dietary Supplement Intervention Trials for the Prevention of Prostate Cancer Recurrence: A Review of the Randomized Controlled Trial Evidence. Journal of Urology, 2008, 180, 2314-2322.	0.4	53
16	Prostate cancer treatment alters QOL, partner's satisfaction. PharmacoEconomics & Outcomes News, 2008, 550, 10-10.	0.0	0
17	Association of Pre-Existing Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. Patient, 2008, 1, 189-200.	2.7	5
18	Management of Prostate Cancer. New England Journal of Medicine, 2008, 359, 2605-2609.	27.0	17
19	Cancer Survivorship Research: Opportunities and Future Needs for Expanding the Research Base. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1551-1557.	2.5	15
20	Comparison between Real-time Intra-operative Ultrasound-based Dosimetry and CT-based Dosimetry for Prostate Brachytherapy Using Cesium-131. Technology in Cancer Research and Treatment, 2008, 7, 463-469.	1.9	7
21	Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. New England Journal of Medicine, 2008, 359, 200-202.	27.0	15
23	Comparison of Cancer Diagnosis and Treatment in Medicare Fee-for-Service and Managed Care Plans. Medical Care, 2008, 46, 1108-1115.	2.4	24
24	Screening for prostate cancer: explaining new trial results and their implications to patients. Medical Journal of Australia, 2009, 191, 226-229.	1.7	12

#	ARTICLE	IF	CITATIONS
25	Penile Rehabilitation and Neuromodulation. Scientific World Journal, The, 2009, 9, 652-664.	2.1	10
26	Factor Analysis of the Expanded Prostate Cancer Index Composite in a Patient Group after Primary (External Beam Radiotherapy and Permanent Iodine-125 Brachytherapy) and Postoperative Radiotherapy for Prostate Cancer. Current Urology, 2009, 2, 122-129.	0.6	23
27	Do Patients with Urodynamically Proven Infravesical Obstruction and Detrusor Overactivity Have a Higher Risk for Long-Term Bothersome Symptoms after Brachytherapy in Comparison to Patients Treated with Radical Prostatectomy for Localized Prostate Cancer?. Current Urology, 2009, 2, 135-141.	0.6	7
28	The psychological aftermath of prostate cancer treatment choices: a comparison of depression, anxiety and quality of life outcomes over the 12 months following diagnosis. Medical Journal of Australia, 2009, 190, S86-9.	1.7	34
29	Individualizing Quality-of-Life Outcomes Reporting: How Localized Prostate Cancer Treatments Affect Patients With Different Levels of Baseline Urinary, Bowel, and Sexual Function. Journal of Clinical Oncology, 2009, 27, 3916-3922.	1.6	181
30	Prospective Study of Determinants and Outcomes of Deferred Treatment or Watchful Waiting Among Men With Prostate Cancer in a Nationwide Cohort. Journal of Clinical Oncology, 2009, 27, 4980-4985.	1.6	83
31	Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era. Journal of Clinical Oncology, 2009, 27, 4300-4305.	1.6	417
32	Health-Related Quality of Life in I-125 Prostate Brachytherapy Patients Treated with and without Volume-Reducing Hormone Therapy: Results of a Short-Term Prospective Study. Journal of Endourology, 2009, 23, 153-160.	2.1	2
33	Risk of Death From Prostate Cancer After Brachytherapy Alone or With Radiation, Androgen Suppression Therapy, or Both in Men With High-Risk Disease. Journal of Clinical Oncology, 2009, 27, 3923-3928.	1.6	73
34	Integrative medicine: complementary therapies and supplements. Nature Reviews Urology, 2009, 6, 228-233.	3.8	17
35	Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. British Journal of Cancer, 2009, 101, 1248-1252.	6.4	43
36	Regarding: "High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series". British Journal of Cancer, 2009, 101, 2057-2058.	6.4	2
37	The psychosocial aspects of sexual recovery after prostate cancer treatment. International Journal of Impotence Research, 2009, 21, 99-106.	1.8	78
38	Health-related Quality of Life using SF-8 and EPIC Questionnaires after Treatment with Radical Retropubic Prostatectomy and Permanent Prostate Brachytherapy. Japanese Journal of Clinical Oncology, 2009, 39, 502-508.	1.3	32
39	A 64-Year-Old Man With Low-Risk Prostate Cancer. JAMA - Journal of the American Medical Association, 2009, 301, 2141.	7.4	18
40	Stereotactic Body Radiotherapy: An Emerging Treatment Approach for Localized Prostate Cancer. Technology in Cancer Research and Treatment, 2009, 8, 387-392.	1.9	141
41	Ceramide-mediated apoptosis following ionizing radiation in human prostate cancer cells: PKC δ joins the fray. Cancer Biology and Therapy, 2009, 8, 64-65.	3.4	3
42	Seminal vesicle sparing: a continuing trend?. Nature Reviews Urology, 2009, 6, 475-476.	3.8	1

#	ARTICLE	IF	CITATIONS
43	Heeding Our Words: Complexities of Research Among Low-Literacy Populations. <i>Journal of Clinical Oncology</i> , 2009, 27, 1938-1940.	1.6	8
44	Preoperative predictors of blood loss at the time of radical prostatectomy: results from the SEARCH database. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 264-268.	3.9	16
45	Counseling patients about sexual health when considering post-prostatectomy radiation treatment. <i>International Journal of Impotence Research</i> , 2009, 21, 275-284.	1.8	12
46	Quality of life after radiation and androgen deprivation. <i>Nature Reviews Urology</i> , 2009, 6, 477-478.	3.8	0
47	Lack of Comprehension of Common Prostate Cancer Terms in an Underserved Population. <i>Journal of Clinical Oncology</i> , 2009, 27, 2015-2021.	1.6	69
48	IL15 Can Reverse the Unresponsiveness of Wilms' Tumor Antigen-Specific CTL in Patients with Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1145-1154.	7.0	19
49	Survivorship Beyond Convalescence: 48-Month Quality-of-Life Outcomes After Treatment for Localized Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 888-892.	6.3	132
50	Evidence-Based Medicine, Conscience-Based Medicine, and the Management of Low-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4935-4936.	1.6	10
51	Health-Related Quality of Life in Cancer Patients—More Answers but Many Questions Remain. <i>Journal of the National Cancer Institute</i> , 2009, 101, 838-839.	6.3	3
52	Patient Anxiety About Prostate Cancer Independently Predicts Early Initiation of Androgen Deprivation Therapy for Biochemical Cancer Recurrence in Older Men: A Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1557-1563.	1.6	50
53	Improving the Utility of Quality-of-Life Data From Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3877-3878.	1.6	1
54	Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes. <i>Journal of Clinical Oncology</i> , 2009, 27, 3452-3458.	1.6	300
55	Patient-reported outcome measures: The importance of patient satisfaction in surgery. <i>Surgery</i> , 2009, 146, 435-443.	1.9	261
56	Non-surgical treatment of localised prostate cancer. <i>Surgical Oncology</i> , 2009, 18, 255-267.	1.6	3
58	Needs Assessment Survey to Justify Establishing a Reproductive Health Clinic at a Comprehensive Cancer Center. <i>Journal of Sexual Medicine</i> , 2009, 6, 149-163.	0.6	73
59	Predictors of Response to Sildenafil Citrate Following Radiation Therapy for Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2009, 6, 1135-1140.	0.6	29
60	Relationship Satisfaction and Erectile Functions in Men Receiving Laparoscopic Radical Prostatectomy: Effects of Provision and Receipt of Spousal Social Support. <i>Journal of Sexual Medicine</i> , 2009, 6, 1438-1450.	0.6	19
61	ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Post-Radical Prostatectomy Pharmacological Penile Rehabilitation: Practice Patterns Among the International Society for Sexual Medicine Practitioners. <i>Journal of Sexual Medicine</i> , 2009, 6, 2032-2038.	0.6	81

#	ARTICLE	IF	CITATIONS
62	Analysis of T1c Prostate Cancers Treated at Very Low Prostate-Specific Antigen Levels. European Urology, 2009, 55, 610-616.	1.9	8
63	Editorial Comment on: Analysis of T1c Prostate Cancers Treated at Very Low Prostate-Specific Antigen Levels. European Urology, 2009, 55, 616.	1.9	0
64	Nerves at the Ventral Prostatic Capsule Contribute to Erectile Function: Initial Electrophysiological Assessment in Humans. European Urology, 2009, 55, 148-155.	1.9	74
65	Editorial Comment on: Nerves at the Ventral Prostatic Capsule Contribute to Erectile Function: Initial Electrophysiological Assessment in Humans. European Urology, 2009, 55, 154-155.	1.9	0
66	Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications. European Urology, 2009, 55, 1321-1332.	1.9	155
67	The Motion: Radiotherapy for Prostate Cancer Preserves Sexual Function to a Greater Extent Than Nerve Sparing Radical Prostatectomy. European Urology, 2009, 56, 212-214.	1.9	8
69	Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee. Cancer, 2009, 115, 1142-1153.	4.1	80
70	Prediction of sexual function after radical prostatectomy. Cancer, 2009, 115, 3150-3159.	4.1	33
71	Anxiety and distress during active surveillance for early prostate cancer. Cancer, 2009, 115, 3868-3878.	4.1	193
72	A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer, 2009, 115, 4695-4704.	4.1	49
73	Radiation dose escalation for localized prostate cancer. Cancer, 2009, 115, 5596-5606.	4.1	49
74	Spanish Researchers at the Forefront of Clinical Investigation: The case of quality of life in prostate cancer. Clinical and Translational Oncology, 2009, 11, 403-404.	2.4	2
75	Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience. Clinical and Translational Oncology, 2009, 11, 470-478.	2.4	20
76	Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors. Journal of Cancer Survivorship, 2009, 3, 233-240.	2.9	9
77	Radiation therapy approaches to the treatment of high-risk prostate cancer. Current Prostate Reports, 2009, 7, 95-101.	0.1	0
78	Radiation therapy approaches to the treatment of high-risk prostate cancer. Current Urology Reports, 2009, 10, 187-193.	2.2	0
80	Oncologic outcome after radical prostatectomy in men with PSA values above 20Âng/ml: a monocentric experience. World Journal of Urology, 2009, 27, 653-658.	2.2	18
81	Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000â€“2006. British Journal of Cancer, 2009, 101, 1839-1845.	6.4	32

#	ARTICLE	IF	CITATIONS
82	Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. BJU International, 2009, 103, 762-767.	2.5	31
83	Prostate cancer: a serious disease suitable for prevention. BJU International, 2009, 103, 864-870.	2.5	38
84	Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. BJU International, 2009, 103, 1173-1178.	2.5	44
85	Salvage permanent perineal radioactive seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU International, 2009, 104, 600-604.	2.5	73
86	Evidence-based urology in practice: intention-to-treat analysis. BJU International, 2009, 104, 582-583.	2.5	2
87	General Care of the Older Cancer Patient. Clinical Oncology, 2009, 21, 86-91.	1.4	7
88	Management of complications of androgen deprivation therapy in the older man. Critical Reviews in Oncology/Hematology, 2009, 70, 235-255.	4.4	62
89	Erectile Function Durability Following Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 639-648.	0.8	50
90	Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy, 2009, 8, 345-352.	0.5	19
91	Dose-escalated radiation therapy for intermediate-risk prostate cancer. Cancer, 2009, 115, 1784-1790.	4.1	17
92	Long-Term Outcomes in Younger Men Following Permanent Prostate Brachytherapy. Journal of Urology, 2009, 181, 1665-1671.	0.4	44
93	Brachytherapy for Localized Prostate Cancer. Urology, 2009, 73, 473-475.	1.0	0
94	Nerve-sparing Prostatectomy and Urinary Function: A Prospective Analysis Using Validated Quality-of-life Measures. Urology, 2009, 73, 1336-1340.	1.0	21
95	Editorial Comment. Urology, 2009, 73, 1340-1341.	1.0	0
96	Overview of Pivotal Studies for Prostate Cancer Risk Reduction, Past and Present. Urology, 2009, 73, S36-S43.	1.0	15
97	Introduction. Urology, 2009, 73, S1-S3.	1.0	0
98	Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers. Urology, 2009, 73, S21-S27.	1.0	21
99	Current Prostate Cancer Treatments: Effect on Quality of Life. Urology, 2009, 73, S28-S35.	1.0	71

#	ARTICLE	IF	CITATIONS
100	Choosing Health, Choosing Treatment: Patient Choice After Diagnosis of Localized Prostate Cancer. Urology, 2009, 74, 968-971.	1.0	9
101	Urinary Side Effects and Complications After Permanent Prostate Brachytherapy: The MD Anderson Cancer Center Experience. Urology, 2009, 74, 601-605.	1.0	59
102	2008 Whitmore Lecture: Radical prostatectomy“where we were and where we are going. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 246-250.	1.6	16
103	Radiation therapy for urologic malignancies in the elderly. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 643-652.	1.6	7
104	Prostate cancer and urinary incontinence. Maturitas, 2009, 63, 323-328.	2.4	21
105	Exercise therapy across the prostate cancer continuum. Prostate Cancer and Prostatic Diseases, 2009, 12, 110-115.	3.9	39
106	Personalized medicine: individualized care of cancer patients. Translational Research, 2009, 154, 303-308.	5.0	31
107	Cancer Screening: The Clash of Science and Intuition. Annual Review of Medicine, 2009, 60, 125-137.	12.2	72
108	Image Guided Photothermal Focal Therapy for Localized Prostate Cancer: Phase I Trial. Journal of Urology, 2009, 182, 1371-1377.	0.4	244
109	Clinical Interpretation of the Expanded Prostate Cancer Index Composite-Short Form Sexual Summary Score. Journal of Urology, 2009, 182, 2844-2849.	0.4	25
110	Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer “a matched-pair comparison. Radiotherapy and Oncology, 2009, 91, 225-231.	0.6	36
111	Dose“volume effects for normal tissues in external radiotherapy: Pelvis. Radiotherapy and Oncology, 2009, 93, 153-167.	0.6	249
112	Prevention and Management of Postprostatectomy Erectile Dysfunction. European Urology Supplements, 2009, 8, 80-87.	0.1	4
113	Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncology, The, 2009, 10, 370-380.	10.7	72
114	Live longer but not better “ yet. Lancet Oncology, The, 2009, 10, 313-314.	10.7	2
116	Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial. Journal of Urology, 2009, 181, 956-962.	0.4	1,137
117	Differing Perceptions of Quality of Life in Patients With Prostate Cancer and Their Doctors. Journal of Urology, 2009, 182, 2296-2302.	0.4	99
119	Erectile Aid Use by Men Treated for Localized Prostate Cancer. Journal of Urology, 2009, 182, 649-654.	0.4	35

#	ARTICLE	IF	CITATIONS
120	Changes in Continence and Erectile Function Between 2 and 4 Years After Radical Prostatectomy. Journal of Urology, 2009, 181, 731-735.	0.4	71
121	Prostogram Predicted Brachytherapy Outcomes are Not Universally Accurate: An Analysis Based on the M. D. Anderson Cancer Center Experience With 125 Iodine Brachytherapy. Journal of Urology, 2009, 181, 1658-1664.	0.4	7
122	Temporal Trends in Adoption of and Indications for the Artificial Urinary Sphincter. Journal of Urology, 2009, 181, 2622-2627.	0.4	72
123	Expanded Prostate Cancer Index Composite Versus Incontinence Symptom Index and Sexual Health Inventory for Men to Measure Functional Outcomes After Prostatectomy. Journal of Urology, 2009, 182, 221-228.	0.4	27
125	Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner?. Current Opinion in Urology, 2009, 19, 303-308.	1.8	22
126	Patient selection for focal therapy of localized prostate cancer. Current Opinion in Urology, 2009, 19, 268-273.	1.8	28
127	Current management of erectile dysfunction after cancer treatment. Current Opinion in Oncology, 2009, 21, 303-309.	2.4	31
128	QUALITY-OF-LIFE CHANGES AND SATISFACTION AFTER PROSTATE CANCER TREATMENT. American Journal of Nursing, 2009, 109, 36-37.	0.4	0
129	Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica, 2009, 94, 602-606.	3.5	41
130	Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ: British Medical Journal, 2009, 339, b4817-b4817.	2.3	227
131	Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4. Nature Reviews Urology, 2009, 6, 124-125.	3.8	3
132	Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors. Current Pharmaceutical Design, 2009, 15, 3496-3501.	1.9	4
133	Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. Yearbook of Oncology, 2009, 2009, 77-78.	0.1	0
134	Is Radical Prostatectomy the "Gold Standard" for Localized Prostate Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 511-515.	1.3	23
135	Longitudinal Analysis of Genitourinary and Bowel Symptoms in Prostate Cancer Patients Following Brachytherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 1-10.	1.3	9
136	Prostate Cancer Screening 2010: Updated Recommendations From the American Cancer Society. Journal of the National Medical Association, 2010, 102, 423-429.	0.8	32
137	Salvage or Adjuvant Radiation Therapy: Counseling Patients on the Benefits. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 228-237.	4.9	29
138	Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 162-200.	4.9	671

#	ARTICLE	IF	CITATIONS
139	A Method for Using Life Tables to Estimate Lifetime Risk for Prostate Cancer Death. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 148-154.	4.9	12
142	Image guidance for focal therapy of prostate cancer. World Journal of Urology, 2010, 28, 727-734.	2.2	35
143	Radiation Doseâ€“Volume Effects and the Penile Bulb. International Journal of Radiation Oncology Biology Physics, 2010, 76, S130-S134.	0.8	131
144	Rectal Doseâ€“Volume Histogram Parameters Are Associated With Long-Term Patient-Reported Gastrointestinal Quality of Life After Conventional and High-Dose Radiation for Prostate Cancer: A Subgroup Analysis of a Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1081-1085.	0.8	38
145	Cognitive impairment in men treated with luteinizing hormoneâ€“releasing hormone agonists for prostate cancer: a controlled comparison. Supportive Care in Cancer, 2010, 18, 21-27.	2.2	31
146	Treatment of localised prostate cancer with radiation therapy: evidence versus opinion. Clinical and Translational Oncology, 2010, 12, 315-317.	2.4	1
147	Unanswered Questions Regarding the Effect of Androgen Deprivation Therapy for Prostate Cancer on Cardiovascular Disease Risk in Black Men. Current Cardiovascular Risk Reports, 2010, 4, 311-317.	2.0	1
148	Contemporary Incidence of Postprostatectomy Incontinence and Impact on Health-related Quality of Life. Current Bladder Dysfunction Reports, 2010, 5, 135-141.	0.5	1
149	The Quality-of-Life Impact of Prostate Cancer Treatments. Current Urology Reports, 2010, 11, 139-146.	2.2	31
150	Association between utility and treatment among patients with prostate cancer. Quality of Life Research, 2010, 19, 711-720.	3.1	8
151	Principles of Cancer Screening: Lessons From History and Study Design Issues. Seminars in Oncology, 2010, 37, 202-215.	2.2	185
152	Leveraging Pervasive Technologies to Improve Collection of Prostate Cancer Outcome Data. Computer, 2010, 43, 35-42.	1.1	3
153	Managing benign prostatic hyperplasia and prostate cancer â€“ the challenges today. Journal of Men's Health, 2010, 7, 113-124.	0.3	2
154	Ethical counseling of an indecisive patient with low-risk prostate carcinoma: A case study. Surgery, 2010, 148, 1022-1025.	1.9	4
155	Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer, 2010, 10, 152.	2.6	69
156	Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer, 2010, 10, 572.	2.6	34
157	Validation study of a web-based assessment of functional recovery after radical prostatectomy. Health and Quality of Life Outcomes, 2010, 8, 82.	2.4	59
158	Chronology of Erectile Function in Patients with Early Functional Erections Following Radical Prostatectomy. Journal of Sexual Medicine, 2010, 7, 803-809.	0.6	20

#	ARTICLE	IF	CITATIONS
159	REVIEW: Utilization of Pharmacotherapy for Erectile Dysfunction Following Treatment for Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2010, 7, 1062-1073.	0.6	14
160	Predicting Erectile Function Recovery after Bilateral Nerve Sparing Radical Prostatectomy: A Proposal of a Novel Preoperative Risk Stratification. <i>Journal of Sexual Medicine</i> , 2010, 7, 2521-2531.	0.6	102
161	Androgen Deprivation Therapy for Prostate Cancer: Recommendations to Improve Patient and Partner Quality of Life. <i>Journal of Sexual Medicine</i> , 2010, 7, 2996-3010.	0.6	116
162	Prostate cancer treatment for economically disadvantaged men. <i>Cancer</i> , 2010, 116, 1378-1384.	4.1	17
163	Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?. <i>Cancer</i> , 2010, 116, 1281-1290.	4.1	97
164	Variations in health-related quality of life in Japanese men who underwent iodine-125 permanent brachytherapy for localized prostate cancer. <i>Brachytherapy</i> , 2010, 9, 300-306.	0.5	18
165	The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement. <i>Brachytherapy</i> , 2010, 9, 145-150.	0.5	4
166	Clinical and dosimetric factors associated with acute rectal toxicity in patients treated with ¹³¹ Cs brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2010, 9, 328-334.	0.5	6
167	Point: Prostate carcinoma treatment for the young patient—The case for brachytherapy. <i>Brachytherapy</i> , 2010, 9, 193-194.	0.5	0
168	Counterpoint: Prostate carcinoma treatment for the young patient—The case for radical prostatectomy. <i>Brachytherapy</i> , 2010, 9, 195-198.	0.5	1
169	Time of Decline in Sexual Function After External Beam Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 31-35.	0.8	37
170	Total Androgen Blockade Versus a Luteinizing Hormone-Releasing Hormone Agonist Alone in Men With High-Risk Prostate Cancer Treated With Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1439-1444.	0.8	11
171	Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397). <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 773-783.	0.8	77
172	No Impairment of Quality of Life 18 Months After High-Dose Intensity-Modulated Radiotherapy for Localized Prostate Cancer: A Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1053-1059.	0.8	36
173	Long-Term Outcome and Toxicity of Salvage Brachytherapy for Local Failure After Initial Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1338-1344.	0.8	142
174	Sexual Function After Stereotactic Body Radiotherapy for Prostate Cancer: Results of a Prospective Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 442-448.	0.8	74
175	Increasing Age and Treatment Modality Are Predictors for Subsequent Diagnosis of Bladder Cancer Following Prostate Cancer Diagnosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1086-1094.	0.8	32
176	Stereotactic body radiotherapy for organ-confined prostate cancer. <i>BMC Urology</i> , 2010, 10, 1.	1.4	148

#	ARTICLE	IF	CITATIONS
177	Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. <i>Prostate</i> , 2010, 70, 1480-1489.	2.3	29
178	Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. <i>Prostate</i> , 2010, 70, 1622-1627.	2.3	22
179	Short-term outcomes of the prospective multicentre â€Prostate Cancer Research International: Active Surveillanceâ€™ study. <i>BJU International</i> , 2010, 105, 956-962.	2.5	157
180	Evidence-based urology in practice: incorporating patient values in evidence-based clinical decision making. <i>BJU International</i> , 2010, 105, 4-5.	2.5	9
181	Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. <i>BJU International</i> , 2010, 106, 791-795.	2.5	28
182	Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. <i>BJU International</i> , 2010, 106, 1524-1527.	2.5	24
183	Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: A prospective study. <i>International Journal of Urology</i> , 2010, 17, 715-719.	1.0	57
184	Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer. <i>Scientific World Journal</i> , The, 2010, 10, 1854-1869.	2.1	10
185	Multimodal Approaches to High-Risk Prostate Cancer. <i>Current Oncology</i> , 2010, 17, 33-37.	2.2	12
186	Is there an optimal management for localized prostate cancer?. <i>Clinical Interventions in Aging</i> , 2010, 5, 187.	2.9	18
187	A simple algorithm to assess patient suitability for Calypso seed implantation for four-dimensional prostate localization. <i>Journal of Applied Clinical Medical Physics</i> , 2010, 11, 252-262.	1.9	4
188	Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL. <i>Archives of Internal Medicine</i> , 2010, 170, 1256-61.	3.8	64
189	Is radical prostatectomy the best option for localized prostate cancer? Current opinion and research. <i>Open Access Surgery</i> , 0, , 47.	0.4	0
190	Active Surveillance for Favorable-Risk Prostate Cancer: A Short Review. <i>Korean Journal of Urology</i> , 2010, 51, 665.	1.2	12
191	Stereotactic Body Radiotherapy as Boost for Organ-confined Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 575-582.	1.9	56
192	Quality-of-Life Impact of Primary Treatments for Localized Prostate Cancer in Patients Without Hormonal Treatment. <i>Journal of Clinical Oncology</i> , 2010, 28, 4687-4696.	1.6	184
193	Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 2653-2659.	1.6	146
194	Evaluation of Health-Related Quality of Life in Patients with Prostate Cancer after Treatment with Radical Retropubic Prostatectomy and Permanent Prostate Brachytherapy. <i>Urologia Internationalis</i> , 2010, 85, 173-179.	1.3	7

#	ARTICLE	IF	CITATIONS
195	Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5038-5045.	1.6	157
196	Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5030-5037.	1.6	103
197	CyberKnife Radiosurgery for Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 463-472.	1.9	23
198	Dutasteride reduces incident prostate cancer in men after negative prostate biopsy. <i>Evidence-Based Medicine</i> , 2010, 15, 119-120.	0.6	1
199	Variability in Anxiety and Depression Over Time Following Diagnosis in Patients with Prostate Cancer. <i>Journal of Psychosocial Oncology</i> , 2010, 28, 644-665.	1.2	20
200	Satisfaction with Care: A Measure of Quality of Care in Prostate Cancer Patients. <i>Medical Decision Making</i> , 2010, 30, 234-245.	2.4	36
201	Urinary Obstructive Problems Exposed But Hormonal Health-Related Quality-of-Life Concerns Eschewed in Prostate Cancer Quality-of-Life Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4667-4668.	1.6	2
202	Treating prostate cancer with radiotherapy. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 583-589.	27.6	17
203	Is focal therapy the future for prostate cancer?. <i>Future Oncology</i> , 2010, 6, 261-268.	2.4	20
204	Intrafascial Nerve-Sparing Radical Prostatectomy with a Laparoscopic Robot-Assisted Extraperitoneal Approach: Early Oncological and Functional Results. <i>Journal of Endourology</i> , 2010, 24, 577-582.	2.1	24
205	A Pilot Study of Intensity Modulated Radiation Therapy with Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Boost in the Treatment of Intermediate- to High-Risk Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 453-462.	1.9	49
206	Quality of life predicts risks of end-stage renal disease and mortality in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1621-1626.	0.7	92
207	The implementation of screening for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 218-227.	3.9	13
208	Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 34-38.	3.9	6
209	A Review of Low-Dose-Rate Prostate Brachytherapyâ€”Techniques and Outcomes. <i>Journal of the National Medical Association</i> , 2010, 102, 500-510.	0.8	12
210	Quality of Life in Patients with Skull Base Tumors: Current Status and Future Challenges. <i>Skull Base</i> , 2010, 20, 011-018.	0.4	44
211	Saturation biopsy does not accurately localize tumors. <i>Nature Reviews Urology</i> , 2010, 7, 479-480.	3.8	1
212	Should prostate-specific antigen screening be offered to asymptomatic men?. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1043-1053.	2.4	4

#	ARTICLE	IF	CITATIONS
213	Use and Evaluation of a CD-ROM-Based Decision Aid for Prostate Cancer Treatment Decisions. Behavioral Medicine, 2010, 36, 130-140.	1.9	23
214	Focal Laser Ablation for Localized Prostate Cancer. Journal of Endourology, 2010, 24, 791-797.	2.1	49
215	Prostate Cancer Screening in Men 75 Years Old or Older: An Assessment of Self-Reported Health Status and Life Expectancy. Journal of Urology, 2010, 183, 1798-1802.	0.4	20
216	Improving Decisions for Men With Prostate Cancer: Translational Outcomes Research. Journal of Urology, 2010, 183, 2186-2192.	0.4	6
217	Readability of Health Related Quality of Life Instruments in Urology. Journal of Urology, 2010, 183, 1977-1981.	0.4	26
218	Do Perceptions of Adverse Events Differ Between Patients and Physicians? Findings From a Randomized, Controlled Trial of Radical Treatment for Prostate Cancer. Journal of Urology, 2010, 184, 525-531.	0.4	15
219	Patient Centered Outcomes in Prostate Cancer Treatment: Predictors of Satisfaction Up to 2 Years After Open Radical Retropubic Prostatectomy. Journal of Urology, 2010, 184, 1977-1981.	0.4	33
220	Prostate Cancer in the Older Man: Conflict Between Tumor Biology and Medical Advancement. Clinics in Geriatric Medicine, 2010, 26, 241-247.	2.6	1
222	Health Related Quality of Life for Men Treated for Localized Prostate Cancer With Long-Term Followup. Journal of Urology, 2010, 183, 2206-2212.	0.4	110
223	Risk of Urinary Incontinence Following Prostatectomy: The Role of Physical Activity and Obesity. Journal of Urology, 2010, 183, 629-633.	0.4	119
225	Chemoprevention of Prostate Cancer. Urologic Clinics of North America, 2010, 37, 11-21.	1.8	16
226	Treatment of localized prostate cancer: when is active surveillance appropriate?. Nature Reviews Clinical Oncology, 2010, 7, 394-400.	27.6	35
227	Prostate Cancer: To Screen or Not to Screen?. Urologic Clinics of North America, 2010, 37, 1-9.	1.8	13
229	Quality of Life After Open or Robotic Prostatectomy, Cryoablation or Brachytherapy for Localized Prostate Cancer. Journal of Urology, 2010, 183, 1822-1829.	0.4	99
230	Focal therapy in prostate cancer: modalities, findings and future considerations. Nature Reviews Urology, 2010, 7, 562-571.	3.8	94
231	Focal Therapy in Prostate Cancer—Report from a Consensus Panel. Journal of Endourology, 2010, 24, 775-780.	2.1	173
234	Management of prostate cancer recurrence after definitive radiation therapy. Cancer Treatment Reviews, 2010, 36, 91-100.	7.7	49
235	Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial. Urology, 2010, 75, 502-509.	1.0	24

#	ARTICLE	IF	CITATIONS
237	Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Protocols. <i>Urology</i> , 2010, 75, 414-418.	1.0	51
239	Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagnetic Tracking: Assessing the Impact of Margin Reduction Study. <i>Urology</i> , 2010, 75, 1004-1008.	1.0	69
240	Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument for Measuring Health-related Quality of Life Among Prostate Cancer Survivors. <i>Urology</i> , 2010, 76, 1245-1250.	1.0	356
241	Radical Cystectomy in Patients Previously Treated for Localized Prostate Cancer. <i>Urology</i> , 2010, 76, 1430-1433.	1.0	15
242	No Long-term Effects of Hormonal Therapy Preceding Brachytherapy on Urinary Function and Health-related Quality of Life Among Prostate Cancer Patients. <i>Urology</i> , 2010, 76, 1150-1156.	1.0	6
243	The second decade of prostate brachytherapy: Evidence and cost based outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 86-90.	1.6	9
244	Limitations of a contemporary prostate biopsy: The blind march forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 546-549.	1.6	17
245	Fascia surrounding the prostate: clinical and anatomical basis of the nerve-sparing radical prostatectomy. <i>Surgical and Radiologic Anatomy</i> , 2010, 32, 663-667.	1.2	25
246	Construction and Evaluation of an Anatomically Correct Multi-Image Modality Compatible Phantom for Prostate Cancer Focal Ablation. <i>Journal of Urology</i> , 2010, 184, 352-357.	0.4	23
247	A Multidisciplinary Approach to Sexual Dysfunction in Medical Education. <i>Academic Psychiatry</i> , 2010, 34, 386-389.	0.9	19
248	Post-Prostatectomy Urinary Incontinence: A Confluence of 3 Factors. <i>Journal of Urology</i> , 2010, 183, 871-877.	0.4	97
249	Correlates of Bother Following Treatment for Clinically Localized Prostate Cancer. <i>Journal of Urology</i> , 2010, 184, 1309-1315.	0.4	50
250	Recovery of Erectile Function After Nerve Sparing Radical Prostatectomy and Penile Rehabilitation With Nightly Intraurethral Alprostadil Versus Sildenafil Citrate. <i>Journal of Urology</i> , 2010, 183, 2451-2456.	0.4	94
251	Unanticipated and Underappreciated Outcomes During Management of Local Stage Prostate Cancer: A Prospective Survey. <i>Journal of Urology</i> , 2010, 184, 120-125.	0.4	10
252	Diet and prostate cancer: mechanisms of action and implications for chemoprevention. <i>Nature Reviews Urology</i> , 2010, 7, 442-453.	3.8	88
253	Costâ€ effectiveness of prostate cancer chemoprevention among high-risk men. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 505-508.	1.4	7
254	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v129-v133.	1.2	279
255	â€Newâ€™ Evidence for Clinical Practice Guidelines. <i>Patient</i> , 2010, 3, 71-77.	2.7	7

#	ARTICLE	IF	CITATIONS
256	Integrating Evidence and Individual Preferences Using a Web-Based Multi-Criteria Decision Analytic Tool. Patient, 2011, 4, 153-162.	2.7	20
258	Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice. Brachytherapy, 2011, 10, 369-375.	0.5	2
259	Does Hormone Therapy Exacerbate the Adverse Effects of Radiotherapy in Men With Prostate Cancer? A Quality of Life Study. Journal of Urology, 2011, 185, 1674-1680.	0.4	13
260	Posterior Rhabdosphincter Reconstruction During Robotic Assisted Radical Prostatectomy: Results From a Phase II Randomized Clinical Trial. Journal of Urology, 2011, 185, 1262-1267.	0.4	66
261	Erectile Dysfunction following Radical Prostatectomy: A Review. British Journal of Medical and Surgical Urology, 2011, 4, 227-242.	0.2	2
262	Comment to: "Results of 125-Iodine seed implant with preplanning system in 250 patients with prostate cancer". Actas Urológicas Españolas (English Edition), 2011, 35, 345-346.	0.2	0
263	Case 5-2011. New England Journal of Medicine, 2011, 364, 667-675.	27.0	4
265	Who Ordered That? The Economics of Treatment Choices in Medical Care. Handbook of Health Economics, 2011, 2, 397-432.	0.2	62
266	Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial). Contemporary Clinical Trials, 2011, 32, 453-460.	1.8	19
267	Searching Robotic Prostatectomy Online: What Information Is Available?. Urology, 2011, 77, 941-945.	1.0	11
270	The Effect of Race and Rural Residence on Prostate Cancer Treatment Choice Among Men in Georgia. Urology, 2011, 77, 581-587.	1.0	28
271	Quality of Life Among Men With Prostate Cancer in Rural Georgia. Urology, 2011, 77, 927-933.	1.0	10
272	Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncology, The, 2011, 12, 891-899.	10.7	311
273	Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. Journal of Urology, 2011, 185, 869-875.	0.4	574
274	Comparison of Health-Related Quality of Life 5 Years After SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. Journal of Clinical Oncology, 2011, 29, 362-368.	1.6	174
275	Incontinence After Radical Prostatectomy: A Patient Centered Analysis and Implications for Preoperative Counseling. Journal of Urology, 2011, 186, 204-208.	0.4	31
276	Patient Preoperative Expectations of Urinary, Bowel, Hormonal and Sexual Functioning Do Not Match Actual Outcomes 1 Year After Radical Prostatectomy. Journal of Urology, 2011, 186, 494-499.	0.4	63
277	Coronary Artery Revascularization and the Risk of Death in Men With Prostate Cancer. Journal of Urology, 2011, 186, 898-902.	0.4	0

#	ARTICLE	IF	CITATIONS
278	Expanded Prostate Cancer Index Composite for Clinical Practice: Development and Validation of a Practical Health Related Quality of Life Instrument for Use in the Routine Clinical Care of Patients With Prostate Cancer. Journal of Urology, 2011, 186, 865-872.	0.4	152
279	Watchful Waiting and Quality of Life Among Prostate Cancer Survivors in the Physicians' Health Study. Journal of Urology, 2011, 186, 1862-1867.	0.4	24
280	The Role of Self-Efficacy in Quality of Life for Disadvantaged Men With Prostate Cancer. Journal of Urology, 2011, 186, 1855-1861.	0.4	26
281	The AdVance® Male Sling: Patient Selection and Workup. European Urology Supplements, 2011, 10, 390-394.	0.1	15
282	Predictors of Urinary Morbidity in Cs-131 Prostate Brachytherapy Implants. International Journal of Radiation Oncology Biology Physics, 2011, 81, 745-750.	0.8	8
283	Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer. Brachytherapy, 2011, 10, 9-14.	0.5	15
284	Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. Lancet, The, 2011, 378, 328-337.	13.7	105
285	Interpreting the Clinical Significance of Quality of Life Score Changes after Radiotherapy for Localized Prostate Cancer. Current Urology, 2011, 5, 137-144.	0.6	13
286	Using Large Institutional or National Databases to Evaluate Prostate Cancer Outcomes and Patterns of Care: Possibilities and Limitations. Scientific World Journal, The, 2011, 11, 147-160.	2.1	6
287	The Debate over Prostate Cancer Screening Guidelines. AMA Journal of Ethics, 2011, 13, 10-15.	0.7	1
288	Prostatic Disease and Sexual Dysfunction. Korean Journal of Urology, 2011, 52, 373.	1.2	11
289	Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment. Cancer Imaging, 2011, 11, S3-S8.	2.8	16
290	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Research and Reports in Urology, 0, Volume 3, 95-104.	1.0	0
291	Outcome of a Modified York Mason Technique in Men With Iatrogenic Urethrorectal Fistula After Radical Prostatectomy. Diseases of the Colon and Rectum, 2011, 54, 1008-1013.	1.3	24
292	Patients' Perspectives on Fecal Incontinence After Brachytherapy for Localized Prostate Cancer. Diseases of the Colon and Rectum, 2011, 54, 615-621.	1.3	5
293	A critical analysis of the long-term impact of brachytherapy for prostate cancer: a review of the recent literature. Current Opinion in Urology, 2011, 21, 219-224.	1.8	17
294	Robotic radical prostatectomy: a critical analysis of surgical quality. Current Opinion in Urology, 2011, 21, 195-199.	1.8	8
295	Robotic-assisted laparoscopic prostatectomy: a critical analysis of its impact on urinary continence. Current Opinion in Urology, 2011, 21, 185-194.	1.8	14

#	ARTICLE	IF	CITATIONS
296	Low-dose rate brachytherapy for men with localized prostate cancer. The Cochrane Library, 2011, , CD008871.	2.8	29
297	Comparative Evaluation of Radiation Treatments for Clinically Localized Prostate Cancer: An Updated Systematic Review. Annals of Internal Medicine, 2011, 155, 171.	3.9	32
298	Five year Expanded Prostate cancer Index Compositeâ€based quality of life outcomes after prostatectomy for localized prostate cancer. BJU International, 2011, 107, 585-590.	2.5	44
299	Early prostate cancer â€“ which treatment do men prefer and why?. BJU International, 2011, 107, 1762-1768.	2.5	73
300	Management of low (favourable)â€risk prostate cancer. BJU International, 2011, 108, 1684-1695.	2.5	27
301	Critical review of â€pentafectaâ€™ outcomes after robotâ€assisted laparoscopic prostatectomy in highâ€volume centres. BJU International, 2011, 108, 1007-1017.	2.5	62
302	Healthâ€related quality of life after radical retropubic prostatectomy and permanent prostate brachytherapy: A 3â€year followâ€up study. International Journal of Urology, 2011, 18, 813-819.	1.0	13
303	Intimacyâ€Enhancing Psychological Intervention for Men Diagnosed with Prostate Cancer and Their Partners: A Pilot Study. Journal of Sexual Medicine, 2011, 8, 1197-1209.	0.6	119
304	What Is the Definition of a Satisfactory Erectile Function After Bilateral Nerve Sparing Radical Prostatectomy?. Journal of Sexual Medicine, 2011, 8, 1210-1217.	0.6	38
305	Radiation-Induced Erectile Dysfunction Using Prostate-Confined Modern Radiotherapy in a Rat Model. Journal of Sexual Medicine, 2011, 8, 2215-2226.	0.6	27
306	Factors Predicting Early and Late Phase Decline of Sexual Health-Related Quality of Life Following Radical Prostatectomy. Journal of Sexual Medicine, 2011, 8, 2935-2943.	0.6	23
307	A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988â€“2006. European Urology, 2011, 59, 88-95.	1.9	159
308	Duloxetine for Mild to Moderate Postprostatectomy Incontinence: Preliminary Results of a Randomised, Placebo-Controlled Trial. European Urology, 2011, 59, 148-154.	1.9	67
309	Impact of 5Î±-Reductase Inhibitors on Men Followed by Active Surveillance for Prostate Cancer. European Urology, 2011, 59, 509-514.	1.9	52
310	Re: Active Surveillance Compared with Initial Treatment for Men with Low-Risk Prostate Cancer: A Decision Analysis. European Urology, 2011, 59, 883-884.	1.9	1
311	Challenges of Interpreting and Improving Radical Prostatectomy Outcomes: Technique, Technology, Training, and Tactical Reporting. European Urology, 2011, 59, 1073-1074.	1.9	5
313	To Infinity and Beyond: The Robotic Toy Story. European Urology, 2011, 60, 263-265.	1.9	18
314	Contemporary Management of Postprostatectomy Incontinence. European Urology, 2011, 59, 985-996.	1.9	201

#	ARTICLE	IF	CITATIONS
315	Urinary Incontinence in Older Adults. Mount Sinai Journal of Medicine, 2011, 78, 558-570.	1.9	12
316	Radical Prostatectomy Versus External-Beam Radiotherapy for Localized Prostate Cancer: Long-Term Effect on Biochemical Controlâ€”In Search of the Optimal Treatment. Annals of Surgical Oncology, 2011, 18, 2980-2987.	1.5	12
318	Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial. Supportive Care in Cancer, 2011, 19, 1117-1124.	2.2	8
319	Anatomical description of the periprostatic nerves in the male rhesus monkey (Macaca mulatta). World Journal of Urology, 2011, 29, 375-380.	2.2	1
320	Nerve-sparing technique and urinary control after robot-assisted laparoscopic prostatectomy. World Journal of Urology, 2011, 29, 21-27.	2.2	51
321	Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study. World Journal of Urology, 2011, 29, 665-670.	2.2	5
322	Is a return to baseline sexual function possible? An analysis of sexual function outcomes following laparoscopic radical prostatectomy. World Journal of Urology, 2011, 29, 29-34.	2.2	35
323	Health services research in urology. World Journal of Urology, 2011, 29, 273-276.	2.2	2
325	Sexual quality of life for localized prostate cancer: a crossâ€cultural study between Japanese and American men. Reproductive Medicine and Biology, 2011, 10, 59-68.	2.4	6
326	Smoking and quality of life among female survivors of breast, colorectal and endometrial cancers in a prospective cohort study. Journal of Cancer Survivorship, 2011, 5, 115-122.	2.9	48
327	The experiences of unpartnered men with prostate cancer: a qualitative analysis. Journal of Cancer Survivorship, 2011, 5, 132-141.	2.9	31
328	Update on Prostate Brachytherapy: Long-term Outcomes and Treatment-related Morbidity. Current Urology Reports, 2011, 12, 237-242.	2.2	18
329	Quality of life of patients after retropubic prostatectomy - Pre- and postoperative scores of the EORTC QLQ-C30 and QLQ-PR25. Health and Quality of Life Outcomes, 2011, 9, 93.	2.4	12
330	Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. Journal of Hematology and Oncology, 2011, 4, 12.	17.0	39
331	A pilot investigation of a multidisciplinary quality of life intervention for men with biochemical recurrence of prostate cancer. Psycho-Oncology, 2011, 20, 435-440.	2.3	17
332	Structural and reliability analysis of a patient satisfaction with cancerâ€related care measure. Cancer, 2011, 117, 854-861.	4.1	77
333	Longâ€term survival after radical prostatectomy versus externalâ€beam radiotherapy for patients with highâ€risk prostate cancer. Cancer, 2011, 117, 2883-2891.	4.1	229
334	Impact of androgen deprivation on physical wellâ€being in patients with prostate cancer. Cancer, 2011, 117, 4406-4413.	4.1	29

#	ARTICLE	IF	CITATIONS
335	The Impact of Pretreatment Prostate Volume on Severe Acute Genitourinary Toxicity in Prostate Cancer Patients Treated With Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 379-384.	0.8	31
336	External Beam Radiotherapy for Prostate Cancer: Urinary Outcomes for Men With High International Prostate Symptom Scores (IPSS). International Journal of Radiation Oncology Biology Physics, 2011, 80, 1080-1086.	0.8	42
337	70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1056-1063.	0.8	389
338	A Matched Control Analysis of Adjuvant and Salvage High-Dose Postoperative Intensity-Modulated Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1316-1322.	0.8	84
339	Health-Related Quality of Life After Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1299-1305.	0.8	56
340	Acute bowel morbidity after prostate brachytherapy with cesium-131. Brachytherapy, 2011, 10, 51-56.	0.5	10
341	Role of MRI in Minimally Invasive Focal Ablative Therapy for Prostate Cancer. American Journal of Roentgenology, 2011, 197, W90-W96.	2.2	49
342	Conservative treatment of postprostatectomy incontinence. Nature Reviews Urology, 2011, 8, 237-238.	3.8	2
343	Active surveillance for low-risk prostate cancer: an update. Nature Reviews Urology, 2011, 8, 312-320.	3.8	63
344	Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2020-2026.	1.6	234
345	Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery. , 2011, , CD008306.		22
346	Vitamin E and the Risk of Prostate Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1549.	7.4	1,458
347	Population-Based Patterns and Predictors of Prostate-Specific Antigen Screening Among Older Men in the United States. Journal of Clinical Oncology, 2011, 29, 1736-1743.	1.6	100
348	A Biopsychosocial Approach to Sexual Recovery After Prostate Cancer Surgery: The Role of Grief and Mourning. Journal of Sex and Marital Therapy, 2011, 37, 130-144.	1.5	48
349	Prediction of Erectile Function Following Treatment for Prostate Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1205.	7.4	253
350	Pros and Cons of Focal Therapy for Localised Prostate Cancer. Prostate Cancer, 2011, 2011, 1-8.	0.6	15
351	Quality of Life of Patients Undergoing Surgical Treatment for Newly-Diagnosed, Clinically Localized Renal Cell Carcinoma. Journal of Psychosocial Oncology, 2011, 29, 593-605.	1.2	15
352	Evolution from active surveillance to focal therapy in the management of prostate cancer. Future Oncology, 2011, 7, 775-787.	2.4	13

#	ARTICLE	IF	CITATIONS
353	Pelvic Anatomy on Preoperative Magnetic Resonance Imaging Can Predict Early Continence After Robot-Assisted Radical Prostatectomy. <i>Journal of Endourology</i> , 2011, 25, 51-55.	2.1	28
354	The Impact of Anterior Urethropy During Robotic Prostatectomy on Urinary and Sexual Outcomes. <i>Journal of Endourology</i> , 2011, 25, 615-619.	2.1	13
355	S�miologie et examen clinique. , 2011, , 43-48.		0
356	Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet. <i>Annals of Oncology</i> , 2011, 22, 723-729.	1.2	24
357	Efficacy and Safety of High-Dose-Rate Brachytherapy of Single Implant with Two Fractions Combined with External Beam Radiotherapy for Hormone-Na�ve Localized Prostate Cancer. <i>Cancers</i> , 2011, 3, 3585-3600.	3.7	6
358	Symptoms of Acute Posttraumatic Stress Disorder in Prostate Cancer Patients Following Radical Prostatectomy. <i>American Journal of Men's Health</i> , 2011, 5, 84-89.	1.6	19
359	Low Incidence of Fatigue after Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 142.	2.8	3
360	Artificial Urinary Sphincter: Long-Term Results and Patient Satisfaction. <i>Advances in Urology</i> , 2012, 2012, 1-4.	1.3	56
361	Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy. <i>Advances in Urology</i> , 2012, 2012, 1-7.	1.3	21
362	Comparative Cost-Effectiveness of Stereotactic Body Radiation Therapy Versus Intensity-Modulated and Proton Radiation Therapy for Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 81.	2.8	60
364	Quality-of-Life Outcomes in High-Risk Prostate Cancer Patients Treated with Helical Tomotherapy in a Hypofractionated Radiation Schedule with Long-Term Androgen Suppression. <i>Current Oncology</i> , 2012, 19, 201-210.	2.2	6
365	Overdiagnosis of Prostate Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 146-151.	2.1	88
366	Living alone, obesity and smoking: Important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer. <i>Acta Oncol�gica</i> , 2012, 51, 722-729.	1.8	47
367	Focal Therapy for Prostatic Carcinoma. <i>Advances in Urology</i> , 2012, 2012, 1-2.	1.3	1
368	Chemoprevention of Prostate Cancer: Myths and Realities. <i>Journal of the American Board of Family Medicine</i> , 2012, 25, 111-119.	1.5	16
369	Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer. <i>Prostate Cancer</i> , 2012, 2012, 1-7.	0.6	33
370	Focal Therapy, Differential Therapy, and Radiation Treatment for Prostate Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-6.	1.3	11
371	Patient Preference and the Impact of Decision-Making Aids on Prostate Cancer Treatment Choices and Post-Intervention Regret. <i>Current Oncology</i> , 2012, 19, 37-44.	2.2	56

#	ARTICLE	IF	CITATIONS
372	Optimizing postoperative sexual function after radical prostatectomy. Therapeutic Advances in Urology, 2012, 4, 347-365.	2.0	12
373	Long-Term Disease-Specific Functioning Among Prostate Cancer Survivors and Noncancer Controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Journal of Clinical Oncology, 2012, 30, 2768-2775.	1.6	67
374	Growth Of High-Cost Intensity-Modulated Radiotherapy For Prostate Cancer Raises Concerns About Overuse. Health Affairs, 2012, 31, 750-759.	5.2	72
375	Active surveillance for prostate cancer. Current Opinion in Oncology, 2012, 24, 243-250.	2.4	41
376	Psychological aspects of active surveillance. Current Opinion in Urology, 2012, 22, 237-242.	1.8	63
377	A Qualitative Inquiry of Patient-Reported Outcomes. Nursing Research, 2012, 61, 283-290.	1.7	9
378	The role of 5-alpha-reductase inhibitors in active surveillance. Current Opinion in Urology, 2012, 22, 243-246.	1.8	2
379	Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncology, 2012, 8, 37-54.	2.4	13
381	Improving Time to Continence After Robot-Assisted Laparoscopic Prostatectomy: Augmentation of the Total Anatomic Reconstruction Technique by Adding Dynamic Detrusor Cuff Trigonoplasty and Suprapubic Tube Placement. Journal of Endourology, 2012, 26, 1546-1552.	2.1	13
382	Survey of Endourology Howard N. Winfield, M.D., Section Editor. Journal of Endourology, 2012, 26, 90-101.	2.1	0
383	Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. British Journal of Cancer, 2012, 106, 638-645.	6.4	36
384	Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer and Prostatic Diseases, 2012, 15, 374-379.	3.9	32
385	Translational genomics: The challenge of developing cancer biomarkers. Genome Research, 2012, 22, 183-187.	5.5	94
386	Preoperative Detection and Localization of Accessory Pudendal Artery with Contrast-enhanced MR Angiography. Radiology, 2012, 262, 903-911.	7.3	10
387	Are Medicare-Based Findings Applicable to All Prostatectomy Patients?. Journal of Clinical Oncology, 2012, 30, 2286-2287.	1.6	4
388	A Comparison of Extraperitoneal and Intraperitoneal Approaches for Robotic Prostatectomy. Surgical Innovation, 2012, 19, 268-274.	0.9	13
389	Variations in the quality of care at radical prostatectomy. Therapeutic Advances in Urology, 2012, 4, 61-75.	2.0	5
390	Increasing Use of Radical Prostatectomy for Nonlethal Prostate Cancer in Sweden. Clinical Cancer Research, 2012, 18, 6742-6747.	7.0	27

#	ARTICLE	IF	CITATIONS
391	Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA ≤ 20 ng/mL. International Journal of Surgical Oncology, 2012, 2012, 1-10.	0.6	2
392	Authentication of Algorithm to Detect Metastases in Men with Prostate Cancer Using ICD-9 Codes. Epidemiology Research International, 2012, 2012, 1-7.	0.2	17
393	Quality of Life in Men Undergoing Active Surveillance for Localized Prostate Cancer. Journal of the National Cancer Institute Monographs, 2012, 2012, 242-249.	2.1	42
394	Intensity-Modulated Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and Morbidity and Disease Control in Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1611.	7.4	392
395	PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update. Current Pharmaceutical Design, 2012, 18, 5590-5606.	1.9	18
396	Androgen Deprivation Therapy: Minimizing Exposure and Mitigating Side Effects. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1088-1096.	4.9	22
397	Interdependent psychological quality of life in dyads adjusting to prostate cancer.. Health Psychology, 2012, 31, 70-79.	1.6	66
398	Quality-of-Life Effects of Prostate-Specific Antigen Screening. New England Journal of Medicine, 2012, 367, 595-605.	27.0	364
399	Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy. International Journal of Urology, 2012, 19, 1083-1089.	1.0	7
400	20-year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU International, 2012, 110, 1709-1713.	2.5	65
401	Is Radical Prostatectomy a Useful Therapeutic Option for High-Risk Prostate Cancer in Older Men?. Oncologist, 2012, 17, 4-8.	3.7	6
402	Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?. Lancet Oncology, The, 2012, 13, e259-e269.	10.7	58
403	Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncology, The, 2012, 13, 622-632.	10.7	359
404	MRI-Guided Interventions for the Treatment of Prostate Cancer. American Journal of Roentgenology, 2012, 199, 714-720.	2.2	37
405	Psychometric validation and reliability analysis of a Spanish version of the patient satisfaction with cancer-related care measure: a patient navigation research program study. Supportive Care in Cancer, 2012, 20, 1949-1956.	2.2	14
406	Active Surveillance for Prostate Cancer: Barriers to Widespread Adoption. European Urology, 2012, 62, 984-985.	1.9	11
407	Early Outcomes From Three Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 213-221.	0.8	95
408	Comparison of Acute and Late Toxicities for Three Modern High-Dose Radiation Treatment Techniques for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 204-212.	0.8	136

#	ARTICLE	IF	CITATIONS
409	Comparison of High-Dose Proton Radiotherapy and Brachytherapy in Localized Prostate Cancer: A Case-Matched Analysis. International Journal of Radiation Oncology Biology Physics, 2012, 82, e25-e31.	0.8	29
410	Long-Term Quality of Life Outcome After Proton Beam Monotherapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e201-e209.	0.8	31
411	Quality of Life After Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 617-623.	0.8	14
412	Is Primary Prostate Cancer Treatment Influenced by Likelihood of Extraprostatic Disease? A Surveillance, Epidemiology and End Results Patterns of Care Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, 88-94.	0.8	13
413	Sexual Function and the Use of Medical Devices or Drugs to Optimize Potency After Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, e765-e771.	0.8	10
414	In Regard to "Dose Escalation in the Radiation Therapy of Prostate Cancer" (Int J Radiat Oncol Biol) Tj ETQq1 1,0,784314 rgBT /Ove	0.8	0
415	Measuring the Structure and Process of End-of-Life Care in Korea: Validation of the Korean Version of the Care Evaluation Scale (CES). Journal of Pain and Symptom Management, 2012, 44, 615-625.e2.	1.2	13
416	Editorial Comment. Journal of Urology, 2012, 187, 123-123.	0.4	0
417	Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy. Journal of Urology, 2012, 187, 569-574.	0.4	35
418	Pretreatment Expectations of Patients Undergoing Robotic Assisted Laparoscopic or Open Retropubic Radical Prostatectomy. Journal of Urology, 2012, 187, 894-898.	0.4	41
419	Recovery of Urinary Function After Radical Prostatectomy: Identification of Trajectory Cluster Groups. Journal of Urology, 2012, 187, 1346-1351.	0.4	15
420	Impact of Multiparametric Endorectal Coil Prostate Magnetic Resonance Imaging on Disease Reclassification Among Active Surveillance Candidates: A Prospective Cohort Study. Journal of Urology, 2012, 187, 1247-1252.	0.4	157
421	Radical Prostatectomy Outcome in Men 65 Years Old or Older With Low Risk Prostate Cancer. Journal of Urology, 2012, 187, 1620-1625.	0.4	20
422	Surgical Practice Patterns for Male Urinary Incontinence: Analysis of Case Logs from Certifying American Urologists. Journal of Urology, 2012, 188, 205-210.	0.4	41
423	Monitoring Quality of Life Among Prostate Cancer Survivors: The Feasibility of Automated Telephone Assessment. Urology, 2012, 80, 1021-1026.	1.0	22
424	Certificate of Need Regulations and the Diffusion of Intensity-modulated Radiotherapy. Urology, 2012, 80, 1015-1020.	1.0	10
425	Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 402-407.	1.6	7
427	Baseline Functional Status May Predict Decisional Regret Following Robotic Prostatectomy. Journal of Urology, 2012, 188, 2213-2218.	0.4	27

#	ARTICLE	IF	CITATIONS
428	Sexuality in Adult Cancer Survivors: Challenges and Intervention. Journal of Clinical Oncology, 2012, 30, 3712-3719.	1.6	323
430	Developing a national radiation oncology registry: From acorns to oaks. Practical Radiation Oncology, 2012, 2, 10-17.	2.1	38
431	The Relationship of the Intensity of Posttreatment Prostate-Specific Antigen Surveillance and Prostate Cancer Outcomes: Results From a Population-Based Cohort. Mayo Clinic Proceedings, 2012, 87, 540-547.	3.0	4
432	Two-step transurethral surgery of the prostate and permanent implant brachytherapy for patients with lower urinary tract symptoms and low- to intermediate-risk prostate cancer. Brachytherapy, 2012, 11, 483-488.	0.5	9
433	Urethra low-dose tunnels: Validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy, 2012, 11, 348-353.	0.5	23
434	Implications of CT imaging for postplan quality assessment in prostate brachytherapy. Brachytherapy, 2012, 11, 435-440.	0.5	12
436	Development and Validation of a Utility Weighting Function for the Patient-Oriented Prostate Utility Scale (PORPUS). Medical Decision Making, 2012, 32, 11-30.	2.4	27
437	Radical Prostatectomy versus Observation for Localized Prostate Cancer. New England Journal of Medicine, 2012, 367, 203-213.	27.0	1,614
438	Decision preparation, satisfaction and regret in a multi-center sample of men with newly diagnosed localized prostate cancer. Patient Education and Counseling, 2012, 88, 262-267.	2.2	66
439	Clinical Outcomes of Intracavernosal Injection in Postprostatectomy Patients: A Single-center Experience. Urology, 2012, 79, 150-155.	1.0	17
440	Understanding Variation in Primary Prostate Cancer Treatment Within the Veterans Health Administration. Urology, 2012, 79, 537-545.	1.0	27
441	Cavernosal Nerve Preservation During Robot-assisted Radical Prostatectomy Is a Graded Rather Than an All-or-none Phenomenon: Objective Demonstration by Assessment of Residual Nerve Tissue on Surgical Specimens. Urology, 2012, 79, 596-600.	1.0	20
442	Effect of Prostate-specific Antigen Screening on Metastatic Disease Burden 10 Years After Diagnosis. Urology, 2012, 80, 367-373.	1.0	8
443	Protocol-based Active Surveillance for Low-risk Prostate Cancer: Anxiety Levels in Both Men and Their Partners. Urology, 2012, 80, 564-569.	1.0	26
445	Beyond PSA: The Next Generation of Prostate Cancer Biomarkers. Science Translational Medicine, 2012, 4, 127rv3.	12.4	378
446	Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer, 2012, 12, 110.	2.6	41
447	Personal preferences and discordant prostate cancer treatment choice in an intervention trial of men newly diagnosed with localized prostate cancer. Health and Quality of Life Outcomes, 2012, 10, 123.	2.4	16
448	Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer. Journal of the National Cancer Institute, 2012, 104, 1335-1342.	6.3	126

#	ARTICLE	IF	CITATIONS
450	Quality of life in men with locally advanced prostate cancer treated with leuporelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. <i>Lancet Oncology</i> , The, 2012, 13, 1260-1270.	10.7	49
451	Validation in Spain of the Quality of Life questionnaire PROSQOLI in patients with advanced prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2012, 36, 410-417.	0.2	1
453	How to select the optimal therapy for early-stage prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 225-234.	4.4	18
454	Correlation of Magnetic Resonance Imaging Tumor Volume with Histopathology. <i>Journal of Urology</i> , 2012, 188, 1157-1163.	0.4	188
455	Stepwise Description and Outcomes of Bladder Neck Sparing During Robot-Assisted Laparoscopic Radical Prostatectomy. <i>Journal of Urology</i> , 2012, 188, 1754-1760.	0.4	49
456	Do Gleason Patterns 3 and 4 Prostate Cancer Represent Separate Disease States?. <i>Journal of Urology</i> , 2012, 188, 1667-1675.	0.4	66
457	Re: Focal Therapy for Localised Unifocal and Multifocal Prostate Cancer: A Prospective Development Study. <i>Journal of Urology</i> , 2012, 188, 1768-1769.	0.4	2
458	Willingness to Pay for Prostate Cancer Treatment among Patients and Their Family Members at 1 Year After Diagnosis. <i>Value in Health</i> , 2012, 15, 716-723.	0.3	11
461	Controversies in the management of localized prostate cancer: Radical prostatectomy still the standard of care. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, e24-e29.	4.4	11
462	EP-1096 EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CANCER: THE POTENTIAL FOR DOSE ESCALATION. <i>Radiotherapy and Oncology</i> , 2012, 103, S424.	0.6	0
463	Nocturia. , 2012, , .		9
464	How to select the optimal therapy for early-stage prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, e6-e15.	4.4	18
465	Treatment of Localized Prostate Cancer. , 2012, , 141-154.		0
466	Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer. <i>Radiation Oncology</i> , 2012, 7, 194.	2.7	20
467	Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy. <i>Radiation Oncology</i> , 2012, 7, 82.	2.7	53
468	PTSD in the Context of Malignant Disease. , 0, , .		0
469	Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience. <i>Canadian Urological Association Journal</i> , 2012, 6, 283.	0.6	30
470	Cancer Screening and Prevention in the Older Patient. , 2012, , 19-28.		0

#	ARTICLE	IF	CITATIONS
471	The Differences in Quality of Life in Prostate Cancer Project: Methods and Design of a Multidisciplinary Population-Based Follow-up Study. American Medical Journal, 2012, 3, 104-114.	1.0	2
472	The side effects of hormonal therapy at the patients with carcinoma of prostate cancer. Wspolczesna Onkologia, 2012, 6, 491-497.	1.4	8
473	Impact of Fellowship Training on One-Year Outcomes of Robotic-Assisted Prostatectomy. Journal of the Society of Laparoendoscopic Surgeons, 2012, 16, 195-201.	1.1	8
474	Monotherapy of androgen deprivation therapy versus radical prostatectomy among veterans with localized prostate cancer: comparative effectiveness analysis of retrospective cohorts. Comparative Effectiveness Research, 2012, , 21.	0.2	0
475	What Men Say About Surviving Prostate Cancer: Complexities Represented in a Decade of Comments. Clinical Journal of Oncology Nursing, 2012, 16, 65-72.	0.6	20
476	Study of dyadic communication in couples managing prostate cancer: a longitudinal perspective. Psycho-Oncology, 2012, 21, 72-81.	2.3	59
477	Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones. Prostate, 2012, 72, 668-676.	2.3	7
478	The effect of urinary incontinence on health utility and health-related quality of life in men following prostate surgery. Neurourology and Urodynamics, 2012, 31, 465-469.	1.5	28
479	Should we screen for and treat lower urinary tract dysfunction after major pelvic surgery?: ICIâ€RS 2011. Neurourology and Urodynamics, 2012, 31, 327-329.	1.5	9
480	Selective detection of histologically aggressive prostate cancer. Cancer, 2012, 118, 2651-2658.	4.1	20
481	Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer, 2012, 118, 4619-4626.	4.1	51
482	Enhancing life after cancer in diverse communities. Cancer, 2012, 118, 5366-5373.	4.1	8
483	Primary care providers' perspectives on discontinuing prostate cancer screening. Cancer, 2012, 118, 5518-5524.	4.1	42
484	Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans. Cancer, 2012, 118, 5679-5687.	4.1	60
485	Temporal predictors of functional outcome after prostatectomy. Nature Reviews Urology, 2012, 9, 300-302.	3.8	0
486	Stereotactic body radiotherapy for prostate cancer: ready for prime time?. Journal of Radiation Oncology, 2012, 1, 17-30.	0.7	4
488	Chemoprevention of prostate cancer: an updated view. World Journal of Urology, 2012, 30, 189-194.	2.2	22
489	Improving quality of medical treatment and care: are surgeonsâ€™ working conditions and job satisfaction associated to patient satisfaction?. Langenbeck's Archives of Surgery, 2012, 397, 973-982.	1.9	27

#	ARTICLE	IF	CITATIONS
491	Advances in the management of high-risk localised and metastatic prostate cancer. BJU International, 2012, 109, 8-13.	2.5	11
492	Perceived family health in persons with prostate cancer and their family members. Journal of Clinical Nursing, 2012, 21, 544-554.	3.0	9
493	American College of Radiology Appropriateness Criteria® Locally Advanced (High-risk) Prostate Cancer. Clinical Oncology, 2012, 24, 43-51.	1.4	3
494	Functional Outcomes and Complications Following Radiation Therapy for Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2012, 61, 112-127.	1.9	224
495	Reporting and Grading of Complications After Urologic Surgical Procedures: An ad hoc EAU Guidelines Panel Assessment and Recommendations. European Urology, 2012, 61, 341-349.	1.9	458
496	A Critical Analysis of the Long-Term Impact of Radical Prostatectomy on Cancer Control and Function Outcomes. European Urology, 2012, 61, 664-675.	1.9	203
497	Technical Refinement and Learning Curve for Attenuating Neurapraxia During Robotic-Assisted Radical Prostatectomy to Improve Sexual Function. European Urology, 2012, 61, 1222-1228.	1.9	49
498	Prediction of Functional Outcomes After Nerve-Sparing Radical Prostatectomy: Results of Conditional Survival Analyses. European Urology, 2012, 62, 42-52.	1.9	75
499	Life-Threatening Disparities: The Treatment of Black and White Cancer Patients. Journal of Social Issues, 2012, 68, 328-357.	3.3	45
500	Therapeutic Effect of Adipose-Derived Stem Cells and BDNF-Immobilized PLGA Membrane in a Rat Model of Cavernous Nerve Injury. Journal of Sexual Medicine, 2012, 9, 1968-1979.	0.6	42
501	Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerve-Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 2187-2194.	0.6	17
502	An Editorial Response to the USPTF. Journal of Men's Health, 2012, 9, 5-8.	0.3	2
503	Enhanced targeted anticancer effects and inhibition of tumor metastasis by the TMTP1 compound peptide TMTP1-TAT-NBD. Journal of Controlled Release, 2012, 161, 893-902.	9.9	34
504	Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population-based analysis. International Journal of Urology, 2012, 19, 836-844.	1.0	85
505	The impact of social networks and partnership status on treatment choice in men with localized prostate cancer. BJU International, 2012, 109, 1006-1012.	2.5	17
506	Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU International, 2012, 109, 1366-1374.	2.5	39
507	Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?. BJU International, 2012, 109, 1824-1830.	2.5	33
508	Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis. BJU International, 2012, 110, 211-216.	2.5	40

#	ARTICLE	IF	CITATIONS
509	Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with $¹²⁵$ iodine brachytherapy. BJU International, 2012, 109, 1661-1665.	2.5	5
510	Predicting erectile function outcome in men after radical prostatectomy for prostate cancer. BJU International, 2012, 110, 422-426.	2.5	41
511	Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance. BJU International, 2012, 110, E50-6.	2.5	38
512	Long-term potency preservation following brachytherapy for prostate cancer. BJU International, 2012, 110, 221-225.	2.5	32
513	Sexual function with localized prostate cancer: active surveillance vs radical therapy. BJU International, 2012, 110, 1032-1039.	2.5	43
514	Anterior suspension combined with posterior reconstruction during robot-assisted laparoscopic prostatectomy improves early return of urinary continence: a prospective randomized multicentre trial. BJU International, 2012, 110, 875-883.	2.5	110
515	Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU International, 2012, 109, 508-513.	2.5	39
516	A review of outcomes of an intracavernosal injection therapy programme. BJU International, 2012, 110, 1787-1791.	2.5	57
517	Assessing couples' preferences for postoperative sexual rehabilitation before radical prostatectomy. BJU International, 2012, 110, 1529-1535.	2.5	8
518	Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer. Cancer, 2012, 118, 258-267.	4.1	8
519	What is the best way to treat high-risk prostate cancer?. Cancer, 2012, 118, 12-14.	4.1	1
520	Outcomes after prostate brachytherapy are even better than predicted. Cancer, 2012, 118, 839-847.	4.1	24
521	A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer, 2012, 118, 500-509.	4.1	161
522	A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU International, 2013, 111, 221-232.	2.5	40
523	Defining the impact of vascular risk factors on erectile function recovery after radical prostatectomy. BJU International, 2013, 111, 653-657.	2.5	27
524	Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiation Oncology, 2013, 8, 118.	2.7	172
525	Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiation Oncology, 2013, 8, 58.	2.7	232
526	Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer. Radiation Oncology, 2013, 8, 30.	2.7	33

#	ARTICLE	IF	CITATIONS
527	The Role of 5 α -Reductase Inhibitors (5-ARIs) in Prostate Cancer Chemoprevention. , 2013, , 391-394.		0
528	In favour of active surveillanceâ€”functional outcomes matter. Nature Reviews Urology, 2013, 10, 263-265.	3.8	0
529	Cancer survivors in Switzerland: a rapidly growing population to care for. BMC Cancer, 2013, 13, 287.	2.6	26
530	A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results. BMC Medical Informatics and Decision Making, 2013, 13, 19.	3.0	10
531	Prostate Cancer Screening: A Complicated Puzzle, Explanation Needed. Journal of General Internal Medicine, 2013, 28, 1549-1550.	2.6	0
532	Does Robotic Prostatectomy Meet Its Promise in the Management of Prostate Cancer?. Current Urology Reports, 2013, 14, 184-191.	2.2	11
533	Long-Term Survival of Participants in the Prostate Cancer Prevention Trial. New England Journal of Medicine, 2013, 369, 603-610.	27.0	233
534	Prostate cancer: Utility of diffusionâ€”weighted imaging as a marker of sideâ€”specific risk of extracapsular extension. Journal of Magnetic Resonance Imaging, 2013, 38, 312-319.	3.4	39
535	Functional outcomes following robotic prostatectomy using athermal, traction free risk-stratified grades of nerve sparing. World Journal of Urology, 2013, 31, 471-480.	2.2	50
536	Impact of late anorectal dysfunction on quality of life after pelvic radiotherapy. International Journal of Colorectal Disease, 2013, 28, 519-526.	2.2	26
539	Proposal of a method to assess and report the extent of residual neurovascular tissue present in radical prostatectomy specimens. BJU International, 2013, 112, E301-6.	2.5	7
540	Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral <scp>PDE5</scp> inhibitor Tadalafil therapy, in men with nerveâ€”sparing radical prostatectomy erectile dysfunction. BJU International, 2013, 112, E169-76.	2.5	32
541	Cautious Optimism for Extreme Dose Escalation in Prostate Cancer. European Urology, 2013, 64, 939-940.	1.9	1
542	Management of sexual problems in cancer patients and survivors. Current Problems in Cancer, 2013, 37, 319-352.	2.0	34
543	Quality of Life and Toxicity From Passively Scattered and Spot-Scanning Proton Beam Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 946-953.	0.8	38
544	Predictors of Pathological Progression among Men with Localized Prostate Cancer Undergoing Active Surveillance: a Sub-Analysis of the REDEEM Study. Journal of Urology, 2013, 190, 2039-2046.	0.4	13
545	Diagnostic and Outcome Differences Between Heterosexual and Nonheterosexual Men Treated for Prostate Cancer. Urology, 2013, 82, 565-571.	1.0	91
546	Editorial Comment. Urology, 2013, 81, 368-369.	1.0	0

#	ARTICLE	IF	CITATIONS
547	Quality of life impact of treatments for localized prostate cancer: Cohort study with a 5year follow-up. Radiotherapy and Oncology, 2013, 108, 306-313.	0.6	72
548	Focal Therapy for Prostate Cancer: Rationale and Treatment Opportunities. Clinical Oncology, 2013, 25, 461-473.	1.4	45
549	Exercise therapy for sexual dysfunction after prostate cancer. Nature Reviews Urology, 2013, 10, 731-736.	3.8	35
550	Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer. New England Journal of Medicine, 2013, 369, 1629-1637.	27.0	127
552	Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort. Journal of Clinical Oncology, 2013, 31, 1428-1434.	1.6	323
553	A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy. European Urology, 2013, 64, 895-902.	1.9	334
554	A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study. Contemporary Clinical Trials, 2013, 36, 68-80.	1.8	67
555	Inherently Multimodal Nanoparticle-Driven Tracking and Real-Time Delineation of Orthotopic Prostate Tumors and Micrometastases. ACS Nano, 2013, 7, 4221-4232.	14.6	101
556	Early Detection, PSA Screening, and Management of Overdiagnosis. Hematology/Oncology Clinics of North America, 2013, 27, 1091-1110.	2.2	9
557	Long-term Outcomes and Toxicity in Patients Treated With Brachytherapy for Prostate Adenocarcinoma Younger Than 60 Years of Age at Treatment With Minimum 10 Years of Follow-up. Urology, 2013, 81, 364-369.	1.0	31
558	A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiation Oncology, 2013, 8, 206.	2.7	48
559	Reporting and grading of complications after urologic surgical procedures: An ad hoc EAU guidelines panel assessment and recommendations. Actas Urológicas Españolas (English Edition), 2013, 37, 1-11.	0.2	11
560	Multi-institutional Prospective Evaluation of Bowel Quality of Life After Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated With Patient-Reported Outcomes: The PROSTQA Experience. International Journal of Radiation Oncology Biology Physics, 2013, 86, 546-553.	0.8	36
561	Prostate Cancer Chemoprevention. Seminars in Oncology, 2013, 40, 276-285.	2.2	23
562	Management of erectile dysfunction in men treated with androgen deprivation therapy. Trends in Urology & Men's Health, 2013, 4, 13-18.	0.4	3
563	The effects of multidisciplinary rehabilitation: RePCA—a randomised study among primary prostate cancer patients. British Journal of Cancer, 2013, 109, 3005-3013.	6.4	41
564	Does a surgeon's annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? - Findings from a prospective national study. Scandinavian Journal of Urology, 2013, 47, 92-100.	1.0	25
565	Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy. International Journal of Urology, 2013, 20, 185-192.	1.0	19

#	ARTICLE	IF	CITATIONS
566	Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy. International Journal of Urology, 2013, 20, 413-419.	1.0	21
567	Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (<scp>CaPSURE</scp>). BJU International, 2013, 111, 213-220.	2.5	34
568	Uncertainty and perception of danger among patients undergoing treatment for prostate cancer. BJU International, 2013, 111, E84-91.	2.5	23
569	Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncology, The, 2013, 14, e524-e534.	10.7	42
570	Effect of information seeking and avoidance behavior on self-rated health status among cancer survivors. Patient Education and Counseling, 2013, 92, 100-106.	2.2	51
571	Multidisciplinary Care and Management Selection in Prostate Cancer. Seminars in Radiation Oncology, 2013, 23, 157-164.	2.2	30
572	Quality of life among prostate cancer patients: A prospective longitudinal population-based study. Radiotherapy and Oncology, 2013, 108, 299-305.	0.6	16
573	Neoadjuvant Androgen Deprivation Therapy Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multicenter Prospective Study. Urology, 2013, 82, 1363-1369.	1.0	20
574	Health-Related Quality of Life After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Results From a Multi-institutional Consortium of Prospective Trials. International Journal of Radiation Oncology Biology Physics, 2013, 87, 939-945.	0.8	173
576	Re: Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort. Journal of Urology, 2013, 190, 1245-1247.	0.4	1
577	Radiation Therapy for Prostate Cancer. Surgical Oncology Clinics of North America, 2013, 22, 483-494.	1.5	1
578	Risk of Incisional Hernia after Minimally Invasive and Open Radical Prostatectomy. Journal of Urology, 2013, 190, 1757-1762.	0.4	16
579	Lifestyle Factors Correlate with the Risk of Late Pelvic Symptoms after Prostatic Radiotherapy. Clinical Oncology, 2013, 25, 246-251.	1.4	34
581	Patient-health care provider communication among patients with newly diagnosed prostate cancer: Findings from a population-based survey. Patient Education and Counseling, 2013, 91, 79-84.	2.2	21
583	Actualizaci3n en c3ncer de pr3stata. Medicine, 2013, 11, 1578-1587.	0.0	1
584	Influence of Preoperative and Postoperative Pelvic Floor Muscle Training (PFMT) Compared with Postoperative PFMT on Urinary Incontinence After Radical Prostatectomy: A Randomized Controlled Trial. European Urology, 2013, 64, 766-772.	1.9	86
585	Proton beam and prostate cancer: An evolving debate. Reports of Practical Oncology and Radiotherapy, 2013, 18, 338-342.	0.6	19
586	Bother problems in prostate cancer patients after curative treatment. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1067-1078.	1.6	22

#	ARTICLE	IF	CITATIONS
587	Trends in the Use of Incontinence Procedures After Radical Prostatectomy: A Population Based Analysis. <i>Journal of Urology</i> , 2013, 189, 602-608.	0.4	102
588	Health-related quality of life for men with prostate cancer—an evaluation of outcomes 12–24 months after treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1504-1510.	1.6	23
589	Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care?. <i>Cancer Treatment Reviews</i> , 2013, 39, 212-218.	7.7	36
590	Contemporary Issues in Radiotherapy for Clinically Localized Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1137-1162.	2.2	4
591	Effect of a Risk-stratified Grade of Nerve-sparing Technique on Early Return of Continence After Robot-assisted Laparoscopic Radical Prostatectomy. <i>European Urology</i> , 2013, 63, 438-444.	1.9	102
592	Long-term Distress After Radical Prostatectomy Versus Watchful Waiting in Prostate Cancer: A Longitudinal Study from the Scandinavian Prostate Cancer Group-4 Randomized Clinical Trial. <i>European Urology</i> , 2013, 64, 920-928.	1.9	73
593	The Burden of Urinary Incontinence and Urinary Bother Among Elderly Prostate Cancer Survivors. <i>European Urology</i> , 2013, 64, 672-679.	1.9	28
594	Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment. <i>Brachytherapy</i> , 2013, 12, 434-441.	0.5	25
595	Men with Low Preoperative Sexual Function May Benefit from Nerve Sparing Radical Prostatectomy. <i>Journal of Urology</i> , 2013, 190, 981-986.	0.4	34
596	Short-term Androgen-Deprivation Therapy Improves Prostate Cancer-Specific Mortality in Intermediate-Risk Prostate Cancer Patients Undergoing Dose-Escalated External Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1012-1017.	0.8	55
597	Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. <i>European Urology</i> , 2013, 64, 372-378.	1.9	71
599	Laparoscopic Prostatectomy for Prostate Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 125-141.	1.5	9
600	A Prospective Study of Transition From Laparoscopic to Robot-assisted Radical Prostatectomy: Quality of Life Outcomes After 36-Month Follow-up. <i>Urology</i> , 2013, 81, 781-786.	1.0	39
601	Preliminary Toxicity Analysis of 3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy on the High-Dose Arm of the Radiation Therapy Oncology Group 0126 Prostate Cancer Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 932-938.	0.8	255
602	Clinical Implementation of Quality of Life Instruments and Prediction Tools for Localized Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. <i>Journal of Urology</i> , 2013, 189, 2092-2098.	0.4	42
603	Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. <i>Practical Radiation Oncology</i> , 2013, 3, 138-144.	2.1	19
604	Patient Demographics, Quality of Life, and Disease Features of Men With Newly Diagnosed Prostate Cancer: Trends in the PSA Era. <i>Urology</i> , 2013, 82, 60-66.	1.0	26
605	Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes. <i>Radiotherapy and Oncology</i> , 2013, 107, 153-158.	0.6	156

#	ARTICLE	IF	CITATIONS
606	Surgeon Variation in Patient Quality of Life After Radical Prostatectomy. <i>Journal of Urology</i> , 2013, 189, 1295-1301.	0.4	12
607	Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 170-175.	3.9	90
608	Prostate cancer screening and the management of clinically localized disease. <i>BMJ, The</i> , 2013, 346, f325-f325.	6.0	73
609	A phase II study of hypofractionated proton therapy for prostate cancer. <i>Acta OncolÃ³gica</i> , 2013, 52, 477-485.	1.8	30
610	Obesity and Prostate Cancer: Weighing the Evidence. <i>European Urology</i> , 2013, 63, 800-809.	1.9	458
611	Pelvic Radiotherapy and Sexual Function in Men and Women. <i>Journal of Sexual Medicine</i> , 2013, 10, 53-64.	0.6	70
612	Active Surveillance of Very-low-risk Prostate Cancer in the Setting of Active Treatment of Benign Prostatic Hyperplasia With 5 α -reductase Inhibitors. <i>Urology</i> , 2013, 81, 979-985.	1.0	19
613	5-Alpha Reductase Inhibitors in Patients on Active Surveillance: Do the Benefits Outweigh the Risk?. <i>Current Urology Reports</i> , 2013, 14, 223-226.	2.2	0
614	MR Imaging of Prostate Cancer in Radiation Oncology: What Radiologists Need to Know. <i>Radiographics</i> , 2013, 33, 741-761.	3.3	46
615	Purple corn color inhibition of prostate carcinogenesis by targeting cell growth pathways. <i>Cancer Science</i> , 2013, 104, 298-303.	3.9	42
616	For which health problems do cancer survivors visit their General Practitioner?. <i>European Journal of Cancer</i> , 2013, 49, 211-218.	2.8	62
617	Long-Term Satisfaction and Predictors of Use of Intracorporeal Injections for Post-Prostatectomy Erectile Dysfunction. <i>Journal of Urology</i> , 2013, 189, 238-242.	0.4	15
618	Prospective evaluation of quality of life 54Âmonths after high-dose intensity-modulated radiotherapy for localized prostate cancer. <i>Radiation Oncology</i> , 2013, 8, 53.	2.7	16
620	Effect of an Adipose-Derived Stem Cell and Nerve Growth Factor-Incorporated Hydrogel on Recovery of Erectile Function in a Rat Model of Cavernous Nerve Injury. <i>Tissue Engineering - Part A</i> , 2013, 19, 14-23.	3.1	49
621	Differing Perceptions of Quality of Life in Patients With Prostate Cancer and Their Doctors. <i>Journal of Urology</i> , 2013, 189, S59-65; discussion S65.	0.4	62
622	MR Imagingâ€“guided Focal Laser Ablation for Prostate Cancer: Phase I Trial. <i>Radiology</i> , 2013, 267, 932-940.	7.3	178
623	Perspectives on knowledge, information seeking and decision-making behaviour about prostate cancer among Australian men. <i>Journal of Men's Health</i> , 2013, , .	0.3	1
624	Prostate Cancer and the Increasing Role of Active Surveillance. <i>Postgraduate Medicine</i> , 2013, 125, 109-116.	2.0	7

#	ARTICLE	IF	CITATIONS
626	Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials. <i>Acta Oncol</i> ³ <i>gica</i> , 2013, 52, 463-469.	1.8	17
627	Outcomes in men with large prostates (â‰¥ 60 cm ³) treated with definitive proton therapy for prostate cancer. <i>Acta Oncol</i> ³ <i>gica</i> , 2013, 52, 470-476.	1.8	10
628	A One-Day Couple Group Intervention to Enhance Sexual Recovery For Surgically Treated Men with Prostate Cancer and Their Partners: A Pilot Study. <i>Urologic Nursing</i> , 2013, 33, 140.	0.1	29
629	Impact of Obesity on Cancer Survivorship and the Potential Relevance of Race and Ethnicity. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1344-1354.	6.3	118
630	Partnersâ€™ Long-term Appraisal of Their Caregiving Experience, Marital Satisfaction, Sexual Satisfaction, and Quality of Life 2 Years After Prostate Cancer Treatment. <i>Cancer Nursing</i> , 2013, 36, 104-113.	1.5	37
631	Anatomic and technical considerations for optimizing recovery of sexual function during robotic-assisted radical prostatectomy. <i>Current Opinion in Urology</i> , 2013, 23, 88-94.	1.8	22
632	High-risk prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 349-354.	1.8	14
633	Comparative Effectiveness of Intensity-Modulated Radiotherapy and Conventional Conformal Radiotherapy in the Treatment of Prostate Cancer After Radical Prostatectomy. <i>JAMA Internal Medicine</i> , 2013, 173, 1136.	5.1	40
634	Survivorship After Prostate Cancer Treatment: Spouses' Quality of Life at 36 Months. <i>Oncology Nursing Forum</i> , 2013, 40, 567-573.	1.2	29
635	Improving Accuracy in Image-Guided Prostate Biopsy by Using Trocar-Sharpended Needles. <i>Urologia Internationalis</i> , 2013, 91, 404-409.	1.3	4
636	Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma. <i>BJU International</i> , 2013, 111, E43-7.	2.5	9
637	Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: a systematic review. <i>Canadian Urological Association Journal</i> , 2013, 7, 463.	0.6	20
638	A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy. <i>BJU International</i> , 2013, 111, 905-913.	2.5	16
639	Determinants of the combined use of external beam radiotherapy and brachytherapy for low-risk, clinically localized prostate cancer. <i>Cancer</i> , 2013, 119, 3619-3628.	4.1	5
640	Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: A study of adverse effects and their relation to quality of life. <i>Prostate</i> , 2013, 73, 1038-1047.	2.3	16
641	Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent postoperative sexual dysfunction. <i>Andrology</i> , 2013, 1, 256-261.	3.5	25
642	Study of generic quality of life in patients operated on for postprostatectomy incontinence. <i>International Journal of Urology</i> , 2013, 20, 889-895.	1.0	13
643	Do cancer and treatment type affect distress?. <i>Psycho-Oncology</i> , 2013, 22, 1766-1773.	2.3	49

#	ARTICLE	IF	CITATIONS
644	Erectile Function Following Prostate Cancer Treatment: Factors Predicting Recovery. Sexual Medicine Reviews, 2013, 1, 91-103.	2.9	5
645	Interview-Based Versus Questionnaire-Based Quality of Life Outcomes Before and After Prostatectomy. Journal of Endourology, 2013, 27, 1411-1416.	2.1	27
646	Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer, 2013, 119, 1729-1735.	4.1	83
647	A randomised, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 81-88.	1.8	28
648	Patient and spouse illness beliefs and quality of life in prostate cancer patients. Psychology and Health, 2013, 28, 355-368.	2.2	32
649	Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer. New England Journal of Medicine, 2013, 368, 436-445.	27.0	803
650	Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. Expert Review of Medical Devices, 2013, 10, 751-763.	2.8	8
651	Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey. Prostate Cancer and Prostatic Diseases, 2013, 16, 341-345.	3.9	13
652	Proton beam therapy and localised prostate cancer: current status and controversies. British Journal of Cancer, 2013, 108, 1225-1230.	6.4	35
653	Measuring symptoms in localized prostate cancer: a systematic review of assessment instruments. Prostate Cancer and Prostatic Diseases, 2013, 16, 111-122.	3.9	41
654	Robotic and standard open radical prostatectomy: oncological and quality-of-life outcomes. Journal of Comparative Effectiveness Research, 2013, 2, 293-299.	1.4	13
655	â€˜Trifectaâ€™ after radical prostatectomy: is there a standard definition?. BJU International, 2013, 112, 60-67.	2.5	35
656	Development of transrectal diffuse optical tomography combined with 3D-transrectal ultrasound imaging to monitor the photocoagulation front during interstitial photothermal therapy of primary focal prostate cancer. , 2013, , .		2
657	Potency preservation following stereotactic body radiation therapy for prostate cancer. Radiation Oncology, 2013, 8, 256.	2.7	27
659	The Impact of Technology Diffusion on Treatment for Prostate Cancer. Medical Care, 2013, 51, 1076-1084.	2.4	12
660	Focal low-dose rate brachytherapy for the treatment of prostate cancer. Cancer Management and Research, 2013, 5, 315.	1.9	5
661	Models of Care and NCCN Guideline Adherence in Very-Low-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1364-1372.	4.9	15
662	Focal Therapy and the Index Lesion Hypothesis in Prostate Cancer. Medical Radiology, 2013, , 173-183.	0.1	0

#	ARTICLE	IF	CITATIONS
663	Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer. Canadian Urological Association Journal, 2013, 7, 411.	0.6	10
664	Changes in health utilities and health-related quality of life over 12 months following radical prostatectomy. Canadian Urological Association Journal, 2013, 3, 445.	0.6	16
665	Should we screen for prostate cancer? A re-examination of the evidence. Medical Journal of Australia, 2013, 198, 525-527.	1.7	14
666	The Role of Active Surveillance in the Management of Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 183-187.	4.9	10
667	Focal therapy for localized prostate cancer – choosing the middle ground. Canadian Urological Association Journal, 2013, 3, 333.	0.6	13
668	Functional Outcomes and Long-term Durability of Artificial Urinary Sphincter Application: Review of 56 Patients With Long-term Follow-up. Korean Journal of Urology, 2013, 54, 373.	1.2	12
669	The Treatment of Iatrogenic Male Incontinence: Latest Results and Future Perspectives. Reviews on Recent Clinical Trials, 2013, 8, 36-41.	0.8	7
670	Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer. Canadian Urological Association Journal, 2013, 4, 105.	0.6	13
671	Overall- and Disease-Specific Survival in Prostate Cancer: Too Long to Wait?. Medical Radiology, 2013, , 65-73.	0.1	1
672	The Prostate Cancer Intervention Versus Observation Trial (PIVOT) in Perspective. Journal of Clinical Medicine Research, 2013, 5, 266-8.	1.2	5
673	Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction. World Journal of Men's Health, 2013, 31, 83.	3.3	29
674	Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. Canadian Urological Association Journal, 2013, 5, 156.	0.6	0
675	The effect of nerve-sparing surgery on patient-reported continence post-radical prostatectomy. Canadian Urological Association Journal, 2013, 3, 465.	0.6	13
677	Charlson Comorbidity Index Is an Important Prognostic Factor for Long-Term Survival Outcomes in Korean Men with Prostate Cancer after Radical Prostatectomy. Yonsei Medical Journal, 2014, 55, 316.	2.2	22
678	Caring for Alaska Native prostate cancer survivors in primary care: a survey of Alaska Tribal Health System providers. International Journal of Circumpolar Health, 2014, 73, 23637.	1.2	3
680	A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men. BioMed Research International, 2014, 2014, 1-8.	1.9	14
681	Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies. Therapeutics and Clinical Risk Management, 2014, 10, 651.	2.0	6
682	Impact of trait anxiety on psychological well-being in men with prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 620-626.	1.5	14

#	ARTICLE	IF	CITATIONS
683	Prospective comparison of the impact of robotic-assisted laparoscopic radical prostatectomy versus open radical prostatectomy on health-related quality of life and decision regret. Canadian Urological Association Journal, 2014, 8, 68.	0.6	25
684	Quality of life in patients with prostate cancer treated with radical image-guided radiotherapy. Wspolczesna Onkologia, 2014, 4, 285-289.	1.4	1
687	Laparoscopic Radical Prostatectomy Monotherapy, a More Aggressive Yet Less Invasive Option, Is Oncologically Effective in Selected Men with High-Risk Prostate Cancer Having Only One D'Amico Risk Factor: Experience from an Asian Tertiary Referral Center. Journal of Endourology, 2014, 28, 165-171.	2.1	6
688	Effectiveness of preoperative pelvic floor muscle training for urinary incontinence after radical prostatectomy: a meta-analysis. BMC Urology, 2014, 14, 99.	1.4	45
689	Proctitis following stereotactic body radiation therapy for prostate cancer. Radiation Oncology, 2014, 9, 277.	2.7	26
690	Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm ³). Radiation Oncology, 2014, 9, 241.	2.7	41
691	Progress and controversies: Radiation therapy for prostate cancer. Ca-A Cancer Journal for Clinicians, 2014, 64, 389-407.	329.8	44
692	Implementation of PSA-based active surveillance in prostate cancer. Biomarkers in Medicine, 2014, 8, 747-753.	1.4	4
693	Impact of comorbidity on health-related quality of life after prostate cancer treatment: combined analysis of two prospective cohort studies. BJU International, 2014, 114, E74-E81.	2.5	27
694	Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer and Prostatic Diseases, 2014, 17, 163-169.	3.9	31
695	Development of clinical models for predicting erectile function after localized prostate cancer treatment. International Journal of Urology, 2014, 21, 1227-1233.	1.0	12
696	Quality of Life and Sexual Health in the Aging of PCa Survivors. International Journal of Endocrinology, 2014, 2014, 1-16.	1.5	13
697	Impact on quality of life of radical prostatectomy after initial active surveillance: more to lose?. Scandinavian Journal of Urology, 2014, 48, 367-373.	1.0	12
698	The effects of retropubic and perineal radical prostatectomy techniques on postoperative urinary continence after surgery: Results of 196 patients. Turk Uroloji Dergisi, 2014, 39, 147-152.	0.4	3
699	Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer. Frontiers in Oncology, 2014, 4, 290.	2.8	13
700	Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. Cancer, 2014, 120, 3642-3650.	4.1	48
701	Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer, 2014, 2014, 1-6.	0.6	13
702	Urinary Continence Outcomes after Puboprostatic Ligament Preserving Open Retropubic Radical Prostatectomy at a Sub-Saharan Hospital. International Scholarly Research Notices, 2014, 2014, 1-4.	0.9	3

#	ARTICLE	IF	CITATIONS
703	Overtreatment of men with early-stage prostate cancer and limited life expectancy. <i>Cancer</i> , 2014, 120, 3592-3594.	4.1	2
704	Molecular markers to guide primary radical treatment selection in localized prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 871-881.	3.1	5
705	Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study. <i>Prostate Cancer</i> , 2014, 2014, 1-8.	0.6	16
706	Suicidal ideation in prostate cancer survivors: Understanding the role of physical and psychological health outcomes. <i>Cancer</i> , 2014, 120, 3393-3400.	4.1	49
707	Failure to address potential bias in non-randomised controlled clinical trials may cause lack of evidence on patient-reported outcomes: a method study. <i>BMJ Open</i> , 2014, 4, e004720-e004720.	1.9	9
708	PROSPECTIVâ€”a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial: TableÂ1. <i>BMJ Open</i> , 2014, 4, e005186.	1.9	10
709	Intensity-Modulated Radiation Therapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 679-680.	27.0	5
710	Localized diseaseâ€”are most men really suitable for focal therapy?. <i>Nature Reviews Urology</i> , 2014, 11, 7-8.	3.8	1
711	Patient-reported outcomes after prostate cancer treatment. <i>Journal of Clinical Urology</i> , 2014, 7, 286-294.	0.1	1
712	Robotic and minimal access surgery: technology and surgical outcomes of radical prostatectomy for prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1317-1321.	2.4	7
713	Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 39-50.	2.4	14
714	Prognostic significance of YWHAZ expression in localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 310-314.	3.9	23
715	Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy. <i>International Journal of Impotence Research</i> , 2014, 26, 201-204.	1.8	10
716	Comprehensive Analysis of Sexual Function Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy. <i>Journal of Endourology</i> , 2014, 28, 172-177.	2.1	20
717	Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. <i>BJU International</i> , 2014, 113, 200-208.	2.5	61
718	Comparative effectiveness study of patientâ€”reported outcomes after proton therapy or intensityâ€”modulated radiotherapy for prostate cancer. <i>Cancer</i> , 2014, 120, 1076-1082.	4.1	82
719	Interstitial rotating shield brachytherapy for prostate cancer. <i>Medical Physics</i> , 2014, 41, 051703.	3.0	30
720	Quality of Life in Patients with Low-Risk Prostate Cancer. A Comparative Retrospective Study: Brachytherapy Versus Robot-Assisted Laparoscopic Prostatectomy Versus Active Surveillance. <i>Journal of Endourology</i> , 2014, 28, 117-124.	2.1	33

#	ARTICLE	IF	CITATIONS
721	Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis. <i>Cancer</i> , 2014, 120, 2432-2439.	4.1	21
722	Objective Assessment of Residual Nerve Tissues in Radical Prostatectomy Specimens by Immunohistochemical Staining of Neuronal Nitric Oxide Synthase-positive Nerves and Its Impact on Postoperative Erectile Function. <i>Urology</i> , 2014, 84, 1395-1401.	1.0	6
723	Reply. <i>Urology</i> , 2014, 84, 1388.	1.0	0
724	Reduced Radiation Tolerance of Penile Structures Associated With Dose-escalated Hypofractionated Prostate Radiotherapy. <i>Urology</i> , 2014, 84, 1383-1388.	1.0	19
725	Editorial Comment. <i>Urology</i> , 2014, 84, 1400-1401.	1.0	0
726	Prospective analysis of penile length changes after radical prostatectomy. <i>BJU International</i> , 2014, 113, E131-6.	2.5	36
727	Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: Baseline results from a shared decision-making trial. <i>Cancer</i> , 2014, 120, 2721-2727.	4.1	49
728	Editorial Comment to Health-related quality of life after carbon-ion radiotherapy for prostate cancer: A 3-year prospective study. <i>International Journal of Urology</i> , 2014, 21, 375-376.	1.0	0
729	Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. <i>Cancer</i> , 2014, 120, 1263-1271.	4.1	38
730	Editorial Comment. <i>Urology</i> , 2014, 84, 1387-1388.	1.0	0
731	Editorial Comment to Transurethral resection of the prostate after radiotherapy for prostate cancer: Impact on quality of life. <i>International Journal of Urology</i> , 2014, 21, 904-904.	1.0	1
732	Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. <i>Cancer Medicine</i> , 2014, 3, 954-961.	2.8	18
733	Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 1223-1229.	3.4	3
735	A multicomponent theory-based intervention improves uptake of pelvic floor muscle training before radical prostatectomy: a "before and after" cohort study. <i>BJU International</i> , 2014, 113, 383-392.	2.5	14
736	Effects of a dietary intervention on gastrointestinal symptoms after prostate cancer radiotherapy: Long-term results from a randomized controlled trial. <i>Radiotherapy and Oncology</i> , 2014, 113, 240-247.	0.6	19
737	Prostate cancer screening comes of age. <i>Lancet, The</i> , 2014, 384, 2004-2006.	13.7	13
738	Erectile Function Outcomes after Robot-Assisted Radical Prostatectomy: Is It Superior to Open Retropubic or Laparoscopic Approach?. <i>Sexual Medicine Reviews</i> , 2014, 2, 10-23.	2.9	10
739	Functional and Oncologic Outcomes of Graded Bladder Neck Preservation During Robot-Assisted Radical Prostatectomy. <i>Journal of Endourology</i> , 2014, 28, 48-55.	2.1	29

#	ARTICLE	IF	CITATIONS
740	Tadalafil for Erectile Dysfunction Prevention After Radiotherapy for Prostate Cancer—Reply. JAMA - Journal of the American Medical Association, 2014, 312, 748.	7.4	1
741	Stereotactic Body Radiation Therapy for Prostate Cancer: The Need to Assess Patient-Reported Outcomes. Journal of Clinical Oncology, 2014, 32, 3456-3456.	1.6	2
742	Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy. International Journal of Clinical Oncology, 2014, 19, 793-799.	2.2	5
743	Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial. BMC Surgery, 2014, 14, 89.	1.3	40
744	Overdetection in screening for prostate cancer. Current Opinion in Urology, 2014, 24, 256-263.	1.8	36
745	ECONOMIC EVALUATION OF DIAGNOSTIC LOCALIZATION FOLLOWING BIOCHEMICAL PROSTATE CANCER RECURRENCE. International Journal of Technology Assessment in Health Care, 2014, 30, 345-353.	0.5	3
746	From the Guest Editor. Cancer Journal (Sudbury, Mass), 2014, 20, 369-370.	2.0	2
747	5-Alpha-reductase inhibitors in diseases of the prostate. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 488-492.	2.3	3
748	ACR Appropriateness Criteria® Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 278-288.	1.3	13
749	Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis. Journal of Radiation Research, 2014, 55, 1033-1047.	1.6	26
750	Late Urinary Symptom Flare After Prostate Stereotactic Body Radiation Therapy. Journal of Clinical Oncology, 2014, 32, 3451-3452.	1.6	8
751	Spacer application for prostate cancer radiation therapy. Future Oncology, 2014, 10, 851-864.	2.4	19
752	Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery. The Cochrane Library, 2014, , CD008306.	2.8	31
753	Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer. JAMA - Journal of the American Medical Association, 2014, 311, 1300.	7.4	55
754	Physician Variation in Management of Low-Risk Prostate Cancer. JAMA Internal Medicine, 2014, 174, 1450.	5.1	104
756	Tadalafil for Erectile Dysfunction Prevention After Radiotherapy for Prostate Cancer. JAMA - Journal of the American Medical Association, 2014, 312, 748.	7.4	1
757	Focusing PSA Testing on Detection of High-Risk Prostate Cancers by Incorporating Patient Preferences Into Decision Making. JAMA - Journal of the American Medical Association, 2014, 312, 995.	7.4	34
758	Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiation Oncology, 2014, 9, 1.	2.7	121

#	ARTICLE	IF	CITATIONS
759	Quality of life and satisfaction with information after radical prostatectomy, radical external beam radiotherapy and postoperative radiotherapy: a long-term follow-up study. <i>Journal of Clinical Nursing</i> , 2014, 23, 3403-3414.	3.0	21
760	The status of surgery in the management of high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 342-351.	3.8	34
761	User-centered design of quality of life reports for clinical care of patients with prostate cancer. <i>Surgery</i> , 2014, 155, 789-796.	1.9	43
762	Long-term Continence Outcomes in Men Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. <i>European Urology</i> , 2014, 65, 52-57.	1.9	56
763	Population-Based Referrals for Adjuvant Radiotherapy After Radical Prostatectomy in Men With Prostate Cancer: Impact of Randomized Trials. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e1-e5.	1.9	13
764	Localized Prostate Cancer in Norway, the United States, and Spain: Between-Country Differences of Variables Before Treatment Among Patients Eligible for Curative Treatment. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e117-e125.	1.9	9
765	Treatment and 5-Year Survival in Patients With Nonmetastatic Prostate Cancer: The Norwegian Experience. <i>Urology</i> , 2014, 83, 146-153.	1.0	22
766	Satisfaction with Information Used to Choose Prostate Cancer Treatment. <i>Journal of Urology</i> , 2014, 191, 1265-1271.	0.4	23
767	The Quadrella: A Novel Approach in Analyzing Optimal Outcomes after Permanent Seed Prostate Brachytherapy. <i>Brachytherapy</i> , 2014, 13, S125.	0.5	0
768	The Quadrella: A novel approach to analyzing optimal outcomes after permanent seed prostate brachytherapy. <i>Radiotherapy and Oncology</i> , 2014, 111, 110-113.	0.6	5
769	High dose rate brachytherapy boost for prostate cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2014, 40, 414-425.	7.7	57
770	MP58-11 NIGHTLY SILDENAFIL USE AFTER RADICAL PROSTATECTOMY HAS ADVERSE EFFECTS ON URINARY CONVALESCENCE: RESULTS FROM A RANDOMIZED TRIAL OF NIGHTLY VS ON-DEMAND DOSING REGIMENS. <i>Journal of Urology</i> , 2014, 191, .	0.4	0
771	Measuring and Predicting Prostate Cancer Related Quality of Life Changes Using EPIC for Clinical Practice. <i>Journal of Urology</i> , 2014, 191, 638-645.	0.4	62
772	Robot-assisted laparoscopic radical prostatectomy after previous open transvesical adenomectomy. <i>Journal of Robotic Surgery</i> , 2014, 8, 85-88.	1.8	1
773	Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival. <i>World Journal of Urology</i> , 2014, 32, 475-479.	2.2	51
774	The effect of meeting physical activity guidelines for cancer survivors on quality of life following radical prostatectomy for prostate cancer. <i>Journal of Cancer Survivorship</i> , 2014, 8, 190-198.	2.9	41
775	Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer. <i>Quality of Life Research</i> , 2014, 23, 1641-1650.	3.1	9
776	Role of transrectal ultrasound in the diagnosis of extracapsular prostate cancer. <i>Journal of Ultrasound</i> , 2014, 17, 47-51.	1.3	0

#	ARTICLE	IF	CITATIONS
777	Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. <i>Radiation Oncology</i> , 2014, 9, 52.	2.7	47
778	Impact of Charlson Comorbidity Index Varies by Age in Patients with Prostate Cancer Treated by Radical Prostatectomy: A Competing Risk Regression Analysis. <i>Annals of Surgical Oncology</i> , 2014, 21, 677-683.	1.5	13
779	Are there specific health-related factors that can accentuate the risk of suicide among men with prostate cancer?. <i>Supportive Care in Cancer</i> , 2014, 22, 1673-1678.	2.2	11
780	Five-year potency preservation after iodine-125 prostate brachytherapy. <i>International Journal of Clinical Oncology</i> , 2014, 19, 940-945.	2.2	13
781	Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 932-942.	27.0	825
782	Importancia de la rehabilitaci3n precoz de los cuerpos cavernosos tras prostatectom3a radical. <i>Revista Internacional De Androlog3a</i> , 2014, 12, 4-9.	0.3	4
783	Addressing overdiagnosis and overtreatment in cancer: a prescription for change. <i>Lancet Oncology</i> , The, 2014, 15, e234-e242.	10.7	423
784	Do Margins Matter? The Influence of Positive Surgical Margins on Prostate Cancer39Specific Mortality. <i>European Urology</i> , 2014, 65, 675-680.	1.9	77
785	Radical Prostatectomy. , 2014, , .		4
786	Abdomen and Thoracic Imaging. , 2014, , .		5
787	Concept and viability of androgen annihilation for advanced prostate cancer. <i>Cancer</i> , 2014, 120, 2628-2637.	4.1	16
788	Patient-reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II). <i>British Journal of Surgery</i> , 2014, 101, 1272-1279.	0.3	113
789	Using patient39reported outcomes to assess and improve prostate cancer brachytherapy. <i>BJU International</i> , 2014, 114, 511-516.	2.5	14
790	Results of a cohort of 200 hormone-na3ve consecutive patients with prostate cancer treated with iodine 125 permanent interstitial brachytherapy by the same multidisciplinary team. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2014, 18, 643-648.	1.4	6
791	Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up. <i>Acta Oncol3gica</i> , 2014, 53, 1380-1389.	1.8	10
792	American Cancer Society prostate cancer survivorship care guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 225-249.	329.8	324
793	National Prostate Cancer Registries: Contemporary Trends of Prostate Cancer in the United States. <i>Urology Practice</i> , 2014, 1, 198-204.	0.5	4
795	Expected population impacts of discontinued prostate3specific antigen screening. <i>Cancer</i> , 2014, 120, 3519-3526.	4.1	90

#	ARTICLE	IF	CITATIONS
796	Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials. Journal of the National Cancer Institute, 2014, 106, .	6.3	83
797	Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy. Radiotherapy and Oncology, 2014, 112, 83-88.	0.6	32
798	Physician Social Networks and Variation in Rates of Complications After Radical Prostatectomy. Value in Health, 2014, 17, 611-618.	0.3	39
800	The Association of Long-term Treatment-related Side Effects With Cancer-specific and General Quality of Life Among Prostate Cancer Survivors. Urology, 2014, 84, 300-306.	1.0	53
801	Re: Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer: The Radiation Therapy Oncology Group [0831] Randomized Clinical Trial. European Urology, 2014, 66, 594-595.	1.9	0
802	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, The, 2014, 384, 2027-2035.	13.7	1,261
803	A decade of progress in detection and treatment. Nature Reviews Urology, 2014, 11, 618-620.	3.8	1
804	Future directions in the prevention of prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 49-60.	27.6	42
805	Prostate cancer outcomes in France: treatments, adverse effects and two-year mortality. BMC Urology, 2014, 14, 48.	1.4	14
806	Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiation Oncology, 2014, 9, 148.	2.7	24
807	Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. Radiation Oncology, 2014, 9, 163.	2.7	26
808	Urinary Incontinence and Prostate Cancer: A Progressive Rehabilitation Program Design. Rehabilitation Nursing, 2014, 39, 271-280.	0.5	13
809	Item response theory analysis of the patient satisfaction with cancer-related care measure: a psychometric investigation in a multicultural sample of 1,296 participants. Supportive Care in Cancer, 2014, 22, 2229-2240.	2.2	12
810	Exploring the role of the partner in couples' sexual recovery after surgery for prostate cancer. Supportive Care in Cancer, 2014, 22, 2509-2515.	2.2	75
811	Health-related quality of life following radical prostatectomy: long-term outcomes. Quality of Life Research, 2014, 23, 2309-2317.	3.1	22
812	Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments. Quality of Life Research, 2014, 23, 2169-2181.	3.1	56
813	Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation. Medical Oncology, 2014, 31, 991.	2.5	6
814	Improving sexual health in men with prostate cancer: randomised controlled trial of exercise and psychosexual therapies. BMC Cancer, 2014, 14, 199.	2.6	22

#	ARTICLE	IF	CITATIONS
815	Effects of surgeon variability on oncologic and functional outcomes in a population-based setting. BMC Urology, 2014, 14, 25.	1.4	20
816	Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity. Radiation Oncology, 2014, 9, 102.	2.7	49
817	New concepts concerning prostate cancer screening. Experimental Biology and Medicine, 2014, 239, 793-804.	2.4	3
818	Long-term erectile function following permanent seed brachytherapy treatment for localized prostate cancer. Radiotherapy and Oncology, 2014, 112, 72-76.	0.6	18
819	Radical Prostatectomy Improves and Prevents Age Dependent Progression of Lower Urinary Tract Symptoms. Journal of Urology, 2014, 191, 412-417.	0.4	31
820	Combined Effects of Brain-Derived Neurotrophic Factor Immobilized Poly-Lactic-Co-Glycolic Acid Membrane with Human Adipose-Derived Stem Cells and Basic Fibroblast Growth Factor Hydrogel on Recovery of Erectile Dysfunction. Tissue Engineering - Part A, 2014, 20, 2446-2454.	3.1	31
821	MP53-06 MAGNETIC RESONANCE IMAGING DETECTED PROSTATE EVASIVE ANTERIOR TUMORS: FURTHER INSIGHTS. Journal of Urology, 2014, 191, .	0.4	1
822	Comparative Effectiveness of External-Beam Radiation Approaches for Prostate Cancer. European Urology, 2014, 65, 162-168.	1.9	24
823	Obesity and prostate cancer: Is there a link?. E-SPEN Journal, 2014, 9, e123-e130.	0.5	0
824	Comparative Effectiveness Research in Radiation Oncology: Stereotactic Radiosurgery, Hypofractionation, and Brachytherapy. Seminars in Radiation Oncology, 2014, 24, 35-42.	2.2	12
825	Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiotherapy and Oncology, 2014, 110, 291-297.	0.6	39
826	Valores de referencia para el cuestionario CAVIPRES-30, un cuestionario global sobre la calidad de vida relacionada con la salud de pacientes con c�ncer de pr�stata. Actas Urol�gicas Espa�olas, 2014, 38, 304-312.	0.7	4
827	Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 41.e23-41.e30.	1.6	74
828	The Epidemiology and Clinical Implications of Genetic Variation in Prostate Cancer. Urologic Clinics of North America, 2014, 41, 277-297.	1.8	13
829	Reference values for the CAVIPRES-30 questionnaire, a global questionnaire on the health-related quality of life of patients with prostate cancer. Actas Urol�gicas Espa�olas (English Edition), 2014, 38, 304-312.	0.2	1
830	Editorial Comment. Urology, 2014, 83, 152-153.	1.0	0
831	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. European Urology, 2014, 66, 666-672.	1.9	97
832	A randomized trial of diet in men with early stage prostate cancer on active surveillance: Rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Contemporary Clinical Trials, 2014, 38, 198-203.	1.8	27

#	ARTICLE	IF	CITATIONS
833	Climacturia after Definitive Treatment of Prostate Cancer. Journal of Urology, 2014, 191, 159-163.	0.4	48
834	Age and Baseline Quality of Life at Radical Prostatectomy—Who Has the Most to Lose?. Journal of Urology, 2014, 192, 396-401.	0.4	24
835	Correlation of Patient Perception of Pad Use with Objective Degree of Incontinence Measured by Pad Test in Men with Post-Prostatectomy Incontinence: The SUFU Pad Test Study. Journal of Urology, 2014, 192, 836-842.	0.4	77
836	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. European Urology, 2014, 66, 550-560.	1.9	553
837	The impact of gastrointestinal and genitourinary toxicity on health related quality of life among irradiated prostate cancer patients. Radiotherapy and Oncology, 2014, 110, 284-290.	0.6	34
838	Five-Year Outcomes from 3 Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 596-602.	0.8	103
839	Muddying the waters by overlooking treatment modality. Nature Reviews Clinical Oncology, 2014, 11, 305-307.	27.6	0
840	Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1795-1800.	2.5	20
841	Value of Diffusion-Weighted Imaging at 3 T for Prediction of Extracapsular Extension in Patients With Prostate Cancer: A Preliminary Study. American Journal of Roentgenology, 2014, 202, 772-777.	2.2	32
842	Jakość życia pacjentów po leczeniu onkologicznym. Zeszyty Naukowe WCO Letters in Oncology Science, 2014, 11, 33-36.	0.2	0
843	Weighted Versus Unweighted Charlson Score to Predict Long-term Other-cause Mortality in Men with Early-stage Prostate Cancer. European Urology, 2014, 66, 1002-1009.	1.9	21
844	Perceptions of Radiation Oncologists and Urologists on Sources and Type of Evidence to Inform Prostate Cancer Treatment Decisions. International Journal of Radiation Oncology Biology Physics, 2014, 89, 277-283.	0.8	3
845	Does the etiology affect the outcome and satisfaction rates of penile prosthesis implantation surgery?. Kaohsiung Journal of Medical Sciences, 2014, 30, 570-573.	1.9	4
846	Prospective Randomized Phase 2 Trial of Intensity Modulated Radiation Therapy With or Without Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 268-276.	0.8	70
848	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	4.9	294
849	Prevention of erectile dysfunction after radiotherapy for prostate cancer. Asian Journal of Andrology, 2014, 16, 805.	1.6	4
850	Combination of clinical characteristics and transrectal ultrasound-guided biopsy to predict lobes without significant cancer: application in patient selection for hemiablativ focal therapy. Prostate International, 2014, 2, 37-42.	2.3	5
852	Recommendations for Prostate Cancer Survivorship Care: An Update to the 2009 Michigan Cancer Consortium Guidelines for the Primary Care Management of Prostate Cancer Post-Treatment Sequelae. Journal of Men's Health, 2014, 11, 95-107.	0.3	7

#	ARTICLE	IF	CITATIONS
853	In Regard to Mariados etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 936-937.	0.8	2
854	Commentary on: Does Surgeon Subjective Nerve Sparing Score Predict Recovery Time of Erectile Function Following Robot-Assisted Radical Prostatectomy?. Journal of Sexual Medicine, 2015, 12, 1497-1498.	0.6	0
855	Treatment preference and patient centered prostate cancer care: Design and rationale. Contemporary Clinical Trials, 2015, 45, 296-301.	1.8	16
856	Patientâ€reported â€ever hadâ€™ and â€currentâ€™ longâ€term physical symptoms after prostate cancer treatments. BJU International, 2015, 116, 397-406.	2.5	42
857	Expectant management for men with early stage prostate cancer. Ca-A Cancer Journal for Clinicians, 2015, 65, 264-282.	329.8	59
858	Brachytherapy: stateâ€ofâ€theâ€art radiotherapy in prostate cancer. BJU International, 2015, 116, 80-88.	2.5	20
859	Prostate cancer survivorship: a nurse-led service model. British Journal of Nursing, 2015, 24, S14-S21.	0.7	16
860	Prostate Cancer. Annals of Internal Medicine, 2015, 163, ITC1-ITC16.	3.9	3
861	Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities. International Journal of Oncology, 2015, 46, 381-388.	3.3	6
862	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 61-68.	4.9	72
863	Prevalence of Baseline Erectile Dysfunction (ED) in an Australian Cohort of Men with Localized Prostate Cancer. Journal of Sexual Medicine, 2015, 12, 1267-1274.	0.6	9
864	Impact of Prostate Cancer Treatment on the Sexual Quality of Life for Men-Who-Have-Sex-with-Men. Journal of Sexual Medicine, 2015, 12, 2378-2386.	0.6	40
865	Prospective qualityâ€ofâ€life outcomes for lowâ€risk prostate cancer: Active surveillance versus radical prostatectomy. Cancer, 2015, 121, 2465-2473.	4.1	52
866	Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer. Radiation Oncology, 2015, 10, 182.	2.7	22
867	Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediateâ€risk disease. Cancer, 2015, 121, 2713-2719.	4.1	29
868	Interventions that may reduce depressive symptoms among prostate cancer patients: a systematic review and metaâ€analysis. Psycho-Oncology, 2015, 24, 1686-1693.	2.3	43
869	Brachytherapy for prostate cancer: feasible but oncological equivalence unproven. BJU International, 2015, 116, 89-91.	2.5	0
870	A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment. BJU International, 2015, 116, 853-861.	2.5	35

#	ARTICLE	IF	CITATIONS
871	Preoperative predictive model of recovery of urinary continence after radical prostatectomy. <i>BJU International</i> , 2015, 116, 577-583.	2.5	88
872	A trial of devices for urinary incontinence after treatment for prostate cancer. <i>BJU International</i> , 2015, 116, 432-442.	2.5	30
873	The Effectiveness of Psychoeducational Interventions Focused on Sexuality in Cancer. <i>Cancer Nursing</i> , 2015, 38, E32-E42.	1.5	12
874	The Risks and Benefits of Current Treatment Options for Prostate Cancer and Future Possibilities in Advanced Imaging and Targeted Therapy: A Review. <i>Archives of Surgical Oncology</i> , 2015, 01, .	0.1	0
875	Coping with Losses, Grief, and Mourning in Prostate Cancer. <i>Advances in Psychosomatic Medicine</i> , 2015, 34, 109-122.	2.2	5
876	Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights. <i>Canadian Urological Association Journal</i> , 2015, 9, 267.	0.6	11
877	The risk factors, diagnosis and treatment guideline of erectile dysfunction. <i>Journal of the Korean Medical Association</i> , 2015, 58, 443.	0.3	5
878	Nightly sildenafil use after radical prostatectomy has adverse effects on urinary convalescence: Results from a randomized trial of nightly vs on-demand dosing regimens. <i>Canadian Urological Association Journal</i> , 2015, 9, 414.	0.6	7
879	Can magnetic resonance imaging solve the prostate cancer conundrum?. <i>Medical Journal of Australia</i> , 2015, 202, 410-411.	1.7	0
880	Factors that influence patient preferences for prostate cancer management options: a systematic review. <i>Patient Preference and Adherence</i> , 2015, 9, 899.	1.8	44
881	Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 151.	2.8	5
882	Circulating Long Noncoding RNA as a Potential Target for Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 13322-13338.	4.1	38
883	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. <i>PLoS ONE</i> , 2015, 10, e0132343.	2.5	28
884	Long-Term Efficacy and Toxicity of Low-Dose-Rate 125 I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 884-893.	0.8	63
885	The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study. <i>BMC Urology</i> , 2015, 15, 28.	1.4	18
886	RNA biomarkers to facilitate the identification of aggressive prostate cancer. <i>Molecular Aspects of Medicine</i> , 2015, 45, 37-46.	6.4	16
887	Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 221-228.	3.9	53
888	Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales. <i>Radiologia Medica</i> , 2015, 120, 1170-1176.	7.7	10

#	ARTICLE	IF	CITATIONS
889	Shared Decision Making and Use of Decision Aids for Localized Prostate Cancer. JAMA Internal Medicine, 2015, 175, 792.	5.1	43
890	Dose-Escalated Robotic SBRT for Stage I&II Prostate Cancer. Frontiers in Oncology, 2015, 5, 48.	2.8	22
891	Reply to G. Gandaglia et al and K. Lu. Journal of Clinical Oncology, 2015, 33, 2833-2834.	1.6	0
892	Doctors' approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study. BMJ Open, 2015, 5, e006367-e006367.	1.9	33
893	Qualitative approach to patient-reported outcomes in oncology: protocol of a French study. BMJ Open, 2015, 5, e008042.	1.9	7
894	The Role of Nutrition and Diet in Prostate Cancer. , 2015, , 167-181.		0
895	Effect of Pubovesical Complex Reconstruction During Robot-Assisted Laparoscopic Prostatectomy on the Recovery of Urinary Continence. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2015, 25, 814-820.	1.0	3
896	Phase I/II prospective trial of cancer-specific imaging using ultrasound spectrum analysis tissue-type imaging to guide dose-painting prostate brachytherapy. Brachytherapy, 2015, 14, 801-808.	0.5	6
898	Radiation for Prostate Cancer: Intensity Modulated Radiation Therapy versus Proton Beam. Journal of Urology, 2015, 193, 1089-1091.	0.4	19
899	Point: Surgery is the most cost-effective option for prostate cancer needing treatment. Brachytherapy, 2015, 14, 753-755.	0.5	0
900	Role of brachytherapy for advanced prostate cancer. Current Problems in Cancer, 2015, 39, 48-51.	2.0	1
901	Surgery for high-risk prostate cancer and metastatic prostate cancer. Current Problems in Cancer, 2015, 39, 33-40.	2.0	3
902	Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. Journal of Cancer Survivorship, 2015, 9, 361-372.	2.9	67
903	Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy, 2015, 14, 160-165.	0.5	14
904	The Case for Prostate Brachytherapy in the Affordable Care Act Era. International Journal of Radiation Oncology Biology Physics, 2015, 91, 465-467.	0.8	7
905	Late rectal toxicity after low-dose-rate brachytherapy: Incidence, predictors, and management of side effects. Brachytherapy, 2015, 14, 148-159.	0.5	24
906	Estimating Preferences for Treatments in Patients With Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 277-287.	0.8	16
907	Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. European Urology, 2015, 67, 993-1005.	1.9	96

#	ARTICLE	IF	CITATIONS
908	Patient-perceived Satisfaction After Definitive Treatment for Men With High-risk Prostate Cancer: Radical Prostatectomy vs Intensity-modulated Radiotherapy With Androgen Deprivation Therapy. <i>Urology</i> , 2015, 85, 407-414.	1.0	12
909	Effects of threeâ€timesâ€perâ€week versus onâ€demand tadalafil treatment on erectile function and continence recovery following bilateral nerve sparing radical prostatectomy: Results of a prospective, randomized, and singleâ€center study. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 90-95.	1.9	18
910	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. <i>European Urology</i> , 2015, 67, 460-467.	1.9	190
911	Feasibility, safety, and efficacy of salvage radical prostatectomy after TookadÂ® Soluble focal treatment for localized prostate cancer. <i>World Journal of Urology</i> , 2015, 33, 965-971.	2.2	31
912	Primary Radical Therapy Selection in High-risk Non-metastatic Prostate Cancer. <i>Clinical Oncology</i> , 2015, 27, 136-144.	1.4	9
913	Technical Aspects of Focal Therapy in Localized Prostate Cancer. , 2015, , .		10
914	Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2015, 33, 1281-1289.	2.2	47
915	TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2015, 49, 51-57.	1.0	11
916	Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer. <i>Scandinavian Journal of Urology</i> , 2015, 49, 58-69.	1.0	6
917	Impact of Age on Quality-of-life Outcomes After Treatment for Localized Prostate Cancer. <i>European Urology</i> , 2015, 68, 480-486.	1.9	42
918	Electrochemical red-ox therapy of prostate cancer in nude mice. <i>Bioelectrochemistry</i> , 2015, 104, 1-9.	4.6	18
919	Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. <i>Journal of the National Cancer Institute</i> , 2015, 107, 366.	6.3	120
920	Influence of radical prostatectomy for prostate cancer on work status and working life 3Âyears after surgery. <i>Journal of Cancer Survivorship</i> , 2015, 9, 172-179.	2.9	16
921	Stereotactic Body Radiotherapy for Prostate Cancer. <i>Clinical Oncology</i> , 2015, 27, 270-279.	1.4	49
922	Evaluation and Management of the Geriatric Urologic Oncology Patient. <i>Current Geriatrics Reports</i> , 2015, 4, 7-15.	1.1	8
924	Long-Term Active Surveillance for Prostate Cancer: Answers and Questions. <i>Journal of Clinical Oncology</i> , 2015, 33, 238-240.	1.6	22
925	A Randomized, Double-Blind, Solifenacin Succinate versus Placebo Control, Phase 4, Multicenter Study Evaluating Urinary Continence after Robotic Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2015, 193, 1305-1310.	0.4	28
926	Global Quality of Life After Curative Treatment for Prostate Cancer: What Matters? A Study Among Members of the Norwegian Prostate Cancer Patient Association. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 518-524.	1.9	16

#	ARTICLE	IF	CITATIONS
927	The impact of hormonal therapy on sexual quality of life in men receiving intensity modulated radiation therapy for prostate cancer. Practical Radiation Oncology, 2015, 5, e223-e228.	2.1	8
928	The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. European Urology, 2015, 67, 1019-1025.	1.9	15
929	A Qualitative Exploration of the Experience of Men With Prostate Cancer Involved in Supervised Exercise Programs. Oncology Nursing Forum, 2015, 42, 24-32.	1.2	37
930	Male Stress Urinary Incontinence Following Surgical Intervention: Procedures, Technical Modifications, and Patient Considerations. , 2015, , 45-72.		4
931	Improving Couples' Quality of Life Through a Web-Based Prostate Cancer Education Intervention. Oncology Nursing Forum, 2015, 42, 183-192.	1.2	60
932	In 2124, Half of All Men Can Count on Developing Prostate Cancer. Current Oncology, 2015, 22, 10-12.	2.2	19
933	Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic. Cancer, 2015, 121, 1484-1491.	4.1	27
934	Fear of recurrence: the importance of self-efficacy and satisfaction with care in gay men with prostate cancer. Psycho-Oncology, 2015, 24, 691-698.	2.3	41
935	Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. European Urology, 2015, 68, 891-898.	1.9	91
936	The association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 38-42.	3.9	16
937	Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?. Frontiers in Oncology, 2015, 5, 77.	2.8	14
938	Treatment decisional regret among men with prostate cancer: Racial differences and influential factors in the North Carolina Health Access and Prostate Cancer Treatment Project (HCA-PaNC). Cancer, 2015, 121, 2029-2035.	4.1	34
939	Genomic Predictors of Outcome in Prostate Cancer. European Urology, 2015, 68, 1033-1044.	1.9	166
940	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncology, The, 2015, 16, 509-521.	10.7	174
941	Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer. Quality of Life Research, 2015, 24, 2397-2402.	3.1	11
942	Physical activity, sedentary behavior, and health-related quality of life in prostate cancer survivors in the health professionals follow-up study. Journal of Cancer Survivorship, 2015, 9, 500-511.	2.9	33
943	Evaluation and Treatment of Overactive Bladder after History of Cancer Treatment. Current Bladder Dysfunction Reports, 2015, 10, 31-38.	0.5	0
944	Extracting the Benefit of Nexrutine® for Cancer Prevention. Current Pharmacology Reports, 2015, 1, 365-372.	3.0	12

#	ARTICLE	IF	CITATIONS
945	Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review. <i>Radiation Oncology</i> , 2015, 10, 49.	2.7	27
946	Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. <i>Radiation Oncology</i> , 2015, 10, 44.	2.7	22
947	Current Trends and New Frontiers in Focal Therapy for Localized Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 35.	2.2	12
948	Radiotherapy for high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 145-154.	3.8	25
949	A genetic-based approach to personalized prostate cancer screening and treatment. <i>Current Opinion in Urology</i> , 2015, 25, 53-58.	1.8	13
950	CE. <i>American Journal of Nursing</i> , 2015, 115, 34-44.	0.4	28
951	The Prostate Cancer Journey. <i>Cancer Nursing</i> , 2015, 38, E1-E12.	1.5	26
953	Prostate-specific Antigen Testing: Good or Bad?. <i>Oncologist</i> , 2015, 20, 233-235.	3.7	2
954	Long-term Health-related Quality of Life After Primary Treatment for Localized Prostate Cancer: Results from the CaPSURE Registry. <i>European Urology</i> , 2015, 68, 600-608.	1.9	156
955	Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer. <i>International Journal of Hyperthermia</i> , 2015, 31, 359-374.	2.5	106
956	A pilot randomized trial of conventional versus advanced pelvic floor exercises to treat urinary incontinence after radical prostatectomy: a study protocol. <i>BMC Urology</i> , 2015, 15, 94.	1.4	28
957	Differential diagnosis of human bladder mucosa pathologies in vivo with cross-polarization optical coherence tomography. <i>Biomedical Optics Express</i> , 2015, 6, 1464.	2.9	48
958	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. <i>Practical Radiation Oncology</i> , 2015, 5, e473-e482.	2.1	24
959	Associations Between Urinary Symptoms and Sexual Health in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 581-590.	2.6	8
961	Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. <i>Journal of Clinical Oncology</i> , 2015, 33, 4158-4166.	1.6	99
962	Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer. <i>Brachytherapy</i> , 2015, 14, 818-825.	0.5	11
963	10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era. <i>Urology</i> , 2015, 86, 783-789.	1.0	12
965	Population-Based Assessment of Determining Treatments for Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 60.	7.1	37

#	ARTICLE	IF	CITATIONS
966	Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme. British Journal of Cancer, 2015, 112, 1594-1602.	6.4	16
967	The impact of prostate cancer on men's everyday life. European Journal of Cancer Care, 2015, 24, 71-84.	1.5	41
968	Urinary Bother as a Predictor of Postsurgical Changes in Urinary Function After Robotic Radical Prostatectomy. Urology, 2015, 86, 817-823.	1.0	7
969	Gleason 6 Prostate Cancer: Translating Biology into Population Health. Journal of Urology, 2015, 194, 626-634.	0.4	75
970	Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiotherapy and Oncology, 2015, 116, 179-184.	0.6	61
971	Timing of Urinary Pad Exchanges Was the Most Important Factor Affecting Quality of Life in the Early Postoperative Period After Robot-Assisted Laparoscopic Radical Prostatectomy. Journal of Endourology, 2015, 29, 1044-1051.	2.1	17
972	Unexpected Long-term Improvements in Urinary and Erectile Function in a Large Cohort of Men with Self-reported Outcomes Following Radical Prostatectomy. European Urology, 2015, 68, 899-905.	1.9	55
973	Dose painting to treat single-lobe prostate cancer with hypofractionated high-dose radiation using targeted external beam radiation: Is it feasible?. Medical Dosimetry, 2015, 40, 256-261.	0.9	7
974	Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. European Urology, 2015, 68, 927-936.	1.9	163
975	Improving What Matters. European Urology, 2015, 68, 384-385.	1.9	5
976	Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 971-977.	0.8	285
977	In Reply to King et al. International Journal of Radiation Oncology Biology Physics, 2015, 93, 937-939.	0.8	1
978	Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. Journal of Urology, 2015, 194, 1601-1606.	0.4	87
980	Place du sexologue dans le parcours de soins en cancérologie: expérience clinique et proposition de protocole dans la prise en charge des troubles sexuels autour de la prostatectomie. Sexologies, 2015, 24, 170-175.	0.8	1
981	Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	1.4	22
982	Radiotherapy in Prostate Cancer. Medical Radiology, 2015, , .	0.1	6
983	Quality of Life After Primary Treatment for Localized Prostate Cancer: Long-term Considerations. European Urology, 2015, 68, 609-610.	1.9	0
984	Editorial Comment. Urology, 2015, 85, 105-106.	1.0	3

#	ARTICLE	IF	CITATIONS
985	Prediction of Long-term Other-cause Mortality in Men With Early-stage Prostate Cancer: Results From the Prostate Cancer Outcomes Study. <i>Urology</i> , 2015, 85, 92-100.	1.0	34
986	Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form. <i>Urology</i> , 2015, 85, 101-106.	1.0	241
987	Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 235-244.	1.6	27
988	Progress in Management of Low-risk Prostate Cancer: How Registries May Change the World. <i>European Urology</i> , 2015, 67, 51-52.	1.9	8
989	Benchmarks for Operative Outcomes of Robotic and Open Radical Prostatectomy: Results from the Health Professionals Follow-up Study. <i>European Urology</i> , 2015, 67, 432-438.	1.9	79
990	Advances in Image-Guided Urologic Surgery. , 2015, , .		3
991	Stereotactic body radiation therapy for prostate cancer: Rational and reasonable. <i>Practical Radiation Oncology</i> , 2015, 5, 188-192.	2.1	11
992	Do we need the nerve sparing radical prostatectomy techniques (intrafascial vs. interfascial) in men with erectile dysfunction? Results of a single-centre study. <i>World Journal of Urology</i> , 2015, 33, 301-307.	2.2	13
993	Predictors of short-term recovery of urinary continence after radical prostatectomy. <i>World Journal of Urology</i> , 2015, 33, 771-779.	2.2	30
994	Oncology Section EDGE Task Force on Prostate Cancer. <i>Rehabilitation Oncology</i> , 2016, 34, 27-35.	0.5	10
995	The benefit of using bladder sub-volume equivalent uniform dose constraints in prostate intensity-modulated radiotherapy planning. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7537-7544.	2.0	14
996	Radical Prostatectomy in Korean Men Aged 75-Years or Older: Safety and Efficacy in Comparison with Patients Aged 65-69 Years. <i>Journal of Korean Medical Science</i> , 2016, 31, 957.	2.5	10
997	A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer. <i>Canadian Urological Association Journal</i> , 2016, 10, 246.	0.6	9
998	A survey of prostate cancer patients'™ perceptions of the support they receive during radical radiotherapy: is there room for improvement?. <i>Journal of Radiotherapy in Practice</i> , 2016, 15, 239-246.	0.5	4
999	Quality of Life: Impact of Prostate Cancer and its Treatment. , 2016, , 579-584.		2
1000	Endoscopic and non-endoscopic approaches for the management of radiation-induced rectal bleeding. <i>World Journal of Gastroenterology</i> , 2016, 22, 6972.	3.3	42
1001	Cancer Related Fatigue and Quality of Life in Patients with Advanced Prostate Cancer Undergoing Chemotherapy. <i>BioMed Research International</i> , 2016, 2016, 1-11.	1.9	61
1002	Gene expression profile comparison in the penile tissue of diabetes and cavernous nerve injury-induced erectile dysfunction rat model. <i>Investigative and Clinical Urology</i> , 2016, 57, 286.	2.0	14

#	ARTICLE	IF	CITATIONS
1003	Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance. Canadian Urological Association Journal, 2016, 10, 383.	0.6	22
1004	Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life. Frontiers in Oncology, 2016, 6, 70.	2.8	10
1005	Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience. Frontiers in Oncology, 2016, 6, 114.	2.8	28
1006	Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction. Frontiers in Oncology, 2016, 6, 122.	2.8	20
1007	Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design. Frontiers in Oncology, 2016, 6, 167.	2.8	15
1008	Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-reported Health-related Quality of Life Outcomes, Patient Satisfaction, and Treatment-related Complications. Medical Care, 2016, 54, 738-744.	2.4	12
1009	Medical hospitalizations in prostate cancer survivors. Medical Oncology, 2016, 33, 81.	2.5	2
1010	Biomarkers for prostate cancer: present challenges and future opportunities. Future Science OA, 2016, 2, FSO72.	1.9	35
1011	Partner's Perspective on Long-term Sexual Dysfunction After Prostate Cancer Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 276-279.	1.3	9
1012	Management of Sexual Dysfunction in Men and Women. , 2016, , .		7
1013	Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening. Journal of Cellular Physiology, 2016, 231, 1870-1875.	4.1	17
1014	Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (<sc>ERSPC</sc>) and Prostate Cancer Prevention Trial (<sc>PCPT</sc>) risk calculators: independent validation and comparison in a contemporary European cohort. BJU International. 2016, 117, 401-408.	2.5	76
1015	Prostate-specific antigen patterns in <sc>US</sc> and European populations: comparison of six diverse cohorts. BJU International, 2016, 118, 911-918.	2.5	5
1016	Emerging minimally invasive procedures for focal treatment of organ-confined prostate cancer. International Journal of Hyperthermia, 2016, 32, 795-800.	2.5	13
1017	Transrectal Elastographic Biopsy and Contrast-Enhanced Transrectal Biopsy May Offer Improvements Over the Current Transrectal Systemic Biopsy Technique. Journal of Diagnostic Medical Sonography, 2016, 32, 61-71.	0.3	0
1018	Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 173-180.	1.3	9
1019	Expectant management of veterans with early-stage prostate cancer. Cancer, 2016, 122, 626-633.	4.1	10
1020	Androgen deprivation therapy use and risk of death in men treated with high-dose radiation for intermediate-risk prostate cancer. Cancer, 2016, 122, 2296-2298.	4.1	0

#	ARTICLE	IF	CITATIONS
1021	Functional Quality-of-Life Outcomes Reported by Men Treated for Localized Prostate Cancer: A Systematic Literature Review. <i>Oncology Nursing Forum</i> , 2016, 43, 199-218.	1.2	30
1022	Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2016, 121, 294-298.	0.6	22
1023	In prostate cancer, urinary and sexual function were worse with prostatectomy than active monitoring or radiotherapy. <i>Annals of Internal Medicine</i> , 2016, 165, JC62.	3.9	0
1024	In localized prostate cancer, active monitoring, prostatectomy, and radiotherapy did not differ for 10-y cancer deaths. <i>Annals of Internal Medicine</i> , 2016, 165, JC63.	3.9	0
1025	Long-term cancer-related fatigue outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with hormonal therapy. <i>Medicine (United States)</i> , 2016, 95, e3948.	1.0	10
1026	Urinary quality of life outcomes in men who were treated with image-guided intensity-modulated radiation therapy for prostate cancer. <i>Advances in Radiation Oncology</i> , 2016, 1, 310-316.	1.2	2
1027	Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e265-e273.	1.9	8
1028	Urinary incontinence after high-dose-rate brachytherapy boost treatment for prostate cancer. <i>Brachytherapy</i> , 2016, 15, 442-449.	0.5	1
1029	Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 313-317.	0.8	51
1030	Psychosocial and physical outcomes of in- and outpatient rehabilitation in prostate cancer patients treated with radical prostatectomy. <i>Supportive Care in Cancer</i> , 2016, 24, 2717-2726.	2.2	18
1031	Macroscopic Hematuria After Conventional or Hypofractionated Radiation Therapy: Results From a Prospective Phase 3 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 304-312.	0.8	16
1032	Long-term satisfaction and tolerability with low-dose flutamide: a 20-year surveillance study on 120 hyperandrogenic women. <i>Gynecological Endocrinology</i> , 2016, 32, 723-727.	1.7	3
1034	MP31-19 THE IMPACT OF PARTNERSHIP STATUS AND SOCIAL SUPPORT ON HEALTH RELATED QUALITY OF LIFE OUTCOMES IN MEN WITH PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
1035	Zoomed echo-planar diffusion tensor imaging for MR tractography of the prostate gland neurovascular bundle without an endorectal coil: a feasibility study. <i>Abdominal Radiology</i> , 2016, 41, 919-925.	2.1	8
1036	Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 392-398.	0.4	15
1037	Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1718-1722.	1.6	1
1038	Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e198-e208.	10.7	54
1039	Lovastatin may reduce the risk of erectile dysfunction following radiation therapy for prostate cancer. <i>Acta Oncologica</i> , 2016, 55, 1500-1502.	1.8	5

#	ARTICLE	IF	CITATIONS
1040	Robot-Assisted Radical Prostatectomy. , 2016, , .		0
1041	The Association Between Evaluation at Academic Centers and the Likelihood of Expectant Management in Low-risk Prostate Cancer. Urology, 2016, 96, 128-135.	1.0	14
1042	U.S. Burden of Cancer by Race and Ethnicity According to Disability-Adjusted Life Years. American Journal of Preventive Medicine, 2016, 51, 673-681.	3.0	24
1044	Physical and emotional health information needs and preferences of long-term prostate cancer survivors. Patient Education and Counseling, 2016, 99, 2049-2054.	2.2	25
1046	Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. International Journal of Radiation Oncology Biology Physics, 2016, 96, 770-777.	0.8	11
1047	Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results from the Randomized Phase III HYPRO Trial. Journal of Sexual Medicine, 2016, 13, 1695-1703.	0.6	8
1048	Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review. BMC Health Services Research, 2016, 16, 541.	2.2	19
1049	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine, 2016, 10, 150-163.	6.1	69
1050	Patient-Reported Convalescence and Quality of Life Recovery. Surgical Innovation, 2016, 23, 598-605.	0.9	11
1051	Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study. Scandinavian Journal of Urology, 2016, 50, 338-345.	1.0	17
1052	Posterior Urethral Suspension During Robot-Assisted Radical Prostatectomy Improves Early Urinary Control: A Prospective Cohort Study. Journal of Endourology, 2016, 30, 1089-1094.	2.1	14
1053	Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries. Scandinavian Journal of Urology, 2016, 50, 330-337.	1.0	15
1054	Symptomatic and quality of life outcomes after treatment for clinically localised prostate cancer: a systematic review. BJU International, 2016, 118, 193-204.	2.5	63
1055	Focal therapy in prostate cancer: A review of seven common controversies. Cancer Treatment Reviews, 2016, 51, 27-34.	7.7	29
1056	Management and treatment of men affected by metastatic prostate cancer: evidence-based recommendations for practice. International Journal of Urological Nursing, 2016, 10, 44-55.	0.2	6
1057	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer, 2016, 122, 3386-3393.	4.1	23
1058	Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsy. BJU International, 2016, 117, 94-101.	2.5	10
1059	Population-based study of long-term functional outcomes after prostate cancer treatment. BJU International, 2016, 117, E36-45.	2.5	58

#	ARTICLE	IF	CITATIONS
1062	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine, 2016, 375, 1425-1437.	27.0	962
1063	Providing prostate cancer survivorship care in Japan: Implications from the USA care model. International Journal of Urology, 2016, 23, 906-915.	1.0	2
1064	Extreme hypofractionation for early prostate cancer: Biology meets technology. Cancer Treatment Reviews, 2016, 50, 48-60.	7.7	40
1065	Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. BJU International, 2016, 118, 869-879.	2.5	52
1066	A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer. BMC Cancer, 2016, 16, 708.	2.6	6
1067	Psychosocial screening for patients with prostate cancer: The development and validation of the psychosocial distress questionnaire-prostate cancer. Journal of Psychosocial Oncology, 2016, 34, 512-529.	1.2	1
1068	Postoperative urinary incontinence exacerbates nocturia-specific quality of life after robot-assisted radical prostatectomy. International Journal of Urology, 2016, 23, 873-878.	1.0	11
1069	A Comparative Study of Liver Disease Care in the USA and Urban and Rural China. Digestive Diseases and Sciences, 2016, 61, 2847-2856.	2.3	2
1070	Factors predicting outcomes of penile rehabilitation with udenafil 50mg following radical prostatectomy. International Journal of Impotence Research, 2016, 28, 25-30.	1.8	3
1071	“Killing two birds with one stone”™: patient-reported quality-of-life outcomes from the Prostate Testing for Cancer and Treatment (ProtecT) trial. BJU International, 2016, 118, 844-845.	2.5	0
1072	Radiomics based targeted radiotherapy planning (Rad-TRaP): a computational framework for prostate cancer treatment planning with MRI. Radiation Oncology, 2016, 11, 148.	2.7	69
1073	Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer. Radiation Oncology, 2016, 11, 117.	2.7	3
1074	Life after prostate cancer diagnosis: protocol for a UK-wide patient-reported outcomes study. BMJ Open, 2016, 6, e013555.	1.9	27
1075	Addressing erectile dysfunction in prostate cancer survivors after radical prostatectomy. Expert Review of Quality of Life in Cancer Care, 2016, 1, 403-420.	0.6	2
1076	Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 261-265.	1.3	7
1077	Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. BJU International, 2016, 118, 372-378.	2.5	56
1078	Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1240-1250.	2.5	32
1079	Evaluation of pelvic floor muscle strength before and after robotic-assisted radical prostatectomy and early outcomes on urinary continence. Journal of Robotic Surgery, 2016, 10, 331-335.	1.8	17

#	ARTICLE	IF	CITATIONS
1080	Is Surgery Still Necessary for Prostate Cancer?. , 2016, , 235-243.		0
1081	Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treatment Reviews, 2016, 48, 50-60.	7.7	53
1082	Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment. Journal of Cancer Research and Clinical Oncology, 2016, 142, 699-706.	2.5	16
1083	The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer. Quality of Life Research, 2016, 25, 2379-2393.	3.1	14
1084	Determining factors affecting healthcare service satisfaction utilizing fuzzy rule-based systems. Journal of Applied Statistics, 2016, 43, 2474-2489.	1.3	3
1085	Evaluation and Management of Postprostatectomy Incontinence: A Systematic Review of Current Literature. European Urology Focus, 2016, 2, 245-259.	3.1	84
1086	Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?. Journal of Sexual Medicine, 2016, 13, 669-678.	0.6	15
1087	Sex differences in the association of physical function and cognitive function with life satisfaction in older age: The Rancho Bernardo Study. Maturitas, 2016, 89, 29-35.	2.4	15
1088	Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial. BMC Cancer, 2016, 16, 299.	2.6	32
1089	Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?. Nature Reviews Urology, 2016, 13, 400-408.	3.8	27
1090	Impact of region contouring variability on image-based focal therapy evaluation. Proceedings of SPIE, 2016, , .	0.8	0
1091	Health-related quality of life before and after head and neck squamous cell carcinoma: Analysis of the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage. Cancer, 2016, 122, 1861-1870.	4.1	22
1092	Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. International Journal of Cancer, 2016, 138, 1388-1400.	5.1	216
1094	CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy, 2016, 8, 145-163.	2.0	110
1095	Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. Radiotherapy and Oncology, 2016, 118, 85-91.	0.6	45
1096	Preparing Patients and Partners for Recovery From the Side Effects of Prostate Cancer Surgery: A Group Approach. Urology, 2016, 88, 36-42.	1.0	26
1097	Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. International Journal of Radiation Oncology Biology Physics, 2016, 95, 680-689.	0.8	79
1098	Omissions in Urology Residency Training Regarding Sexual Dysfunction Subsequent to Prostate Cancer Treatment: Identifying a Need. Urology, 2016, 90, 19-26.	1.0	10

#	ARTICLE	IF	CITATIONS
1099	Prostate Cancer Patients' Preferences for Intermittent vs. Continuous Androgen Deprivation—A Pilot Institutional Study. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2016, 47, 108-112.e2.	0.3	1
1100	Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 849-858.	2.5	19
1101	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1875-1891.	1.5	7
1102	Design and feasibility of integrating personalized PRO dashboards into prostate cancer care. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 38-47.	4.4	52
1104	Brachytherapy for Prostate Cancer: An Overview. , 2016, , 399-411.		0
1105	The Role of Magnetic Resonance Imaging in Prostate Cancer: Focusing on What Really Matters. <i>European Urology</i> , 2016, 70, 574-575.	1.9	0
1106	Prostate Cancer in Gay, Bisexual, and Other Men Who Have Sex with Men: A Review. <i>LGBT Health</i> , 2016, 3, 32-41.	3.4	64
1107	Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men: analysis from a national population-based multicenter study. <i>International Journal of Impotence Research</i> , 2016, 28, 74-79.	1.8	20
1108	Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy. <i>Brachytherapy</i> , 2016, 15, 288-295.	0.5	20
1109	Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the Exercising Together project. <i>Journal of Cancer Survivorship</i> , 2016, 10, 633-644.	2.9	104
1110	Ultrasound-responsive microbubbles for sonography-guided siRNA delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1139-1149.	3.3	39
1111	Racial Disparities in Sexual Dysfunction Outcomes After Prostate Cancer Treatment: Myth or Reality?. <i>Journal of Racial and Ethnic Health Disparities</i> , 2016, 3, 154-159.	3.2	9
1112	Outcomes for prostate glands >60cc treated with low-dose-rate brachytherapy. <i>Brachytherapy</i> , 2016, 15, 163-168.	0.5	5
1114	Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer. <i>Acta Oncologica</i> , 2016, 55, 807-813.	1.8	14
1115	Cryotherapy for Prostate Cancer. , 2016, , 165-171.		2
1116	Prostate cancer in men of African origin. <i>Nature Reviews Urology</i> , 2016, 13, 99-107.	3.8	96
1117	Laser Interstitial Thermal Therapy. , 2016, , 153-159.		0
1118	Work ability in prostate cancer survivors after radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2016, 50, 116-122.	1.0	18

#	ARTICLE	IF	CITATIONS
1119	Male Sling and Artificial Urethral Sphincter for Male Stress Urinary Incontinence Among Certifying American Urologists. <i>Urology</i> , 2016, 87, 95-99.	1.0	21
1120	Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 182-189.	2.0	16
1121	Interventional Urology. , 2016, , .		4
1122	Prostate-Specific Antigen Screening Guidelines. , 2016, , 111-116.		3
1124	Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. <i>European Urology</i> , 2016, 69, 576-581.	1.9	42
1125	Piloting prostate cancer patient-reported outcomes in clinical practice. <i>Supportive Care in Cancer</i> , 2016, 24, 1983-1990.	2.2	16
1126	Nerve-sparing Technique During Radical Prostatectomy and its Effect on Urinary Continence. <i>European Urology</i> , 2016, 69, 590-591.	1.9	6
1128	Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. <i>BJU International</i> , 2016, 117, 469-477.	2.5	81
1129	Factors Associated with Men's Assessment of Prostate Cancer Treatment Choice. <i>Journal of Cancer Education</i> , 2016, 31, 301-307.	1.3	10
1130	Advanced Reconstruction of Vesicourethral Support (ARVUS) during Robot-assisted Radical Prostatectomy: One-year Functional Outcomes in a Two-group Randomised Controlled Trial. <i>European Urology</i> , 2017, 71, 822-830.	1.9	54
1131	Do Prostate Cancer Patients With Markedly Elevated PSA Benefit From Radiation Therapy?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 605-611.	1.3	5
1132	What is the best way to radiate the prostate in 2016?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 59-68.	1.6	31
1133	Preoperative Membranous Urethral Length Measurement and Continence Recovery Following Radical Prostatectomy: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2017, 71, 368-378.	1.9	164
1134	Permanent and High Dose Rate Brachytherapy (Technique, Indications, Results, Morbidity). , 2017, , 187-202.		1
1135	Post-Prostatectomy Radiation Therapy: Balancing Disease Control and Functional Outcomes. <i>Journal of Urology</i> , 2017, 197, 541-542.	0.4	0
1136	Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer. <i>Journal of Radiation Research</i> , 2017, 58, 260-266.	1.6	15
1137	Marital relationship and health-related quality of life after prostate cancer diagnosis. <i>International Journal of Urological Nursing</i> , 2017, 11, 73-81.	0.2	4
1138	Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. <i>Health Affairs</i> , 2017, 36, 108-115.	5.2	25

#	ARTICLE	IF	CITATIONS
1139	A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 234-242.	1.6	13
1140	Suicide in patients with genitourinary malignancies. <i>European Journal of Cancer Care</i> , 2017, 26, e12635.	1.5	8
1141	Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration. <i>Journal of Urology</i> , 2017, 198, 86-91.	0.4	20
1142	Regret and fear in prostate cancer: The relationship between treatment appraisals and fear of recurrence in prostate cancer survivors. <i>Psycho-Oncology</i> , 2017, 26, 1825-1831.	2.3	19
1143	Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer. <i>Quality of Life Research</i> , 2017, 26, 1635-1645.	3.1	24
1144	Quantifying 125 I placement accuracy in prostate brachytherapy using postimplant transrectal ultrasound images. <i>Brachytherapy</i> , 2017, 16, 306-312.	0.5	5
1145	First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life. <i>Journal of Medical Radiation Sciences</i> , 2017, 64, 180-187.	1.5	13
1146	PI-RADSv2: How we do it. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 11-23.	3.4	13
1147	Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. <i>European Urology</i> , 2017, 72, 617-624.	1.9	50
1148	Early detection and management of symptoms using an interactive smartphone application (Interaktor) during radiotherapy for prostate cancer. <i>Supportive Care in Cancer</i> , 2017, 25, 2195-2204.	2.2	76
1149	American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy—A systematic literature review. <i>Brachytherapy</i> , 2017, 16, 245-265.	0.5	46
1150	Development of a new nomogram to predict insignificant prostate cancer in patients undergoing radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2017, 51, 27-32.	1.0	14
1151	Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer. <i>Clinical Oncology</i> , 2017, 29, 412-420.	1.4	43
1152	Long Term Patient Reported Urinary Function Following External Beam Radiotherapy for Prostate Cancer. <i>Clinical Oncology</i> , 2017, 29, 421-428.	1.4	7
1153	Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. <i>Journal of Urology</i> , 2017, 198, 600-607.	0.4	16
1155	Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population. <i>BJU International</i> , 2017, 120, 520-529.	2.5	24
1156	When should active surveillance for prostate cancer stop if no progression is detected?. <i>Prostate</i> , 2017, 77, 962-969.	2.3	11
1157	Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 127-136.	3.9	24

#	ARTICLE	IF	CITATIONS
1158	Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 2017, 25, 1873-1879.	2.2	29
1159	A Pragmatic Randomized Controlled Trial Examining the Impact of the Retzius-sparing Approach on Early Urinary Continence Recovery After Robot-assisted Radical Prostatectomy. European Urology, 2017, 72, 677-685.	1.9	154
1161	Physicians' Perceptions of Factors Influencing the Treatment Decision-making Process for Men With Low-risk Prostate Cancer. Urology, 2017, 107, 86-95.	1.0	8
1162	Prostate MR Imaging. Radiologic Clinics of North America, 2017, 55, 303-320.	1.8	13
1163	Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade. Cancer Medicine, 2017, 6, 1827-1836.	2.8	25
1164	Brachytherapy in the Management of Prostate Cancer. Surgical Oncology Clinics of North America, 2017, 26, 491-513.	1.5	17
1165	ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 1-10.	1.3	10
1166	Clinical factors and dosimetry associated with the development of prostate brachytherapy-related urethral strictures: A matched case-control study. Brachytherapy, 2017, 16, 797-805.	0.5	6
1167	The New US Preventive Services Task Force "Draft Recommendation for Prostate Cancer Screening. European Urology, 2017, 72, 326-328.	1.9	2
1168	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. Journal of Urology, 2017, 198, 1061-1068.	0.4	31
1169	Patient-reported outcome measures in urology. Current Opinion in Urology, 2017, 27, 366-374.	1.8	29
1170	Comparing quality of life outcomes after prostate cancer treatment. Nature Reviews Urology, 2017, 14, 396-397.	3.8	1
1171	Acute Side Effects of Radiation Therapy. , 2017, , .		7
1172	Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1053-1058.	0.8	6
1173	External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. International Journal of Radiation Oncology Biology Physics, 2017, 98, 304-317.	0.8	25
1174	Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1141.	7.4	250
1175	Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. JAMA - Journal of the American Medical Association, 2017, 317, 1126.	7.4	261
1176	Long-term survival of patients aged 80 years or older treated with radical prostatectomy for prostate cancer. European Journal of Surgical Oncology, 2017, 43, 1581-1588.	1.0	6

#	ARTICLE	IF	CITATIONS
1177	Sustained improvements in pain, mood, function and opioid use post interdisciplinary pain rehabilitation in patients weaned from high and low dose chronic opioid therapy. <i>Pain</i> , 2017, 158, 1380-1394.	4.2	49
1178	Patient-reported outcomes in cancer survivorship. <i>Acta Oncologica</i> , 2017, 56, 166-173.	1.8	39
1179	Focal therapy for localized unifocal and multifocal prostate cancer: A prospective development study using real time MR guided focused ultrasound. <i>AIP Conference Proceedings</i> , 2017, , .	0.4	0
1180	Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life. <i>Radiation Oncology</i> , 2017, 12, 53.	2.7	6
1181	Assessing robot-assisted laparoscopic prostatectomy. <i>Lancet, The</i> , 2017, 389, 799.	13.7	5
1182	Psychological resilience aspects that mediate the depressive effects of urinary incontinence in prostate cancer survivors 10 years after treatment with radiation and hormone ablation. <i>Journal of Psychosocial Oncology</i> , 2017, 35, 438-450.	1.2	13
1183	Urinary continence recovery after radical prostatectomy – anatomical/reconstructive and nerve-sparing techniques to improve outcomes. <i>BJU International</i> , 2017, 120, 185-196.	2.5	22
1184	Patient-reported Quality of Life After Proton Beam Therapy for Prostate Cancer: The Effect of Prostate Size. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 704-710.	1.9	6
1185	Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. <i>Cancer</i> , 2017, 123, 1635-1642.	4.1	14
1186	Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 722-731.	0.8	38
1187	Breast, prostate, and thyroid cancer screening tests and overdiagnosis. <i>Current Problems in Cancer</i> , 2017, 41, 71-79.	2.0	14
1188	Decline in acute urinary toxicities with increased institutional experience: 15-year experience of permanent seed prostate brachytherapy in a single Australasian institution. <i>Brachytherapy</i> , 2017, 16, 313-322.	0.5	6
1189	Total depression and subtypes in prostate cancer survivors 10 years after treatment. <i>European Journal of Cancer Care</i> , 2017, 26, e12630.	1.5	6
1190	Avoidance of late rectal toxicity after high-dose-rate brachytherapy boost treatment for prostate cancer. <i>Brachytherapy</i> , 2017, 16, 193-200.	0.5	8
1191	MRI-guided focal laser ablation for prostate cancer followed by radical prostatectomy: correlation of treatment effects with imaging. <i>World Journal of Urology</i> , 2017, 35, 703-711.	2.2	42
1192	A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 962-975.	0.8	45
1193	ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2017, 16, 266-276.	0.5	26
1195	Racial and Ethnic Variation in Health-Related Quality of Life Scores Prior to Prostate Cancer Treatment. <i>Sexual Medicine</i> , 2017, 5, e219-e228.	1.6	2

#	ARTICLE	IF	CITATIONS
1197	Current Role of Magnetic Resonance Imaging in Prostate Cancer. <i>Current Radiology Reports</i> , 2017, 5, 1.	1.4	1
1198	African-American Prostate Cancer Disparities. <i>Current Urology Reports</i> , 2017, 18, 81.	2.2	77
1200	The Natural History of Erectile Dysfunction After Prostatic Radiotherapy: A Systematic Review and Meta-Analysis. <i>Journal of Sexual Medicine</i> , 2017, 14, 1071-1078.	0.6	50
1202	Long-term outcomes in patients treated with proton therapy for localized prostate cancer. <i>Cancer Medicine</i> , 2017, 6, 2234-2243.	2.8	39
1203	Are we underestimating the rates of incontinence after prostate cancer treatment? Results from NHANES. <i>International Urology and Nephrology</i> , 2017, 49, 1715-1721.	1.4	17
1204	Establishment of a Web-based System for Collection of Patient-reported Outcomes After Radical Prostatectomy in a Statewide Quality Improvement Collaborative. <i>Urology</i> , 2017, 107, 96-102.	1.0	25
1205	The health-related quality of life of patients with prostate cancer and their spouses before treatment compared with the general population. <i>International Journal of Nursing Practice</i> , 2017, 23, e12572.	1.7	5
1206	Multisource Rotating Shield Brachytherapy Apparatus for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 719-728.	0.8	12
1207	Prospective evaluation of a specific technique of sexual function preservation in external beam radiotherapy for prostate cancer. <i>British Journal of Radiology</i> , 2017, 90, 20160877.	2.2	8
1208	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 869-885.	1.9	182
1209	Caution with Use of the EPIC-50 Urinary Bother Scale: How Voiding Dysfunction Modifies its Performance. <i>Journal of Urology</i> , 2017, 198, 1397-1403.	0.4	3
1210	Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy. <i>Journal of Radiation Oncology</i> , 2017, 6, 295-300.	0.7	0
1211	Predictors of recurrent hospital admissions among prostate cancer survivors. <i>Medical Oncology</i> , 2017, 34, 150.	2.5	1
1212	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 604.e17-604.e24.	1.6	2
1213	Prostate Cancer in the Elderly Male: Diagnostic and Management Considerations. <i>Current Geriatrics Reports</i> , 2017, 6, 133-138.	1.1	2
1214	Does Patient Preference Measurement in Decision Aids Improve Decisional Conflict? A Randomized Trial in Men with Prostate Cancer. <i>Patient</i> , 2017, 10, 785-798.	2.7	21
1215	Rectal protection in prostate stereotactic radiotherapy: a retrospective exploratory analysis of two rectal displacement devices. <i>Journal of Medical Radiation Sciences</i> , 2017, 64, 266-273.	1.5	13
1216	Surgical Treatment of Male Postprostatectomy Incontinence: Current Concepts. <i>European Urology Focus</i> , 2017, 3, 364-376.	3.1	40

#	ARTICLE	IF	CITATIONS
1217	Reporting Erectile Function Outcomes After Radiation Therapy for Prostate Cancer: Challenges in Data Interpretation. <i>Journal of Sexual Medicine</i> , 2017, 14, 1260-1269.	0.6	13
1218	Development of an Activatable Fluorescent Probe for Prostate Cancer Imaging. <i>Bioconjugate Chemistry</i> , 2017, 28, 2069-2076.	3.6	26
1219	Intraoperative Retrograde Perfusion Sphincterometry to Evaluate Efficacy of Autologous Vas Deferens 6-Branch Suburethral Sling to Properly Restore Sphincteric Apparatus During Robot-Assisted Radical Prostatectomy. <i>Journal of Endourology</i> , 2017, 31, 878-885.	2.1	7
1220	A Walking Intervention Among Men With Prostate Cancer: A Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1021-e1028.	1.9	20
1221	The Null Effect of Bladder Neck Size on Incontinence Outcomes after Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 198, 1404-1408.	0.4	8
1222	Enhancing prostate cancer survivorship care through self-management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 564-568.	1.6	8
1223	International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 97.	2.4	18
1224	Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 181.	1.6	6
1225	Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study. <i>Scandinavian Journal of Urology</i> , 2017, 51, 33-37.	1.0	7
1226	Optimal design of longitudinal data analysis using generalized estimating equation models. <i>Biometrical Journal</i> , 2017, 59, 315-330.	1.0	16
1227	Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. <i>Prostate</i> , 2017, 77, 437-445.	2.3	24
1228	Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. <i>European Urology</i> , 2017, 72, 307-314.	1.9	19
1229	Sperm preservation and neutron contamination following proton therapy for prostate cancer study. <i>Acta Oncologica</i> , 2017, 56, 17-20.	1.8	6
1230	Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 197, 109-114.	0.4	23
1231	The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis. <i>Abdominal Radiology</i> , 2017, 42, 260-270.	2.1	44
1232	Risk of hospitalisation after primary treatment for prostate cancer. <i>BJU International</i> , 2017, 120, 48-55.	2.5	3
1233	From QOL to QALYs: Comparing nononcologic outcomes in prostate cancer survivors across treatments. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 69-75.	1.6	4
1234	Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. <i>European Urology</i> , 2017, 71, 729-737.	1.9	110

#	ARTICLE	IF	CITATIONS
1235	Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. <i>Journal of Urology</i> , 2017, 197, 376-384.	0.4	18
1236	A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 197, 369-375.	0.4	19
1237	The Impact of Partnership Status and Social Support on Health Related Quality of Life Outcomes in Men with Prostate Cancer. <i>Urology Practice</i> , 2017, 4, 225-231.	0.5	0
1238	Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer. <i>Practical Radiation Oncology</i> , 2017, 7, e117-e124.	2.1	10
1239	Long-term outcome of the adjustable transobturator male system (ATOMS): results of a European multicentre study. <i>BJU International</i> , 2017, 119, 785-792.	2.5	69
1240	Ureterorenoscopy with stenting and its effect on male sexual function: A controlled randomised prospective study. <i>Andrologia</i> , 2017, 49, e12746.	2.1	16
1241	Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality. <i>World Journal of Urology</i> , 2017, 35, 713-720.	2.2	23
1242	The Surgical Management of Prostate Cancer. <i>Seminars in Oncology</i> , 2017, 44, 347-357.	2.2	60
1243	Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy. <i>Radiation Oncology</i> , 2017, 12, 125.	2.7	7
1244	Researching the Research in Prostate Cancer: A Comparative Bibliometric Analysis of the Top 100 Cited Articles in the Field of Prostate Cancer. <i>Current Urology</i> , 2017, 11, 26-35.	0.6	8
1245	Crossing the perspectives of patients, families, and physicians on cancer treatment: A qualitative study. <i>Oncotarget</i> , 2017, 8, 22113-22122.	1.8	13
1246	Literature review of factors affecting continence after radical prostatectomy. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2017, 38, 9-17.	1.1	24
1247	The emerging role of patient reported outcomes in urology. <i>Canadian Urological Association Journal</i> , 2017, 11, 411.	0.6	1
1248	Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 227.	2.8	5
1249	Focal therapy for prostate cancer: the technical challenges. <i>Journal of Contemporary Brachytherapy</i> , 2017, 4, 383-389.	0.9	10
1250	Robot-assisted radical prostatectomy has lower biochemical recurrence than laparoscopic radical prostatectomy: Systematic review and meta-analysis. <i>Investigative and Clinical Urology</i> , 2017, 58, 152.	2.0	29
1251	Pelvic Radiation and Normal Tissue Toxicity. <i>Seminars in Radiation Oncology</i> , 2017, 27, 358-369.	2.2	56
1252	The efficacy and feasibility of total reconstruction versus nontotal reconstruction of the pelvic floor on short-term and long-term urinary continence rates after radical prostatectomy: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2017, 15, 228.	1.9	11

#	ARTICLE	IF	CITATIONS
1253	Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. <i>Radiation Oncology</i> , 2017, 12, 138.	2.7	14
1254	The Future of Altered Fractionation. <i>Medical Radiology</i> , 2017, , 41-63.	0.1	0
1255	Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2306-2314.	1.6	81
1256	The controversy surrounding penile rehabilitation after radical prostatectomy. <i>Translational Andrology and Urology</i> , 2017, 6, 2-11.	1.4	23
1257	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 896.	7.4	252
1258	The Role of Urodynamics in Post-Prostatectomy Incontinence. <i>Current Urology Reports</i> , 2018, 19, 21.	2.2	18
1259	Quality of life up to 10Âyears after external beam radiotherapy and/or brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2018, 17, 517-523.	0.5	9
1260	Racial disparity in oncologic and qualityâ€ofâ€life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial. <i>Cancer</i> , 2018, 124, 2841-2849.	4.1	7
1261	Comparison of erectile dysfunction guidelines between the UK (BSSM/NICE) and Europe (EAU). <i>Journal of Clinical Urology</i> , 2018, 11, 122-126.	0.1	2
1262	De novo overactive bladder after robotâ€assisted laparoscopic radical prostatectomy. <i>Neurourology and Urodynamics</i> , 2018, 37, 2008-2014.	1.5	27
1264	Prostate Cancer Screening. <i>Medical Clinics of North America</i> , 2018, 102, 199-214.	2.5	134
1265	Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data. <i>BMJ Open</i> , 2018, 8, e019409.	1.9	8
1266	Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. <i>Acta OncolÃ³gica</i> , 2018, 57, 582-588.	1.8	17
1267	Usability and acceptance evaluation of ACESO: a Web-based breast cancer survivorship tool. <i>Journal of Cancer Survivorship</i> , 2018, 12, 316-325.	2.9	7
1268	Complications of curative radiation treatment for early prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e392-e398.	1.1	2
1269	Quality of life among men with low-risk prostate cancer during the first year following diagnosis: the PREPARE prospective cohort study. <i>Translational Behavioral Medicine</i> , 2018, 8, 156-165.	2.4	9
1270	Impact of age on quality of life in patients with localized prostate cancer treated with highâ€dose rate brachytherapy combined with external beam radiotherapy. <i>International Journal of Urology</i> , 2018, 25, 366-371.	1.0	6
1271	Exploring the lived experience of gay men with prostate cancer: A phenomenological study. <i>European Journal of Oncology Nursing</i> , 2018, 33, 62-69.	2.1	25

#	ARTICLE	IF	CITATIONS
1272	Expecting the worst? The relationship between retrospective and prospective appraisals of illness on quality of life in prostate cancer survivors. <i>Psycho-Oncology</i> , 2018, 27, 1237-1243.	2.3	15
1273	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 702-709.	0.8	1
1274	Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-caesium: Results of a prospective phase II study. <i>Brachytherapy</i> , 2018, 17, 265-276.	0.5	12
1275	The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study. <i>Journal of Urology</i> , 2018, 199, 1202-1209.	0.4	49
1276	Bowel and urinary quality of life after whole-pelvic versus prostate-only volumetric-modulated arc therapy for localized prostate cancer. <i>Practical Radiation Oncology</i> , 2018, 8, e49-e55.	2.1	4
1277	Predictors of Patient and Partner Satisfaction Following Radical Prostatectomy. <i>Sexual Medicine Reviews</i> , 2018, 6, 295-301.	2.9	19
1279	Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up. <i>BJU International</i> , 2018, 121, 781-790.	2.5	26
1280	Predictors of long-term distress in female partners of men diagnosed with prostate cancer. <i>Psycho-Oncology</i> , 2018, 27, 946-954.	2.3	21
1281	The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 36.	2.4	18
1282	Quality Indicators for Global Benchmarking of Localized Prostate Cancer Management. <i>Journal of Urology</i> , 2018, 200, 319-326.	0.4	11
1283	Finding Value for Protons: The Case of Prostate Cancer?. <i>Seminars in Radiation Oncology</i> , 2018, 28, 131-137.	2.2	4
1284	Functional outcomes of robot-assisted radical prostatectomy in patients eligible for active surveillance. <i>World Journal of Urology</i> , 2018, 36, 1391-1397.	2.2	4
1285	Rectal ulcer and pseudomalignant epithelial changes after prostate seed brachytherapy: A rare complication with a diagnostic pitfall. <i>Annals of Diagnostic Pathology</i> , 2018, 34, 131-134.	1.3	1
1286	Relative efficiency of unequal versus equal cluster sizes in cluster randomized trials using generalized estimating equation models. <i>Biometrical Journal</i> , 2018, 60, 616-638.	1.0	17
1287	Decisional Quality in Patients With Small Renal Masses. <i>Urology</i> , 2018, 116, 76-80.	1.0	2
1289	Robot-assisted transvesical partial prostatectomy using a purpose-built single-port robotic system. <i>BJU International</i> , 2018, 122, 520-524.	2.5	37
1290	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	4.9	476
1291	Hypofractionated Versus Standard Fractionated Proton-beam Therapy for Low-risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 115-120.	1.3	30

#	ARTICLE	IF	CITATIONS
1292	Factors associated with current and severe physical side-effects after prostate cancer treatment: What men report. <i>European Journal of Cancer Care</i> , 2018, 27, e12589.	1.5	19
1293	Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 558-567.	1.3	27
1294	Information Seeking and Satisfaction with Information Sources Among Spouses of Men with Newly Diagnosed Local-Stage Prostate Cancer. <i>Journal of Cancer Education</i> , 2018, 33, 325-331.	1.3	14
1295	Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. <i>European Urology</i> , 2018, 73, 11-20.	1.9	76
1296	Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison. <i>Psycho-Oncology</i> , 2018, 27, 316-324.	2.3	28
1297	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	2.5	24
1298	Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e181-e192.	1.9	4
1299	Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance. <i>Journal of the National Cancer Institute</i> , 2018, 110, 420-425.	6.3	17
1300	Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 374-382.	0.8	42
1301	Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 383-390.	0.8	7
1302	Summary statement on screening for prostate cancer in Europe. <i>International Journal of Cancer</i> , 2018, 142, 741-746.	5.1	29
1303	Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. <i>BJU International</i> , 2018, 121, 540-548.	2.5	22
1304	Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer. <i>European Urology</i> , 2018, 73, 859-867.	1.9	33
1305	A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. <i>Practical Radiation Oncology</i> , 2018, 8, 40-47.	2.1	27
1306	Racial or Ethnic and Socioeconomic Disparities in Prostate Cancer Survivors' Prostate-specific Quality of Life. <i>Urology</i> , 2018, 112, 132-137.	1.0	24
1307	Crioterapia frente a high intensity focused ultrasound en el tratamiento del cáncer de próstata: resultados oncológicos y funcionales. <i>Actas Urológicas Españolas</i> , 2018, 42, 355-364.	0.7	2
1308	Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer. <i>Urology Practice</i> , 2018, 5, 471-479.	0.5	1
1309	Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance. <i>Cancer</i> , 2018, 124, 507-513.	4.1	6

#	ARTICLE	IF	CITATIONS
1310	Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals followâ€³ study. Prostate, 2018, 78, 202-212.	2.3	7
1311	Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance. Prostate Cancer and Prostatic Diseases, 2018, 21, 355-363.	3.9	2
1312	Washington State Spirits Privatization: How Satisfied were Liquor Purchasers Before and After, and by Type of Retail Store in 2014?. Substance Use and Misuse, 2018, 53, 1260-1266.	1.4	7
1313	Assessing the measurement invariance of the Brief Multidimensional Studentsâ€™ Life Satisfaction Scale in Chinese and American adolescents. Quality of Life Research, 2018, 27, 259-266.	3.1	8
1314	Coping and adjustment in men with prostate cancer: a systematic review of qualitative studies. Journal of Cancer Survivorship, 2018, 12, 155-168.	2.9	49
1315	Health-related-quality-of-life and toxicity after single fraction 19â€³Gy high-dose-rate prostate brachytherapy: Phase II trial. Radiotherapy and Oncology, 2018, 126, 278-282.	0.6	18
1316	Prospective Outcome Analysis of the Safety and Efficacy of Partial and Complete Cryoablation in Organ-confined Prostate Cancer. Urology, 2018, 112, 126-131.	1.0	16
1317	Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment. European Journal of Cancer Care, 2018, 27, e12729.	1.5	21
1318	A Younger Man With Localized Prostate Cancer Asks, â€œWhich Type of Radiation Is Right for Me?â€³. Journal of Clinical Oncology, 2018, 36, 1780-1784.	1.6	1
1319	A PERCEPÃƒO DE HOMENS E COMPANHEIRAS ACERCA DA DISFUNÃƒO ERÃ‰IL PÃƒS-PROSTATECTOMIA RADICAL. Texto E Contexto Enfermagem, 2018, 27, .	0.4	4
1320	Optimization of Risk Stratification in Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 528-532.	1.6	4
1321	Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1823-1830.	1.6	70
1324	Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques. Journal of Contemporary Brachytherapy, 2018, 10, 495-502.	0.9	15
1325	Quality of life worsened the most severely in patients immediately after intensity-modulated radiation therapy for prostate cancer. Research and Reports in Urology, 2018, Volume 10, 169-180.	1.0	2
1326	The Role of Preoperative Puborectal Muscle Function Assessed by Transperineal Ultrasound in Urinary Continence Outcomes at 3, 6, and 12 Months After Robotic-Assisted Radical Prostatectomy. International Neurourology Journal, 2018, 22, 114-122.	1.2	13
1327	Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer. Current Opinion in Urology, 2018, 28, 493-498.	1.8	8
1328	Impact of Pelvic Radiation Therapy on Inflatable Penile Prosthesis Reoperation Rates. Journal of Sexual Medicine, 2018, 15, 1653-1658.	0.6	3
1329	Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1438-1447.	0.8	39

#	ARTICLE	IF	CITATIONS
1330	Cancer de la prostate localis�� �� haut risque de r��cidive: r��sultats de la prise charge. African Journal of Urology, 2018, 24, 296-302.	0.4	1
1331	Artificial urinary sphincters for treating postprostatectomy incontinence: A contemporary experience from the UK. Research and Reports in Urology, 2018, Volume 10, 63-68.	1.0	7
1332	Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes. European Urology Oncology, 2018, 1, 540-547.	5.4	47
1333	Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis. International Urology and Nephrology, 2018, 50, 2113-2121.	1.4	3
1334	Functional and Oncological Outcomes of Robotic Radical Prostatectomy. , 2018, , 409-425.		0
1335	Psychometric Evaluation of PROMIS Sexual Function and Satisfaction Measures in a Longitudinal Population-Based Cohort of Men With Localized Prostate Cancer. Journal of Sexual Medicine, 2018, 15, 1792-1810.	0.6	12
1336	Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea. Thyroid, 2018, 28, 1587-1594.	4.5	141
1337	Changes in health-related quality of life after radical prostatectomy for prostate cancer: A longitudinal cohort study in Korea. Investigative and Clinical Urology, 2018, 59, 313.	2.0	8
1338	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer���From Cell Line Models to Liquid Biopsies. Diagnostics, 2018, 8, 60.	2.6	15
1339	Single perineal incision placement of artificial urinary sphincter with cadaveric correlation of sub-dartos pump placement. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 355-361.	1.5	2
1340	A Combination of Findings Obtained from Pre- and Postoperative Imaging Predict Recovery of Urinary Continence After Non-nerve-sparing Laparoscopic Radical Prostatectomy. Anticancer Research, 2018, 38, 5525-5530.	1.1	5
1341	Current status and progress of focal therapy in Asia. Current Opinion in Urology, 2018, 28, 529-535.	1.8	1
1342	Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 287-295.	0.8	62
1343	High-Intensity Focused Ultrasound (HIFU) Options for High-Risk Prostate Cancer. , 2018, , 157-168.		0
1344	Focal Treatment for Unilateral Prostate Cancer Using High-Intensity Focal Ultrasound: A Comprehensive Study of Pooled Data. Journal of Endourology, 2018, 32, 797-804.	2.1	16
1345	Prostate Cancer Screening Trends After United States Preventative Services Task Force Guidelines in an Underserved Population. Health Equity, 2018, 2, 55-61.	1.9	10
1347	Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study. European Urology Oncology, 2018, 1, 37-45.	5.4	16
1348	Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial. European Urology Oncology, 2018, 1, 134-142.	5.4	11

#	ARTICLE	IF	CITATIONS
1349	Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. Practical Radiation Oncology, 2018, 8, 445-451.	2.1	1
1350	Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients. PLoS ONE, 2018, 13, e0194173.	2.5	24
1351	Quality of Life Among Black Prostate Cancer Survivors: An Integrative Review. American Journal of Men's Health, 2018, 12, 1648-1664.	1.6	16
1352	Image-guided radiotherapy for prostate cancer. Translational Andrology and Urology, 2018, 7, 308-320.	1.4	44
1353	A Model to Predict Psychological- and Health-Related Adjustment in Men with Prostate Cancer: The Role of Post Traumatic Growth, Physical Post Traumatic Growth, Resilience and Mindfulness. Frontiers in Psychology, 2018, 9, 136.	2.1	25
1354	Low dose rate prostate brachytherapy. Translational Andrology and Urology, 2018, 7, 341-356.	1.4	30
1355	Site-dependent differences in the composite fibers of male pelvic plexus branches: an immunohistochemical analysis of donated elderly cadavers. BMC Urology, 2018, 18, 47.	1.4	4
1357	Identifying the Best Candidate for Radical Prostatectomy in High-Risk Prostate Cancer. , 2018, , 11-19.		0
1358	MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. American Journal of Roentgenology, 2018, 211, 595-604.	2.2	16
1359	Comparison of Late Urinary Symptoms Following SBRT and SBRT with IMRT Supplementation for Prostate Cancer. Current Urology, 2018, 11, 218-224.	0.6	5
1361	Prostate Cancer Survivorship. , 2018, , .		0
1362	Quality of life after low-dose rate-brachytherapy for prostate carcinoma “ long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series. Health and Quality of Life Outcomes, 2018, 16, 21.	2.4	10
1363	Prehabilitation for radical prostatectomy: A multicentre randomized controlled trial. Surgical Oncology, 2018, 27, 289-298.	1.6	83
1364	Assessment of donor satisfaction as an essential part of living donor kidney transplantation: an eleven-year retrospective study. Transplant International, 2018, 31, 1332-1344.	1.6	16
1366	Study design and protocol for a culturally adapted cognitive behavioral stress and self-management intervention for localized prostate cancer: The Encuentros de Salud study. Contemporary Clinical Trials, 2018, 71, 173-180.	1.8	13
1367	Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking. Advances in Radiation Oncology, 2018, 3, 630-638.	1.2	13
1368	Association between EBRT dose volume histograms and quality of life in prostate cancer patients. Reports of Practical Oncology and Radiotherapy, 2018, 23, 360-368.	0.6	10
1369	Preoperative Prostate MRI: A Road Map for Surgery. American Journal of Roentgenology, 2018, 211, 383-391.	2.2	26

#	ARTICLE	IF	CITATIONS
1370	Cryotherapy versus high-intensity focused ultrasound for treating prostate cancer: Oncological and functional results. <i>Actas Urológicas Españolas (English Edition)</i> , 2018, 42, 355-364.	0.2	0
1371	Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care. <i>Future Oncology</i> , 2018, 14, 2821-2832.	2.4	27
1372	Prolonged Duration of Incontinence for Men Before Initial Anti-incontinence Surgery: An Opportunity for Improvement. <i>Urology</i> , 2018, 119, 149-154.	1.0	9
1373	Perioperative Educational Interventions and Contemporary Sexual Function Outcomes of Radical Prostatectomy. <i>Sexual Medicine Reviews</i> , 2019, 7, 293-305.	2.9	7
1374	Ablation energies for focal treatment of prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 409-418.	2.2	34
1375	Physical activity and associations with treatment-induced adverse effects among prostate cancer patients. <i>Supportive Care in Cancer</i> , 2019, 27, 1001-1011.	2.2	5
1376	Sexual Health Recovery For Prostate Cancer Survivors: The Proposed Role Of Acceptance And Mindfulness-Based Interventions. <i>Sexual Medicine Reviews</i> , 2019, 7, 627-635.	2.9	11
1378	Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. <i>Tumori</i> , 2019, 105, 516-523.	1.1	8
1379	Brachytherapy: An overview for clinicians. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 386-401.	329.8	150
1380	Patient-reported sexual quality of life after different types of radical prostatectomy and radiotherapy: Analysis of a population-based prospective cohort. <i>Cancer</i> , 2019, 125, 3657-3665.	4.1	9
1381	Surgery for Male Stress Incontinence: Which Technique and When?. <i>European Urology Focus</i> , 2019, 5, 310-311.	3.1	5
1382	Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study. <i>BMC Cancer</i> , 2019, 19, 947.	2.6	4
1383	Adherence and barriers to penile rehabilitation over 2 years following radical prostatectomy. <i>BMC Urology</i> , 2019, 19, 89.	1.4	9
1384	Patient-reported health-related quality of life up to three years after the treatment with permanent brachytherapy: Outcome of the large-scale, prospective longitudinal study in Japanese "Prostate Cancer Outcome Study by Permanent I-125 Seed Implantation (J-POPS). <i>Brachytherapy</i> , 2019, 18, 806-813.	0.5	8
1386	Are TRUS-guided prostate biopsies in clinical practice robust enough to make a correct assessment of the surgical strategy in prostatectomies? Poor correlation between preoperative prostate biopsies and postoperative specimens. <i>Scandinavian Journal of Urology</i> , 2019, 53, 282-286.	1.0	1
1387	Quality of life outcomes after low dose-rate brachytherapy for localized prostate cancer: Current status and future perspectives. <i>International Journal of Urology</i> , 2019, 26, 1099-1105.	1.0	2
1388	Factors affecting urinary continence and sexual potency recovery after robotic-assisted radical prostatectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 703-712.	1.5	15
1389	Exercise Participation Experiences of Colorectal Cancer Survivors. <i>Asian Oncology Nursing</i> , 2019, 19, 98.	0.6	6

#	ARTICLE	IF	CITATIONS
1390	Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. <i>International Journal of Hyperthermia</i> , 2019, 36, 914-924.	2.5	6
1391	Comparison of Rating Scale, Time Tradeoff, and Conjoint Analysis Methods for Assessment of Preferences in Prostate Cancer. <i>Medical Decision Making</i> , 2019, 39, 816-826.	2.4	3
1392	Sildenafil Protects Endothelial Cells From Radiation-Induced Oxidative Stress. <i>Journal of Sexual Medicine</i> , 2019, 16, 1721-1733.	0.6	21
1393	Obstacles in prostate cancer screening: Current issues and future solutions. <i>Journal of Clinical Urology</i> , 2019, 12, 111-116.	0.1	0
1394	Creating a potential diagnostic for prostate cancer risk stratification (InformMDx [®]) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7). <i>Clinical Science</i> , 2019, 133, 269-286.	4.3	8
1395	The Quality of Life among Men Receiving Active Surveillance for Prostate Cancer: An Integrative Review. <i>Healthcare (Switzerland)</i> , 2019, 7, 14.	2.0	10
1396	Cost-Effectiveness Analysis of Silicone versus Saline Implant-Based Breast Reconstruction Using the BREAST-Q. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 276e-284e.	1.4	11
1397	Dose optimization and endorectal balloon for internal pudendal arteries sparing in prostate SBRT. <i>Physica Medica</i> , 2019, 61, 28-32.	0.7	8
1398	Fluorescence Detection of Prostate Cancer by an Activatable Fluorescence Probe for PSMA Carboxypeptidase Activity. <i>Journal of the American Chemical Society</i> , 2019, 141, 10409-10416.	13.7	69
1399	Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities. <i>International Journal of Urology</i> , 2019, 26, 950-954.	1.0	17
1400	Prostate brachytherapy with iodine-125 seeds: analysis of a single institutional cohort. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 288-298.	1.5	2
1401	Optimal designs in three-level cluster randomized trials with a binary outcome. <i>Statistics in Medicine</i> , 2019, 38, 3733-3746.	1.6	4
1402	Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. <i>European Urology</i> , 2019, 76, 228-237.	1.9	6
1403	Prostate cancer in sexual minorities and the influence of HIV status. <i>Nature Reviews Urology</i> , 2019, 16, 404-421.	3.8	17
1404	Weakly supervised natural language processing for assessing patient-centered outcome following prostate cancer treatment. <i>JAMIA Open</i> , 2019, 2, 150-159.	2.0	35
1405	Treatment-Related Sexual Side Effects From the Perspective of Partners of Men With Prostate Cancer. <i>Journal of Sex and Marital Therapy</i> , 2019, 45, 440-451.	1.5	5
1406	Does exercise impact gut microbiota composition in men receiving androgen deprivation therapy for prostate cancer? A single-blinded, two-armed, randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e024872.	1.9	8
1407	Cognitive function, depression, and anxiety in patients undergoing radical prostatectomy with and without adjuvant treatment. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 819-829.	2.2	14

#	ARTICLE	IF	CITATIONS
1408	Perplexity of penile rehabilitation following radical prostatectomy. Turkish Journal of Urology, 2019, 45, 77-82.	1.3	8
1409	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Molecular Metabolism, 2019, 25, 119-130.	6.5	55
1410	Original kinesio tape application for temporary diastasis recti reduction: a single case study. International Journal of Therapy and Rehabilitation, 2019, 26, 1-6.	0.3	0
1411	Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 334-342.	0.8	10
1412	Recent advances in radiotherapy and its associated side effects in cancer—a review. Journal of Basic and Applied Zoology, 2019, 80, .	0.9	63
1413	What Patients and Partners Want in Interventions That Support Sexual Recovery After Prostate Cancer Treatment: An Exploratory Convergent Mixed Methods Study. Sexual Medicine, 2019, 7, 184-191.	1.6	28
1414	Detrusorrhaphy during Robot-Assisted Radical Prostatectomy: Early Recovery of Urinary Continence and Surgical Technique. BioMed Research International, 2019, 2019, 1-8.	1.9	5
1415	Longitudinal Comparison of Patient-Level Outcomes and Costs Across Prostate Cancer Treatments With Urinary Problems. American Journal of Men's Health, 2019, 13, 155798831983532.	1.6	2
1416	Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer. European Urology, 2019, 76, 391-397.	1.9	11
1417	An examination of the relationship between patient satisfaction with healthcare and quality of life in a geriatric population with cancer in the Southeastern United States. Journal of Geriatric Oncology, 2019, 10, 787-791.	1.0	5
1418	Factors related to self-rated health and life satisfaction one year after radical prostatectomy for localised prostate cancer: a cross-sectional survey. Scandinavian Journal of Caring Sciences, 2019, 33, 688-697.	2.1	8
1419	Patient Experience Factors and Health-Related Quality of Life in Hospitalized Individuals. , 2019, 46, 238-247.		6
1420	Predictors for immediate recovery of continence following Retzius-sparing robot-assisted radical prostatectomy: a case-control study. International Urology and Nephrology, 2019, 51, 825-830.	1.4	11
1421	End-to-side Somatic-to-autonomic Nerve Grafting to Restore Erectile Function and Improve Quality of Life After Radical Prostatectomy. European Urology, 2019, 76, 189-196.	1.9	13
1422	Long-Term Patient-Reported Rectal Bleeding and Bowel-Related Quality of Life After Cs-131 Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 622-630.	0.8	12
1423	Morphologic changes after bladder neck intussusception in laparoscopic radical prostatectomy contribute to early postoperative continence. International Urology and Nephrology, 2019, 51, 1157-1165.	1.4	1
1424	Patient-reported outcomes and urodynamic findings in men with persistent lower urinary tract symptoms following robot-assisted radical prostatectomy. Neurourology and Urodynamics, 2019, 38, 1353-1362.	1.5	9
1425	Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial. Journal of Clinical Oncology, 2019, 37, 1326-1335.	1.6	23

#	ARTICLE	IF	CITATIONS
1426	Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. <i>Urology</i> , 2019, 127, 53-60.	1.0	11
1427	Dose to the penile bulb and individual patient anatomy are predictive of erectile dysfunction in men treated with ¹²⁵ I low dose rate brachytherapy for localized prostate cancer. <i>Acta Oncologica</i> , 2019, 58, 1029-1035.	1.8	7
1428	Diffuse Peripheral Zone T2 Hypointensity. <i>Journal of Computer Assisted Tomography</i> , 2019, 43, 641-644.	0.9	2
1430	Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. <i>European Urology Oncology</i> , 2019, 2, 189-195.	5.4	10
1431	Active Treatment in Low-Risk Prostate Cancer: A Population-Based Study. <i>Current Oncology</i> , 2019, 26, 535-540.	2.2	6
1432	High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores. <i>Brachytherapy</i> , 2019, 18, 793-799.	0.5	8
1433	MRI-guided, transrectal, intraprostatic steam application as potential focal therapeutic modality for prostatic diseases in a large animal translational model: A feasibility follow-up study. <i>PLoS ONE</i> , 2019, 14, e0226764.	2.5	3
1434	Predictors for lower urinary tract symptoms and the urinary specific quality of life in prostate cancer patients. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 482-487.	1.4	4
1435	Sexual Preservation With Radiotherapy: Think Target, Not Tool. <i>Journal of Sexual Medicine</i> , 2019, 16, 1871-1873.	0.6	0
1436	Robotic radical prostatectomy after aborted prostatectomy: still feasible? The experience from a tertiary care center. <i>Journal of Robotic Surgery</i> , 2019, 13, 407-412.	1.8	2
1437	Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer. <i>Journal of Radiation Research</i> , 2019, 60, 270-280.	1.6	8
1438	Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer. <i>European Journal of Cancer Care</i> , 2019, 28, e12949.	1.5	11
1439	MRI -guided transurethral insonation of silica-shell phase-shift emulsions in the prostate with an advanced navigation platform. <i>Medical Physics</i> , 2019, 46, 774-788.	3.0	2
1440	Retzius-sparing versus standard robot-assisted radical prostatectomy: a prospective randomized comparison on immediate continence rates. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 2187-2196.	2.4	76
1441	Sleep quality mediating the association of personality traits and quality of life among underground workers and surface workers of Chinese coal mine: A multi-group SEM with latent response variable mediation analysis. <i>Psychiatry Research</i> , 2019, 272, 196-205.	3.3	7
1442	Outcomes of Prostatectomy versus Radiation Therapy in the Management of Clinically Localized Prostate Cancer Patients Within the PLCO Trial. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e329-e338.	1.9	2
1443	Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 11.	2.4	17
1444	Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors. <i>Supportive Care in Cancer</i> , 2019, 27, 3365-3373.	2.2	17

#	ARTICLE	IF	CITATIONS
1445	Functional results in the treatment of localized prostate cancer. An updated literature review. Revista Internacional De Andrología, 2019, 17, 143-154.	0.3	1
1446	Long-term oncological and functional outcomes support use of low-dose-rate brachytherapy with or without external beam radiation in young men (≤60 years) with localized prostate cancer. Brachytherapy, 2019, 18, 192-197.	0.5	7
1447	50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. International Journal of Radiation Oncology Biology Physics, 2019, 103, 320-334.	0.8	28
1448	A pilot evaluation of the expanded prostate cancer index composite for clinical practice (EPIC-CP) tool in Ontario. Quality of Life Research, 2019, 28, 771-782.	3.1	12
1449	Stereotactic Radiosurgery for Prostate Cancer. , 2019, , .		1
1450	Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. American Journal of Roentgenology, 2019, 212, 351-356.	2.2	46
1451	Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands. Brachytherapy, 2019, 18, 13-21.	0.5	7
1452	Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 324-330.	1.6	11
1453	Quality of Life After Open Radical Prostatectomy Compared with Robot-assisted Radical Prostatectomy. European Urology Focus, 2019, 5, 389-398.	3.1	38
1454	Modeling recovery curves with application to prostatectomy. Biostatistics, 2019, 20, 549-564.	1.5	4
1455	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. Journal of the National Cancer Institute, 2020, 112, 179-190.	6.3	71
1456	Quality of life among patients after cystoprostatectomy as the treatment for locally advanced prostate cancer with bladder invasion. Aging Male, 2020, 23, 847-853.	1.9	3
1457	Pfilates and Hypopressives for the Treatment of Urinary Incontinence After Radical Prostatectomy: Results of a Feasibility Randomized Controlled Trial. PM and R, 2020, 12, 55-63.	1.6	12
1458	Sexual well-being and diurnal cortisol after prostate cancer treatment. Journal of Health Psychology, 2020, 25, 1796-1801.	2.3	1
1459	Contrast media kinetics in multiparametric magnetic resonance imaging before radical prostatectomy predicts the probability of postoperative incontinence. World Journal of Urology, 2020, 38, 1741-1748.	2.2	7
1460	A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy. Asian Journal of Urology, 2020, 7, 161-169.	1.2	7
1461	Comparative analysis of penile implants in patients with vasculogenic erectile dysfunction versus postradical prostatectomy erectile dysfunction. International Journal of Impotence Research, 2020, 32, 606-610.	1.8	1
1463	Is there still a role for bilateral orchidectomy in androgen-deprivation therapy for metastatic prostate cancer?. Arab Journal of Urology Arab Association of Urology, 2020, 18, 9-13.	1.5	3

#	ARTICLE	IF	CITATIONS
1464	Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e21-e27.	1.9	4
1465	Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan. <i>International Journal of Urology</i> , 2020, 27, 17-23.	1.0	17
1466	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. <i>Cancer</i> , 2020, 126, 583-592.	4.1	9
1467	Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 225-230.	1.6	19
1468	Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening. <i>Cancer</i> , 2020, 126, 694-696.	4.1	9
1469	Nonlinear microscopy for detection of prostate cancer: analysis of sensitivity and specificity in radical prostatectomies. <i>Modern Pathology</i> , 2020, 33, 916-923.	5.5	15
1470	Male Sexual and Reproductive Health—Does the Urologist Have a Role in Addressing Gender Inequality in Life Expectancy?. <i>European Urology Focus</i> , 2020, 6, 791-800.	3.1	11
1471	Financial toxicity associated with treatment of localized prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 28-40.	3.8	44
1472	Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). <i>Cancer Epidemiology</i> , 2020, 64, 101623.	1.9	14
1473	Mapping the prevalence of the neglected sexual side effects after prostate cancer treatment and the questionnaires used in their screening: a scoping review protocol. <i>Systematic Reviews</i> , 2020, 9, 214.	5.3	3
1474	Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. <i>BMJ, The</i> , 2020, 371, m3503.	6.0	43
1475	The Pelvic Health Physical Therapy and the Prostatectomy. , 0, , .		0
1476	Postoperative membranous urethral length is the single most important surgical factor predicting recovery of postoperative urinary continence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 930.e7-930.e12.	1.6	10
1477	Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy. <i>International Journal of Urology</i> , 2020, 27, 1087-1093.	1.0	3
1478	Simultaneous Detection of Signal Regions Using Quadratic Scan Statistics With Applications to Whole Genome Association Studies. <i>Journal of the American Statistical Association</i> , 2022, 117, 823-834.	3.1	6
1479	Transitioning from conformal radiotherapy to intensity-modulated radiotherapy after radical prostatectomy: Clinical benefit, oncologic outcomes and incidence of gastrointestinal and urinary toxicities. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 568-573.	0.6	3
1480	Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.. <i>The Cochrane Library</i> , 2020, , .	2.8	3
1481	Dosimetric correlations with urinary quality of life in patients receiving post-prostatectomy radiation therapy. <i>Journal of Radiation Oncology</i> , 2020, 9, 97-102.	0.7	0

#	ARTICLE	IF	CITATIONS
1482	Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 7925-7934.	2.8	6
1483	Prognostic classifier for predicting biochemical recurrence in localized prostate cancer patients after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 493.e17-493.e25.	1.6	4
1484	Disability, psychological distress and quality of life in relation to cancer diagnosis and cancer type: population-based Australian study of 22,505 cancer survivors and 244,000 people without cancer. <i>BMC Medicine</i> , 2020, 18, 372.	5.5	53
1485	Unmet supportive care needs and determinants among cancer patients treated at University of Gondar Specialized Hospital, Northwest Ethiopia: A prospective cross-sectional study. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1869-1877.	0.9	5
1486	Overtreatment and Underutilization of Watchful Waiting in Men With Limited Life Expectancy: An Analysis of the Michigan Urological Surgery Improvement Collaborative Registry. <i>Urology</i> , 2020, 145, 190-196.	1.0	4
1487	Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1196-1203.	0.8	10
1488	Retzius-sparing robot-assisted radical prostatectomy improves early recovery of urinary continence: a randomized, controlled, single-blind trial with a 1-year follow-up. <i>BJU International</i> , 2020, 126, 633-640.	2.5	33
1489	Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study. <i>BMC Cancer</i> , 2020, 20, 757.	2.6	15
1490	Study protocol: a lifestyle intervention for African American and Hispanic prostate cancer survivors on active surveillance and their partners. <i>Pilot and Feasibility Studies</i> , 2020, 6, 111.	1.2	2
1491	Role of prehabilitation following major uro-oncologic surgery: a narrative review. <i>World Journal of Urology</i> , 2022, 40, 1289-1298.	2.2	18
1492	Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials. <i>Cancer Medicine</i> , 2020, 9, 7363-7374.	2.8	19
1493	Management of male sexual dysfunction after cancer treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 389-394.	1.6	7
1494	Factors affecting health-related quality of life among prostate cancer patients: A systematic review. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1997-2010.	0.9	17
1495	The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts. <i>Journal of Clinical Medicine</i> , 2020, 9, 2987.	2.4	11
1496	Phenotyping severity of patient-centered outcomes using clinical notes: A prostate cancer use case. <i>Learning Health Systems</i> , 2020, 4, e10237.	2.0	11
1497	Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 628-635.	1.3	6
1498	Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.. <i>The Cochrane Library</i> , 2020, 2020, CD013641.	2.8	28
1499	Cultural Adaptation of Evidence-Based Lifestyle Interventions for African American Men With Prostate Cancer: A Dyadic Approach. <i>American Journal of Men's Health</i> , 2020, 14, 155798832094544.	1.6	3

#	ARTICLE	IF	CITATIONS
1500	Complications after male adjustable suburethral sling implantation. <i>Wideochirurgia I Inne Techniki Maloinwazyjne</i> , 2020, 15, 496-502.	0.7	2
1501	The implementation of a novel patient symptom screening tool: The Odette Cancer Centre (OCC) experience. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2020, 51, 546-549.	0.3	0
1502	Do mobile health (mHealth) services ensure the quality of health life? An integrated approach from a developing country context. <i>Journal of Marketing Communications</i> , 2022, 28, 152-182.	4.0	22
1503	Dynamic contrast enhancement in prostate MRI as predictor of erectile function and recovery after radical prostatectomy. <i>Aging Male</i> , 2020, 23, 1518-1526.	1.9	1
1505	Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution. <i>BMC Urology</i> , 2020, 20, 163.	1.4	3
1506	Long-term follow-up 3Âyears after a randomized rehabilitation study among radiated prostate cancer survivors. <i>Journal of Cancer Survivorship</i> , 2021, 15, 668-676.	2.9	9
1507	Anatomical robotic prostatectomy: technical factors to achieve superb continence and erectile function. <i>Translational Andrology and Urology</i> , 2020, 9, 887-897.	1.4	3
1508	Healthâ€related quality of life in longâ€term prostate cancer survivors after nerveâ€sparing and nonâ€nerveâ€sparing radical prostatectomyâ€Results from the multiregional PROCAS study. <i>Cancer Medicine</i> , 2020, 9, 5416-5424.	2.8	6
1509	Challenges in Reporting the Effect of Radiotherapy on Erectile Function. <i>Journal of Sexual Medicine</i> , 2020, 17, 1053-1059.	0.6	5
1510	Do voiding urodynamic parameters predict the success of adjustable transobturator male system (ATOMS) to treat postprostatectomy urinary incontinence?. <i>Neurourology and Urodynamics</i> , 2020, 39, 1746-1752.	1.5	7
1511	Prostate MRI Essentials. , 2020, , .		1
1512	The effect of radiation therapy on post-prostatectomy urinary function. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 442-446.	0.6	4
1513	Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results. <i>Advances in Radiation Oncology</i> , 2020, 5, 388-395.	1.2	2
1514	Associations between selfâ€reported physical activity, quality of life, and emotional wellâ€being in men with prostate cancer on active surveillance. <i>Psycho-Oncology</i> , 2020, 29, 1044-1050.	2.3	8
1515	High-intensity interval training produces a significant improvement in fitness in less than 31 days before surgery for urological cancer: a randomised control trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 696-704.	3.9	38
1516	A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 794.e1-794.e9.	1.6	4
1517	Magnetic Resonance Imaging Assessment After Therapy in Prostate Cancer. <i>Topics in Magnetic Resonance Imaging</i> , 2020, 29, 47-58.	1.2	5
1518	Perceived impact of diabetes management in patients with cancer: the experience of a tertiary referral center. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2020, 29, 903.	1.6	0

#	ARTICLE	IF	CITATIONS
1519	Health-related quality of life in Japanese patients with prostate cancer following proton beam therapy: an institutional cohort study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 519-527.	1.3	2
1520	Retropubic vs transobturator Argus adjustable male sling: Results from a multicenter study. <i>Neurourology and Urodynamics</i> , 2020, 39, 987-993.	1.5	7
1521	Use of Duloxetine for Postprostatectomy Stress Urinary Incontinence: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 618-628.	3.1	18
1522	A Pilot Study Assessing Aspects of Sexual Function Predicted to Be Important After Treatment for Prostate Cancer in Gay Men: An Underserved Domain Highlighted. <i>LGBT Health</i> , 2020, 7, 271-276.	3.4	15
1523	Effect of different communication strategies about stopping cancer screening on screening intention and cancer anxiety: a randomised online trial of older adults in Australia. <i>BMJ Open</i> , 2020, 10, e034061.	1.9	11
1524	Retzius-sparing Robotic-assisted Radical Prostatectomy Facilitates Early Continence Regardless of Neurovascular Bundle Sparing. <i>Anticancer Research</i> , 2020, 40, 4075-4080.	1.1	6
1525	Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15). <i>Frontiers in Oncology</i> , 2020, 10, 1060.	2.8	7
1526	Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation. <i>JCO Oncology Practice</i> , 2020, 16, e1524-e1531.	2.9	6
1527	Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT). <i>Frontiers in Oncology</i> , 2019, 9, 1528.	2.8	5
1528	MiRNA-Based Inspired Approach in Diagnosis of Prostate Cancer. <i>Medicina (Lithuania)</i> , 2020, 56, 94.	2.0	10
1529	The role of cystoprostatectomy in management of locally advanced prostate cancer: a systematic review. <i>World Journal of Surgical Oncology</i> , 2020, 18, 14.	1.9	2
1530	Do features of randomized controlled trials of pelvic floor muscle training for postprostatectomy urinary incontinence differentiate successful from unsuccessful patient outcomes? A systematic review with a series of meta-analyses. <i>Neurourology and Urodynamics</i> , 2020, 39, 533-546.	1.5	15
1531	A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The APBS Trial (NCT03380806). <i>Clinical Genitourinary Cancer</i> , 2020, 18, e410-e415.	1.9	6
1532	Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 149.	7.4	172
1534	The Impact of Three Different Bladder Neck Reconstruction Techniques on Urinary Continence after Laparoscopic Radical Prostatectomy. <i>Journal of Endourology</i> , 2020, 34, 663-670.	2.1	2
1535	Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life. <i>BJU International</i> , 2020, 126, 367-372.	2.5	16
1536	High-intensity focused ultrasound for prostate cancer. <i>Expert Review of Medical Devices</i> , 2020, 17, 427-433.	2.8	34
1537	Examined and Positive Lymph Node Counts Are Associated with Mortality in Prostate Cancer: A Population-Based Analysis. <i>Urologia Internationalis</i> , 2020, 104, 699-709.	1.3	6

#	ARTICLE	IF	CITATIONS
1538	Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 118-123.	2.0	10
1539	Risk of erectile dysfunction after modern radiotherapy for intact prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 128-134.	3.9	10
1540	Early Effects of High-intensity Focused Ultrasound (HIFU) Treatment for Prostate Cancer on Fecal Continence and Anorectal Physiology. <i>Urology</i> , 2021, 148, 211-216.	1.0	0
1541	T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. <i>European Radiology</i> , 2021, 31, 325-332.	4.5	3
1542	Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial. <i>European Urology</i> , 2021, 79, 188-197.	1.9	29
1543	Pelvic Anatomical Features After Retzius-Sparing Robot-Assisted Radical Prostatectomy Intended for Early Recovery of Urinary Symptoms. <i>Journal of Endourology</i> , 2021, 35, 296-304.	2.1	11
1544	Daily urine loss immediately after urethral catheter removal may be an effective predictor of long-term urinary incontinence following robot-assisted laparoscopic radical prostatectomy. <i>International Journal of Clinical Practice</i> , 2021, 75, e13736.	1.7	2
1545	Evaluation of long-term living conditions in patients treated for localised prostate cancer. <i>European Journal of Cancer Care</i> , 2021, 30, e13333.	1.5	0
1546	Optimizing Surgical Techniques in Robot-Assisted Radical Prostatectomy. <i>Urologic Clinics of North America</i> , 2021, 48, 1-9.	1.8	3
1547	Prevalence of post-prostatectomy erectile dysfunction and a review of the recommended therapeutic modalities. <i>International Journal of Impotence Research</i> , 2021, 33, 401-409.	1.8	26
1548	Urinary Outcomes for Men With High Baseline International Prostate Symptom Scores Treated With Prostate SBRT. <i>Advances in Radiation Oncology</i> , 2021, 6, 100582.	1.2	3
1549	The Role of Educational Level and Cognitive Status in Men Undergoing Artificial Urinary Sphincter Implantation. <i>Urology</i> , 2021, 147, 243-249.	1.0	3
1550	The EPIC-26 domain scores after radical prostatectomy are associated with the personality trait of neuroticism. <i>International Urology and Nephrology</i> , 2021, 53, 691-698.	1.4	4
1551	Effect of the exercise programme on the quality of life of prostate cancer survivors: A randomized controlled trial. <i>International Journal of Nursing Practice</i> , 2021, 27, e12883.	1.7	21
1552	Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 11-25.	2.2	23
1553	How to implement the requirements of a quality assurance system for prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 41-47.	2.2	1
1554	Inverse planning in high-dose rate brachytherapy improves quality of life of prostate cancer patients compared with forward planning. <i>International Journal of Clinical Oncology</i> , 2021, 26, 728-735.	2.2	0
1555	Strahlentherapie: Methodenspezifische Komplikationen. , 2021, , 453-466.		0

#	ARTICLE	IF	CITATIONS
1556	Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 1-11.	0.9	2
1557	Improving Outcomes for Early Return of Potency. , 2021, , 1073-1079.		0
1558	Pelvic floor muscle exercise with biofeedback helps regain urinary continence after robot-assisted radical prostatectomy. <i>Yeungnam University Journal of Medicine</i> , 2021, 38, 39-46.	1.4	3
1559	Advancement and properties of circular RNAs in prostate cancer: An emerging and compelling frontier for discovering. <i>International Journal of Biological Sciences</i> , 2021, 17, 651-669.	6.4	8
1560	Long-term outcomes of a prospective randomized trial of 131Cs/125I permanent prostate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 38-43.	0.5	3
1561	Dynamic Changes of Generic Quality of Life after Different Treatments for Localized Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 158.	2.4	4
1562	The Management of Prostate Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 3-23.	0.1	0
1563	MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4941-4953.	4.1	9
1564	Differences in Implementation Outcomes of a Shared Decision-Making Program for Men with Prostate Cancer between an Academic Medical Center and County Health Care System. <i>Medical Decision Making</i> , 2021, 41, 120-132.	2.4	2
1565	The Use of Theory to Develop Physical Activity Interventions in Urological Cancer Survivors: A Narrative Review. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151109.	1.5	1
1566	Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 131-136.	1.3	6
1567	Accuracy of Urologic Conditions Portrayed on <i>Greyâ€™s Anatomy</i>. <i>Health Education and Behavior</i> , 2022, 49, 323-325.	2.5	3
1568	Biochemical recurrence of pathological T2+ localized prostate cancer after robotic-assisted radical prostatectomy: A 10-year surveillance. <i>World Journal of Clinical Cases</i> , 2021, 9, 1026-1036.	0.8	2
1569	Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Sexual Function â€“ A Randomized Clinical Trial. <i>Journal of Sexual Medicine</i> , 2021, 18, 327-338.	0.6	6
1570	Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 235-245.	10.7	88
1571	Peritricuspid annular prostate pellet. <i>BMJ Case Reports</i> , 2021, 14, e238076.	0.5	0
1572	Is Retzius-sparing robot-assisted laparoscopic radical prostatectomy effective in early continence? A single-center experience of the first 50 patients. <i>Turkish Journal of Urology</i> , 2021, 47, 25-130.	1.3	1
1573	Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer. <i>Cureus</i> , 2021, 13, e13780.	0.5	1

#	ARTICLE	IF	CITATIONS
1574	Evaluation of Patient- and Surgeon-Specific Variations in Patient-Reported Urinary Outcomes 3 Months After Radical Prostatectomy From a Statewide Improvement Collaborative. JAMA Surgery, 2021, 156, e206359.	4.3	13
1575	Oncologic Outcomes of Radical Prostatectomy and High-Dose Intensity-Modulated Radiotherapy with Androgen-Deprivation Therapy for Relatively Young Patients with Unfavorable Intermediate-Risk Prostate Adenocarcinoma. Cancers, 2021, 13, 1517.	3.7	7
1576	Quality of Life in Brain Tumor Patients and Their Relatives Heavily Depends on Social Support Factors during the COVID-19 Pandemic. Cancers, 2021, 13, 1276.	3.7	13
1577	Association between cystographic anastomotic urinary leakage following retropubic radical prostatectomy and early urinary incontinence. Yeungnam University Journal of Medicine, 2021, 38, 142-147.	1.4	1
1578	Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy. Nature Reviews Urology, 2021, 18, 259-281.	3.8	29
1579	The interaction between inflammation, urinary symptoms and erectile dysfunction in early-stage prostate cancer treated with brachytherapy. Andrologia, 2021, 53, e14070.	2.1	1
1580	A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer, 2021, 127, 2631-2640.	4.1	3
1581	Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 1041-1047.	3.9	13
1582	Visualizing the urethra by magnetic resonance imaging without usage of a catheter for radiotherapy of prostate cancer. Physics and Imaging in Radiation Oncology, 2021, 18, 1-4.	2.9	8
1583	Comparative effectiveness of robotic and open radical prostatectomy. Translational Andrology and Urology, 2021, 10, 2158-2170.	1.4	3
1584	Retzius-sparing versus standard robot-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer. BJU International, 2021, 128, 12-20.	2.5	16
1585	One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study. BMC Urology, 2021, 21, 81.	1.4	1
1586	External beam radiation therapy carries lower risk of sexual dysfunction as compared to radical prostatectomy in treatment of patients with localized prostate cancer. Clinical Research in Practice the Journal of Team Hippocrates, 2021, 7, .	0.1	0
1587	Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. BMC Cancer, 2021, 21, 538.	2.6	29
1588	A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2171-2186.	3.6	14
1589	The one hundred most cited publications in prostate brachytherapy. Brachytherapy, 2021, 20, 611-623.	0.5	1
1590	Institute for Clinical and Economic Review. , 2021, , 112-141.		0
1591	Effect of Exercise Adjunct to Radiation and Androgen Deprivation Therapy on Patient-Reported Treatment Toxicity in Men With Prostate Cancer: A Secondary Analysis of 2 Randomized Controlled Trials. Practical Radiation Oncology, 2021, 11, 215-225.	2.1	8

#	ARTICLE	IF	CITATIONS
1592	Predictive Factors of De Novo Overactive Bladder After Radical Prostatectomy in Patients With Clinically Localized Prostate Cancer: A Prospective Observational Study. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 109-116.	0.1	1
1593	The Role of Aerobic Exercise in Erectile Dysfunction: A Review of Randomized Controlled Trials. <i>Exercise Science</i> , 2021, 30, 147-157.	0.3	1
1594	Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 238-247.	3.9	2
1595	Promoter Methylation of PRKCB, ADAMTS12, and NAALAD2 Is Specific to Prostate Cancer and Predicts Biochemical Disease Recurrence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6091.	4.1	11
1596	Active surveillance for prostate cancer—will the discoveries of the last 5 years change the future?. <i>Translational Andrology and Urology</i> , 2021, 10, 2828-2831.	1.4	6
1597	Prostate Cancer From a Sex and Gender Perspective: A Review. <i>Sexual Medicine Reviews</i> , 2022, 10, 142-154.	2.9	13
1598	Focal therapy for localized cancer: a patent review. <i>Expert Review of Medical Devices</i> , 2021, 18, 751-769.	2.8	1
1599	Ten-year treatment complication outcomes of radical prostatectomy vs external beam radiation vs brachytherapy for 1503 patients with intermediate risk prostate cancer. <i>Brachytherapy</i> , 2021, 20, 1083-1089.	0.5	7
1601	Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01). <i>European Urology</i> , 2021, 79, 750-759.	1.9	54
1602	Patient surgical satisfaction after da Vinci® single-port and multi-port robotic-assisted radical prostatectomy: propensity score-matched analysis. <i>Journal of Robotic Surgery</i> , 2022, 16, 473-481.	1.8	17
1603	Intraoperative and postoperative surgical complications after ureteroscopy, retrograde intrarenal surgery, and percutaneous nephrolithotomy: a systematic review. <i>Minerva Urology and Nephrology</i> , 2021, 73, 309-332.	2.5	38
1604	A Study of Predictive Models for Early Outcomes of Post-Prostatectomy Incontinence: Machine Learning Approach vs. Logistic Regression Analysis Approach. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6225.	2.5	4
1605	Understanding Treatment Tolerability in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2150-2163.	1.6	33
1606	Efficacy of transcutaneous perineal electrostimulation versus intracavitary anal electrostimulation in the treatment of urinary incontinence after a radical prostatectomy: Randomized controlled trial. <i>Neurourology and Urodynamics</i> , 2021, 40, 1761-1769.	1.5	5
1607	Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. <i>Journal of Personalized Medicine</i> , 2021, 11, 664.	2.5	11
1608	Quality of Life After Prostate Cancer Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 727-730.	0.8	3
1609	Clipless Robotic-assisted Radical Prostatectomy and Impact on Outcomes. <i>European Urology Focus</i> , 2022, 8, 1176-1185.	3.1	7
1610	Quality of life in urologic cancer patients: importance of and satisfaction with specific quality of life domains. <i>Quality of Life Research</i> , 2022, 31, 759-767.	3.1	7

#	ARTICLE	IF	CITATIONS
1611	A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1082-1089.	0.8	19
1612	Co-creating an empowering health education intervention for urological cancer patients. <i>Health Education Journal</i> , 2021, 80, 948-960.	1.2	2
1613	Medium-term oncological and functional outcomes of hemi-gland brachytherapy using iodine-125 seeds for intermediate-risk unilateral prostate cancer. <i>Brachytherapy</i> , 2021, 20, 842-848.	0.5	5
1614	Psycho-Oncology: A Bibliometric Review of the 100 Most-Cited Articles. <i>Healthcare (Switzerland)</i> , 2021, 9, 1008.	2.0	4
1615	Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 1107-1113.	0.5	2
1616	Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil. <i>International Journal of Urology</i> , 2021, 28, 1171-1176.	1.0	1
1618	Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. <i>Journal of Urology</i> , 2022, 207, 127-136.	0.4	7
1619	Gamma-H2AX Foci Decay Ratio as a Stronger Predictive Factor of Late Radiation Toxicity Than Dose-Volume Parameters in a Prospective Cohort of Prostate Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 212-221.	0.8	4
1620	PSA: Declining utilization of prostate brachytherapy. <i>Brachytherapy</i> , 2021, , .	0.5	5
1621	Novel platinum bipolar electrode for irreversible electroporation in prostate cancer: preclinical study in the beagle prostate. <i>Scientific Reports</i> , 2021, 11, 17194.	3.3	9
1622	Oncological and Functional Outcomes of Patients Undergoing Individualized Partial Gland Cryoablation of the Prostate: A Single-Institution Experience. <i>Journal of Endourology</i> , 2021, 35, 1290-1299.	2.1	15
1623	Visceral adiposity is associated with worse urinary and sexual function recovery after radical prostatectomy: Results from a longitudinal cohort study. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 285-290.	0.8	2
1624	Proton therapy for prostate cancer: current state and future perspectives. <i>British Journal of Radiology</i> , 2022, 95, 20210670.	2.2	5
1625	Reconstruction of the Denonvillier's fascia and posterior ligament of the external urethral sphincter: Assessment of its effect on urinary continence after laparoscopic radical prostatectomy. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 274-279.	0.8	1
1626	Erectile dysfunction resulting from pelvic surgery is associated with changes in cavernosal gene expression indicative of cavernous nerve injury. <i>Andrologia</i> , 2022, 54, e14247.	2.1	2
1627	Clinical use of expanded prostate cancer index composite-based health-related quality of life outcomes after robot-assisted radical prostatectomy for localized prostate cancer. <i>Prostate International</i> , 2021, 10, 62-67.	2.3	3
1628	Radiotherapy or Surgery? Comparative, Qualitative Assessment of Online Patient Education Materials on Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 3420-3429.	2.2	9
1629	An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?. <i>European Urology</i> , 2022, 81, 5-33.	1.9	66

#	ARTICLE	IF	CITATIONS
1630	Long-term functional outcomes after robot-assisted prostatectomy compared to laparoscopic prostatectomy: Results from a national retrospective cluster study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2658-2666.	1.0	7
1631	Hard Times: Prostate Cancer Patients's™ Experiences with Erectile Aids. <i>Journal of Sexual Medicine</i> , 2021, 18, 1775-1787.	0.6	1
1632	Cryopreserved placental tissue allograft accelerates time to continence following robot-assisted radical prostatectomy. <i>Journal of Robotic Surgery</i> , 2021, 15, 877-883.	1.8	3
1633	Sexual function and rehabilitation after radiation therapy for prostate cancer: a review. <i>International Journal of Impotence Research</i> , 2021, 33, 410-417.	1.8	7
1634	High Dose Rate Prostate Brachytherapy. <i>Practical Guides in Radiation Oncology</i> , 2021, , 127-151.	0.1	0
1635	Efficacy of transcutaneous perineal electrostimulation versus intracavitary anal electrostimulation in the treatment of urinary incontinence after a radical prostatectomy: randomized controlled trial study protocol. <i>BMC Urology</i> , 2021, 21, 12.	1.4	6
1636	Epidemiology of Nocturia: Evaluation of Prevalence, Incidence, Impact and Risk Factors. , 2012, , 77-107.		2
1637	Multi-Atlas-Based Segmentation of Pelvic Structures from CT Scans for Planning in Prostate Cancer Radiotherapy. , 2014, , 623-656.		20
1638	Restoring Intimacy in Relationships Affected by Cancer. , 2011, , 739-750.		2
1639	MRI-Guided Laser Ablation for Localized Prostate Cancer. , 2013, , 297-307.		3
1640	Impact of Obesity, Race, and Ethnicity on Cancer Survivorship. , 2014, , 63-90.		4
1641	Urinary Incontinence: Conservative and Medical Management and Injectable Therapy. , 2016, , 31-52.		1
1642	Active Surveillance and Patient Support Intervention. , 2016, , 309-315.		2
1643	Cancer of the Prostate. , 2010, , 925-986.		2
1644	Epidemiology, Etiology, and Prevention of Prostate Cancer. , 2012, , 2704-2725.e7.		12
1645	Definitive Therapy for Localized Prostate Cancer. , 2012, , 2771-2788.e6.		2
1646	Cryotherapy for Prostate Cancer. , 2012, , 2873-2896.e4.		4
1647	Sexuality and intimacy after cancer. , 2011, , 590-616.		2

#	ARTICLE	IF	CITATIONS
1649	Quality of Life After Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: 5-Year Results. International Journal of Radiation Oncology Biology Physics, 2017, 99, 374-377.	0.8	34
1650	Genitourinary Prosthetic Use among Prostate Cancer Survivors Treated with Radical Prostatectomy. Urology Practice, 2019, 6, 123-128.	0.5	1
1651	Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian Journal of Andrology, 2012, 14, 226-231.	1.6	56
1652	Can erectile function be predicted after prostate cancer treatment?. Asian Journal of Andrology, 2012, 14, 134-135.	1.6	2
1653	Implications of the prostate intervention versus observation trial (PIVOT). Asian Journal of Andrology, 2012, 14, 803-804.	1.6	4
1654	Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 898-904.	1.3	10
1655	Interpretation of Domain Scores on the EPICâ€”How Does the Domain Score Translate into Functional Outcomes?. Journal of Urology, 2019, 202, 1150-1158.	0.4	11
1656	Understanding Variation in the Quality of the Surgical Treatment of Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 278-283.	3.8	2
1657	Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. Journal of Clinical Oncology, 2012, 30, 7-7.	1.6	10
1658	The impact of combining human and online supportive resources for prostate cancer patients. Journal of Community and Supportive Oncology, 2017, 15, e321-e329.	0.1	8
1659	Using electronic health record data to identify prostate cancer patients that may qualify for active surveillance. EGEMS (Washington, DC), 2017, 4, 8.	2.0	7
1660	New Paradigms for Patient-Centered Outcomes Research in Electronic Medical Records: An example of detecting urinary incontinence following prostatectomy. EGEMS (Washington, DC), 2017, 4, 1.	2.0	23
1661	Quality of Life after Post-Prostatectomy Intensity Modulated Radiation Therapy: Pelvic Nodal Irradiation Is Not Associated with Worse Bladder, Bowel, or Sexual Outcomes. PLoS ONE, 2015, 10, e0141639.	2.5	12
1662	Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial. International Journal of Particle Therapy, 2016, 3, 27-36.	1.8	14
1663	Race Does Not Affect Tumor Control, Adverse Effects, or Quality of Life after Proton Therapy. International Journal of Particle Therapy, 2017, 3, 461-472.	1.8	2
1664	Understanding Variation in the Quality of the Surgical Treatment of Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 278-283.	3.8	3
1665	Does Obesity Impact Treatment Outcome for Prostate Cancer Patients Treated with Radiotherapy: The Weighted Debate. Journal of Cancer Prevention & Current Research, 2014, 1, .	0.1	2
1667	68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients. Oncotarget, 2017, 8, 12247-12258.	1.8	21

#	ARTICLE	IF	CITATIONS
1668	Comparisons of health-related quality of life among surgery and radiotherapy for localized prostate cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 99057-99065.	1.8	11
1669	Understanding the roles of randomized trials for robotic prostatectomy. <i>Annals of Translational Medicine</i> , 2016, 4, 467-467.	1.7	1
1670	Clinical Potential of Statins in Prostate Cancer Radiation Therapy. , 2017, 37, 5363-5372.		19
1671	Assessing the Acceptability and Usability of an Interactive Serious Game in Aiding Treatment Decisions for Patients with Localized Prostate Cancer. <i>Journal of Medical Internet Research</i> , 2011, 13, e4.	4.3	72
1672	Hemiablative Focal Low Dose Rate Brachytherapy: A Phase II Trial Protocol. <i>JMIR Research Protocols</i> , 2016, 5, e98.	1.0	4
1673	Adoption, Acceptability, and Effectiveness of a Mobile Health App for Personalized Prostate Cancer Survivorship Care: Protocol for a Realist Case Study of the Ned App. <i>JMIR Research Protocols</i> , 2017, 6, e197.	1.0	21
1674	Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using a Couple-Focused mHealth Symptom Self-Management Program: Protocol for a Feasibility Study. <i>JMIR Research Protocols</i> , 2018, 7, e51.	1.0	9
1675	Efficacy of modified radical prostatectomy technique for recovery of urinary incontinence in high-grade prostate cancer. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 605-614.	3.9	10
1676	Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-490.	2.8	79
1677	A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review. <i>Health Technology Assessment</i> , 2016, 20, 1-144.	2.8	43
1678	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-176.	2.8	22
1679	Impact of Androgen Deprivation Therapy Associated to Conformal Radiotherapy in the Treatment of Dâ€™Amico Intermediate-/High-Risk Prostate Cancer in Older Patients. <i>Cancers</i> , 2021, 13, 75.	3.7	4
1680	Interfraction variation and dosimetric changes during image-guided radiation therapy in prostate cancer patients. <i>Radiation Oncology Journal</i> , 2019, 37, 127-133.	1.5	15
1681	Urinary adverse effects of pelvic radiotherapy. <i>Translational Andrology and Urology</i> , 2014, 3, 186-95.	1.4	34
1682	The primary health care physician and the cancer patient: tips and strategies for managing sexual health. <i>Translational Andrology and Urology</i> , 2015, 4, 218-31.	1.4	20
1683	Psychosexual care in prostate cancer survivorship: a systematic review. <i>Translational Andrology and Urology</i> , 2015, 4, 413-20.	1.4	12
1684	PSA-måling og prostatakreft â€“ overdiagnostisering og overbehandling?. <i>Tidsskrift for Den Norske Lægeforening</i> , 2013, 133, 1711-1716.	0.2	14
1685	Penile rehabilitation following prostate cancer treatment: review of current literature. <i>Asian Journal of Andrology</i> , 2015, 17, 916.	1.6	18

#	ARTICLE	IF	CITATIONS
1686	Radical prostatectomy in patients aged 75 years or older: review of the literature. Asian Journal of Andrology, 2019, 21, 32.	1.6	12
1687	Erectile dysfunction in prostate cancer patients treated with intensity-modulated radiation therapy. Indian Journal of Cancer, 2020, 57, 70.	0.2	4
1688	Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017. Urology Annals, 2018, 10, 138.	0.6	12
1689	A novel human cadaver model to investigate a retrourethral transobturator male sling procedure. Investigative and Clinical Urology, 2019, 60, 367.	2.0	2
1690	Health-Related Quality of Life Changes in Prostate Cancer Patients after Radical Prostatectomy: A Longitudinal Cohort Study. Cancer Research and Treatment, 2019, 51, 556-567.	3.0	14
1691	Quality of Life in Men Treated for Early Prostate Cancer: A Prospective Patient Preference Cohort Study. Journal of Cancer Therapy, 2011, 02, 448-457.	0.4	2
1693	Robot-assisted radical prostatectomy in low- and high-risk prostate cancer patients. Turkish Journal of Urology, 2017, 43, 36-41.	1.3	4
1694	A single institution study on patient's self-reporting appraisal and functional outcomes of the first set of men following radical perineal prostatectomy. Central European Journal of Urology, 2012, 65, 124-129.	0.3	2
1695	A Prospective Analysis of the Effects of Nerve-Sparing Radical Prostatectomy on Urinary Continence Based on Expanded Prostate Cancer Index Composite and International Index of Erectile Function Scoring Systems. International Neurourology Journal, 2018, 22, 123-132.	1.2	5
1696	Daily Pad Usage Versus the International Consultation on Incontinence Questionnaire Short Form for Continence Assessment Following Radical Prostatectomy. International Neurourology Journal, 2020, 24, 156-162.	1.2	13
1697	Erectile Dysfunction as a Complication After Treatment of Prostate Cancer. Materia Socio-medica, 2011, 23, 230.	0.7	3
1698	Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. Canadian Urological Association Journal, 2011, 5, e156-e161.	0.6	7
1699	Quality of life after radical prostatectomy: Continuing to improve on our track record. Canadian Urological Association Journal, 2015, 9, 188.	0.6	1
1700	Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight. World Journal of Methodology, 2016, 6, 65.	3.5	17
1701	Digoxin Effectively Inhibited Cell Growth and Induced Senescence in Cervical Cancer Cell Line. Gene, Cell and Tissue, 2017, 4, .	0.2	3
1702	A Methodological Critique of the ProPublica Surgeon Scorecard. , 2015, , .		19
1703	Review of Selenium and Prostate Cancer Prevention. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2181-2184.	1.2	9
1704	Intensity-modulated Radiotherapy Combined with Endocrine Therapy for Intermediate and Advanced Prostate Cancer: Long-term Outcome of Chinese Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4711-4715.	1.2	9

#	ARTICLE	IF	CITATIONS
1705	Associations between Quality of Life and Marital Status in Cancer Patients and Survivors. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5287-5291.	1.2	12
1706	Factors Affecting the Quality of Life of Korean Cancer Survivors Who Return to the Workplace. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8783-8788.	1.2	14
1707	Lithocholic acid induces endoplasmic reticulum stress, autophagy and mitochondrial dysfunction in human prostate cancer cells. PeerJ, 2016, 4, e2445.	2.0	52
1708	Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry. Cureus, 2015, 7, e395.	0.5	25
1709	Prostate Cancer: Locoregional Disease. UNIPA Springer Series, 2021, , 791-803.	0.1	0
1710	<i>De Novo</i> Urinary Storage Symptoms Are Common after Radical Prostatectomy: Incidence, Natural History and Predictors. Journal of Urology, 2022, 207, 601-608.	0.4	5
1711	The role of metformin, statins and diet in men on active surveillance for prostate cancer. World Journal of Urology, 2022, 40, 61-69.	2.2	4
1712	Effects of Exercise on Sexual Dysfunction in Patients with Prostate Cancer – A Systematic Review. Journal of Sexual Medicine, 2021, 18, 1899-1914.	0.6	4
1713	Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancer. Andrologia, 2022, 54, e14288.	2.1	1
1714	125I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer. Brachytherapy, 2022, 21, 85-93.	0.5	3
1715	Quality of Life in Men Undergoing Radical Prostatectomy for Prostate Cancer. , 2010, , 2875-2885.		0
1717	La chirurgie radicale pour cancer prostatique. , 2011, , 159-172.		0
1718	Penile Rehabilitation After Robotic Radical Prostatectomy: The Best Strategy. , 2011, , 361-370.		0
1719	Managing Symptoms over Time. , 2011, , 53-83.		0
1721	Patient Selection for Robotic Radiosurgery for Clinically Localized Prostate Cancer: Come One, Come All. , 2012, , 165-175.		1
1722	Paying Project Participants: Dilemmas in Research with Poor, Marginalized Populations. Advances in Social Work, 2011, 12, 218-225.	0.7	2
1725	A Review of Quality of Life Following Treatments for Localized Prostate Cancer. , 0, ,		0
1727	Treatment Modalities of Post-prostatectomy Incontinence: A Historical Perspective as Well as Current Therapy Options. , 2012, , 319-345.		0

#	ARTICLE	IF	CITATIONS
1728	Outcomes Research. , 2012, , 140-156.e8.		0
1729	Individual and Mass Screening. , 2012, , 25-37.		0
1730	Ligoni ³ , sergan ³ plau ³ bei prostatos v ³ iai ³ , su sveikata susijusios gyvenimo kokyb ³ s vertinimas. Health Sciences, 2012, 22, 113-118.	0.0	0
1731	Patient Selection for Active Surveillance. , 2012, , 9-21.		0
1732	Active Surveillance: The European Experience. , 2012, , 81-94.		0
1736	The Role of 5 α -Reductase Inhibitors (5-ARIs) in Expectant Management of Low-Risk Prostate Cancer. , 2012, , 153-156.		0
1737	Robot-Assisted Radical Prostatectomy. , 2012, , 105-111.		0
1738	Contemporary External Beam Radiotherapy. , 2012, , 243-261.		0
1739	Clinical Implications of Measuring Quality-of-Life in Early Stage Prostate Cancer. , 2012, , 297-317.		0
1740	Surgery, Brachytherapy, or External Beam Radiation for Low- and Intermediate-Risk Disease?. , 2012, , 263-269.		0
1741	Prostate Cancer Screening: A Review of the Evidence with Clinical Practice Implications. , 2012, , 25-49.		0
1743	Radical Treatment for Localized Disease: An Overview of Options and Strategies for Decision Making. , 2013, , 609-614.		0
1744	Comparative Effectiveness of Treatment Alternatives for Localized Prostate Cancer. , 2013, , 593-605.		0
1745	Quality of Life and Management of Localized Disease. , 2013, , 615-619.		0
1746	Management of Radiation Adverse Effects. , 2013, , 1019-1027.		0
1747	Active Surveillance for Favorable-Risk Prostate Cancer. , 2013, , 621-629.		4
1749	The opportunity cost of androgen suppression in locally advanced prostate cancer. Asian Journal of Andrology, 2013, 15, 356-357.	1.6	0
1750	Postoperative Management and Preoperative Considerations: Urinary Incontinence and Anastomotic Stricture. , 2014, , 189-208.		0

#	ARTICLE	IF	CITATIONS
1751	Comparison of Health Related Quality of Life and Other Clinical Parameters between 20 g and 18 g Needles for Permanent Low-Dose-Rate Implantation in Localized Prostate Cancer. Journal of Nuclear Medicine & Radiation Therapy, 2014, 06, .	0.2	0
1753	Nocturia. , 2014, , 223-250.		0
1755	Brachytherapy. , 2015, , 79-96.		0
1757	Expectant Management of Localized Prostate Cancer. , 2015, , 719-730.		0
1759	Focal Therapy: Current Status and Future Directions. , 2015, , 235-246.		0
1760	Patient Selection for Focal Therapy for Prostate Cancer. , 2015, , 29-37.		0
1762	Dealing with Pelvic Dysfunction: Multi and Interdisciplinary Team Approach. , 2015, , 49-56.		0
1763	Prostate Cancer Diagnostic and Evaluation in Gaza-Strip, Palestine. Health, 2015, 07, 1552-1559.	0.3	0
1764	Posttraumatic Stress Disorder in Prostate Cancer. , 2015, , 1-7.		0
1766	Future Uro-technologies: Hope or Hell for Prostate Cancer Patients?. , 2015, , 135-142.		0
1768	Optimal management of prostate cancer with lethal biology - state-of-the-art local therapy. Asian Journal of Andrology, 2015, 17, 888.	1.6	1
1769	Comparative Effectiveness Research in Urologic Cancers. Cancer Treatment and Research, 2015, 164, 221-235.	0.5	0
1770	Post-RT Urinary Incontinence and Stricture. , 2016, , 139-149.		0
1771	Introduction: Urinary Function Alterations in Men with Prostate Cancer. , 2016, , 3-11.		0
1772	Radiation therapy for prostate cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2016, 5, 71.	0.2	0
1773	The Effect of Radical Prostatectomy on Sexual Function. , 2016, , 241-252.		0
1774	Decision Support for Low-Risk Prostate Cancer. , 2016, , 207-213.		1
1775	Post-Traumatic Stress Disorder in Prostate Cancer. , 2016, , 383-390.		0

#	ARTICLE	IF	CITATIONS
1776	Penile Rehabilitation: Recovering Erectile Function Following Prostate Cancer Treatment. , 2016, , 211-225.		0
1777	Stereoscopic Motion Magnification in Minimally-Invasive Robotic Prostatectomy. Lecture Notes in Computer Science, 2016, , 35-45.	1.3	1
1778	Erectile Dysfunction in the Setting of Prostate Cancer. , 2016, , 73-86.		0
1779	Quality of Life Evaluation: What Is Published and Practical for Routine Use. , 2016, , 247-255.		0
1780	Psychosocial factors and treatment satisfaction after radical prostatectomy. Journal of Community and Supportive Oncology, 2016, 16, e130-e137.	0.1	1
1781	The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer. Cureus, 2016, 8, e669.	0.5	6
1782	Outcome Changes after Diverse Radical Prostatectomy among Prostate Cancer Patients: Comparison of One and Five Years of Follow-Up. Archives of Nursing Practice and Care, 0, , 001-006.	0.2	0
1784	Positioning Focal Therapy from Consensus to Guidelines. Current Clinical Urology, 2017, , 447-463.	0.0	0
1785	Radiation Proctitis. , 2017, , 165-172.		0
1786	Complex evaluation of prognostic factors for biochemical recurrence after radical prostatectomy for patients with clinical locally advanced prostate cancer. Health of Man, 2017, .	0.0	1
1787	Brachytherapy guideline in prostate cancer (high and low dose rate). Revista Da Associação Médica Brasileira, 2017, 63, 293-298.	0.7	0
1788	Practical Exercise Intervention to Reduce Adverse Effects for Prostate Cancer Patients. Exercise Science, 2017, 26, 152-158.	0.3	2
1789	PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Opinion: No. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 390-393.	1.5	2
1790	Is There a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of 5-ARIs, Statins, and Metformin. Current Clinical Urology, 2018, , 199-206.	0.0	1
1791	Ethical and Legal Considerations in Active Surveillance for Prostate Cancer. Current Clinical Urology, 2018, , 31-39.	0.0	0
1793	æ”³⁄₄å°„ç·šã«ã,â,«æŠ—è...«ç~å...ç—«ã®æ’æ€ŠåCE—ã”å...ç—«æ”³⁄₄å°„ç·šç™,æ³·¼¹Immunoï¼Radiotherapyï¼%ã®å·f½æ€Š. Skin Can		
1794	Needs of Patients with Prostate Cancer for Home Care. Asia-Pacific Journal of Oncology Nursing, 2018, 5, 408-414.	1.6	3
1796	Psychosexual Impairment, Degree of Surgery and Erectile Aids. , 2018, , 69-70.		0

#	ARTICLE	IF	CITATIONS
1797	Other Literature on Survivorship Care as an Unmet Need. , 2018, , 155-161.		0
1798	Study on the Quality of Life Among the Cancer Patients at the Sari Comprehensive Cancer Center in 2017. Materia Socio-medica, 2018, 30, 127.	0.7	3
1799	Expending the Paradigm: Active Surveillance for Intermediate Risk Prostate Cancer. Open Journal of Urology, 2018, 08, 248-256.	0.1	0
1800	The problem of early continence recovery after radical prostatectomy. Onkourologiya, 2018, 13, 70-78.	0.3	1
1801	Anterior Reconstruction After Radical Prostatectomy. , 2018, , 391-400.		0
1802	Overview of Toxicity Outcomes with Prostate SBRT and Comparison to Other Treatment Interventions (Urinary, Rectal and Sexual Outcomes). , 2019, , 111-127.		0
1803	Quality of Life Outcomes After SBRT. , 2019, , 129-139.		0
1804	Techniques for Reducing Toxicity After SBRT. , 2019, , 141-151.		0
1805	POSTOPERATIVE COMPLICATIONS OF MINIMALLY INVASIVE THERAPIES FOR PROSTATE CANCER. Onkourologiya, 2018, 14, 43-50.	0.3	2
1806	Combined hormonal and radionuclide-medication therapy of prostate cancer. Urology, 2018, 22, .	0.1	0
1808	Adjustable sling for the treatment of post-prostatectomy urinary incontinence: systematic review and meta-analysis. Einstein (Sao Paulo, Brazil), 2019, 17, eRW4508.	0.7	3
1809	Menâ€™s Health and Cancerâ€™The Case of Prostate Cancer. , 2019, , 145-163.		1
1810	Results of a Continent of Urine After an Open Retropubic Prostatectomy with Preservation of the Puboprostatic Ligament. Health of Man, 2019, .	0.0	0
1811	What the Urologist Wants to Know from Prostate MRI. , 2020, , 13-35.		0
1812	Rehabilitation in der Uroonkologie: Erektile Dysfunktion. Springer Reference Medizin, 2020, , 1-9.	0.0	0
1813	Mediation Effect of Friendsâ€™ Support on the Relationship Between Sex-Related Symptoms and Quality of Life in Patients After Radical Prostatectomy. , 2020, , .		0
1814	Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer. Journal of Contemporary Brachytherapy, 2020, 12, 540-546.	0.9	8
1815	Wide-field optical spectroscopy system integrating reflectance and spatial frequency domain imaging to measure attenuation-corrected intrinsic tissue fluorescence in radical prostatectomy specimens. Biomedical Optics Express, 2020, 11, 2052.	2.9	4

#	ARTICLE	IF	CITATIONS
1816	Quality of life evaluation of patients after radical treatment of prostate cancer. Proceedings of the National Academy of Sciences of Belarus, Medical Series, 2020, 17, 275-286.	0.1	0
1817	Radiotherapy for Prostate Cancer. , 2021, , 55-75.		1
1818	Minimally invasive magnetic resonance image-guided prostate interventions. British Journal of Radiology, 2022, 95, 20210698.	2.2	7
1819	Prostatectomy with or without post-operative radiotherapy: long-term adverse effects and quality of life. Scandinavian Journal of Urology, 2021, 55, 9-16.	1.0	1
1820	Penile reinnervation as a new technique for treating erectile dysfunction in patients after radical prostatectomy. Urology Herald, 2020, 8, 135-144.	0.4	0
1821	Cancer of the Urinary Tract and Genital Organs: Female and Male. , 2020, , 69-84.		0
1823	Stereotactic body radiotherapy as a boost after external beam radiotherapy for high-risk prostate cancer patients. Indian Journal of Cancer, 2020, .	0.2	1
1824	Focal Ablation Therapy for Prostate Cancer: A Literature Review. Advanced Ultrasound in Diagnosis and Therapy, 2020, 4, 308.	0.1	0
1825	Accuracy of Diagnosis with Non-contrast Magnetic Resonance Imaging/Transrectal Ultrasound Fusion-Guided Transperineal Prostate Biopsy. Juntendo Medical Journal, 2020, 66, 46-51.	0.1	0
1826	Physical rehabilitation methods in patients with prostate cancer: a scientometric analysis of evidence-based studies. Onkologiya Zhurnal Imeni P A Gertsena, 2020, 9, 18.	0.2	0
1827	Management of low (favourable)-risk prostate cancer. BJU International, 2011, , no-no.	2.5	0
1829	A rare complication of the AMS Advanceâ„¢ male sling system for the treatment of stress urinary incontinence: A case report. Urology Case Reports, 2020, 32, 101250.	0.3	0
1830	Prostate cancer screening: why it's not for every man. Medscape Journal of Medicine, 2008, 10, 124.	0.6	2
1831	Vascular targeted photodynamic therapy for localized prostate cancer. Reviews in Urology, 2008, 10, 254-61.	0.9	22
1832	Status of radical prostatectomy in 2009: is there medical evidence to justify the robotic approach?. Reviews in Urology, 2009, 11, 61-70.	0.9	35
1833	Radical retropubic prostatectomy: comparison of the open and robotic approaches for treatment of prostate cancer. Reviews in Urology, 2012, 14, 20-7.	0.9	6
1834	Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience. Canadian Urological Association Journal, 2012, 6, E283-6.	0.6	14
1835	Commentary. Urology Annals, 2013, 5, 23-4.	0.6	0

#	ARTICLE	IF	CITATIONS
1836	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Open Access Journal of Urology, 2011, 3, 95-104.	0.3	1
1837	Treatment options for localized prostate cancer. Canadian Family Physician, 2013, 59, 1269-74.	0.4	37
1838	Short-, Intermediate-, and Long-term Quality of Life Outcomes Following Radical Prostatectomy for Clinically Localized Prostate Cancer. Reviews in Urology, 2013, 15, 161-77.	0.9	23
1839	Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Reviews in Urology, 2014, 16, 55-66.	0.9	47
1840	Preoperative risk factors for early postoperative urinary continence recovery after non-nerve-sparing radical prostatectomy in Chinese patients: a single institute retrospective analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 14105-9.	1.3	5
1842	Oncology Section EDGE Task Force on Prostate Cancer: A Systematic Review of Outcome Measures for Health-Related Quality of Life. Rehabilitation Oncology, 2016, 34, 27-35.	0.5	6
1843	Utilization of individualized prostate cancer and genomic biomarkers for the practicing urologist. Reviews in Urology, 2017, 19, 97-105.	0.9	0
1844	Prostate cancer survivorship care in the Veterans Health Administration. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2014, 31, 10-17.	0.6	7
1845	Obesity and prostate cancer: A narrative review. Critical Reviews in Oncology/Hematology, 2022, 169, 103543.	4.4	29
1846	Cosmetic Appeal, HRQoL, and Effectiveness of Simple and Pseudotesticular Techniques of Orchidectomy in Prostate Cancer. Prostate Cancer, 2021, 2021, 1-12.	0.6	1
1847	Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKADÂ®) for Localized Prostate Cancer. Urologia Internationalis, 2021, , 1-6.	1.3	5
1848	Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 531-538.	3.9	15
1849	Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1â€“2b Study). European Urology, 2022, 81, 396-406.	1.9	11
1850	Prevalence of Hand Joint Symptoms in Androgen Deprivation Therapy Among Japanese Patients with Prostate Cancer. Urological Science, 2020, 31, 15-20.	0.6	1
1851	Importance of Family History in the Era of Exome Analysis: A Report of a Family with Multiple Concurrent Genetic Diseases. Human Heredity, 2021, 86, 28-33.	0.8	1
1852	Longitudinal Changes in Health-related Quality of Life After 125I Low-dose-rate Brachytherapy for Localized Prostate Cancer. Anticancer Research, 2020, 40, 6443-6456.	1.1	5
1853	Sexual dysfunction associated with prostate cancer treatment in Japanese men: a qualitative research. Supportive Care in Cancer, 2022, 30, 3201-3213.	2.2	3
1854	Assessing Inter-Fraction Changes in The Size and Position of The Penile Bulb During Daily MR-Guided Radiation Therapy to The Prostate Bed: Do We Need to Adjust How We Plan Radiation in The Post-Radical Prostatectomy Setting to Reduce Risk of Erectile Dysfunction?. Clinical Genitourinary Cancer, 2022,...	1.9	1

#	ARTICLE	IF	CITATIONS
1855	Searching for a harmonious survival: the experience of quality of life of urological cancer survivors. <i>Supportive Care in Cancer</i> , 2022, 30, 3485.	2.2	1
1856	Impact of postanesthesia care unit delirium on self-reported cognitive function and perceived health status: a prospective observational cohort study. <i>Quality of Life Research</i> , 2022, , 1.	3.1	1
1857	The effects of social distancing and self-isolation on functional outcomes after radical prostatectomy during the COVID-19 pandemic. <i>Current Urology</i> , 2022, Publish Ahead of Print, .	0.6	0
1858	Association of Novel Androgen Receptor Axis-Targeted Therapies With Diarrhea in Patients With Prostate Cancer: A Bayesian Network Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 800823.	2.6	2
1859	Modified female midâ€œurethral sling for the treatment of incontinence after prostate treatment: Oneâ€œcenter experience. <i>Prostate</i> , 2022, 82, 598-604.	2.3	0
1860	Assess and Evaluation the Quality Of Life (QoL) Among Cancer Patients Undergoing Treatment by Using EORTC QLQ-30 Scale. <i>National Journal of Community Medicine</i> , 2022, 13, 64-73.	0.2	1
1861	Artificial Urinary Sphincter Is Better Than Slings for Moderate Male Stress Urinary Incontinence With Acceptable Complication Rate: A Systematic Review and Meta-Analysis. <i>Frontiers in Surgery</i> , 2022, 9, 841555.	1.4	3
1862	MRI-Based Radiotherapy Planning to Reduce Rectal Dose in Excess of Tolerance. <i>Prostate Cancer</i> , 2022, 2022, 1-9.	0.6	3
1863	Development of a Sexual Quality of Life Questionnaire for Men-Who-Have-Sex-With-Men With Prostate Cancer. <i>Sexual Medicine</i> , 2022, 10, 100480-100480.	1.6	6
1864	Impacto de la prostatectomÃa radical y la radioterapia en la calidad de vida de pacientes con cÃncer de prÃstata clÃnicamente localizado. <i>Revista Mexicana De UrologÃa</i> , 2021, 81, 1-14.	0.0	0
1866	The Association of Patient Satisfaction and Quality of Care: Theory, Evidence, and Application. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1867	Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2022, 14, 15-22.	0.9	2
1868	The health-related quality of life in patients with prostate cancer managed with active surveillance using the Expanded Prostate Cancer Index Composite survey: Systematic review and meta-analysis. <i>Arab Journal of Urology Arab Association of Urology</i> , 2022, 20, 1-10.	1.5	0
1869	Value of Different Magnetic Resonance Imaging-based Measurements of Anatomical Structures on Preoperative Prostate Imaging in Predicting Urinary Continence After Radical Prostatectomy in Men with Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1211-1225.	3.1	7
1870	Association between Fecal Incontinence and Lower Urinary Tract Symptoms and their Impact on the Quality of Life of Patients with Prostate Cancer. <i>Journal of Coloproctology</i> , 2022, 42, 032-037.	0.1	0
1871	Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. <i>Nature Reviews Urology</i> , 2022, 19, 263-279.	3.8	5
1872	Dosimetric evaluation of high-Z inhomogeneity used for hip prosthesis: A multi-institutional collaborative study. <i>Physica Medica</i> , 2022, 95, 148-155.	0.7	6
1873	A Comparison between Patient- and Physician-Reported Late Radiation Toxicity in Long-Term Prostate Cancer Survivors. <i>Cancers</i> , 2022, 14, 1670.	3.7	3

#	ARTICLE	IF	CITATIONS
1874	Prospective quality of life in men choosing open vs. robotic radical prostatectomy: long-term results from a racially diverse multi-institutional database. <i>World Journal of Urology</i> , 2022, 40, 1427-1436.	2.2	2
1875	Dosimetric outcomes of preoperative treatment planning with intraoperative optimization using stranded seeds in prostate brachytherapy. <i>PLoS ONE</i> , 2022, 17, e0265143.	2.5	0
1876	Mirabegron Reduces Urinary Frequency and Improves Overactive Bladder Symptoms at 3 Months After 125I-brachytherapy for Prostate Cancer: An Open-Labelled, Randomized, Non-Placebo-Controlled Study. <i>Urology</i> , 2022, 161, 87-92.	1.0	1
1877	A modified Delphi study to identify screening items to assess neglected sexual side-effects following prostate cancer treatment. <i>BMC Urology</i> , 2022, 22, 34.	1.4	1
1878	Available evidence on HIFU for focal treatment of prostate cancer: a systematic review. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2022, 48, 263-274.	1.5	16
1879	Long-term outcomes of whole gland high-intensity focused ultrasound for localized prostate cancer. <i>International Urology and Nephrology</i> , 2022, 54, 1233-1238.	1.4	2
1880	Post-prostatectomy incontinence in patients with adjuvant radiotherapy: is there a therapeutic space for transobturator sling?. <i>Pelviperrineology</i> , 2022, 41, 54-62.	0.1	0
1881	Safety and Feasibility of Soractelite Transperineal Focal Laser Ablation for Prostate Cancer and Short-term Quality of Life Analysis from a Multicenter Pilot Study. <i>European Urology Open Science</i> , 2022, 39, 48-54.	0.4	5
1882	Stability of health-related quality of life and morbidity burden from 18 months after diagnosis of prostate cancer: results of a UK-wide population-based outcome cohort. <i>Supportive Care in Cancer</i> , 2022, 30, 3151-3164.	2.2	1
1884	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	5.9	16
1885	A Comprehensive Evaluation of Health-Related Life Quality Assessment Through Head and Neck, Prostate, Breast, Lung, and Skin Cancer in Adults. <i>Frontiers in Public Health</i> , 2022, 10, 789456.	2.7	7
1886	Development and Validation of Dynamic Multivariate Prediction Models of Sexual Function Recovery in Patients with Prostate Cancer Undergoing Radical Prostatectomy: Results from the MUSIC Statewide Collaborative. <i>European Urology Open Science</i> , 2022, 40, 1-8.	0.4	3
1890	Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 190-195.	1.3	2
1892	Artificial intelligence supporting cancer patients across Europe – The ASCAPE project. <i>PLoS ONE</i> , 2022, 17, e0265127.	2.5	9
1897	Stereotactic body radiotherapy of prostate cancer: influence of intrafraction motion of prostate on final dose distribution. <i>Voprosy Onkologii</i> , 2022, 68, 215-223.	0.2	0
1898	Retzius-Sparing vs. Modified Anatomical Structure Preserving and Retzius-Repairing Robotic-Assisted Radical Prostatectomy: A Prospective Randomized Comparison on Functional Outcomes with a 1-Year Follow-Up. <i>Journal of Endourology</i> , 2022, 36, 1214-1222.	2.1	4
1899	Relative Incidence of Emergency Department Visits After Treatment for Prostate Cancer with Radiation Therapy or Radical Prostatectomy. <i>Practical Radiation Oncology</i> , 2022, , .	2.1	0
1900	Toward Incorporating Health-Related Quality of Life as Coprimary End Points in Clinical Trials: Time to Achieve Clinically Important Differences and QoL Profiles. <i>Journal of Clinical Oncology</i> , 2022, 40, 2378-2388.	1.6	3

#	ARTICLE	IF	CITATIONS
1901	Evaluating post radical prostatectomy mechanisms of early continence. Prostate, 2022, 82, 1186-1195.	2.3	10
1902	Patient age as a predictive factor in biochemical recurrence following brachytherapy: Oncological outcomes at a single center. Prostate International, 2022, 10, 224-228.	2.3	4
1903	Patient Reported Outcomes for Quality of Life (QOL) By Expanded Prostate Cancer Index (EPIC) on Average 15 Years Post Treatment. Clinical and Translational Radiation Oncology, 2022, , .	1.7	3
1904	Interventional oncology update. European Journal of Radiology Open, 2022, 9, 100430.	1.6	2
1905	Understanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer Patients. Cancer Treatment and Research Communications, 2022, 32, 100588.	1.7	4
1906	Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers. Cancers, 2022, 14, 2996.	3.7	9
1907	PSA: role in screening and monitoring patients with prostate cancer. , 2022, , 131-172.		2
1908	A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patientâ€reported quality of life. Prostate, 2022, 82, 1338-1345.	2.3	2
1909	Current trends in erectile rehabilitation after radical prostatectomy: Results from a worldwide survey. Andrologia, 2022, 54, .	2.1	2
1910	Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics. Prostate Cancer and Prostatic Diseases, 2024, 27, 58-64.	3.9	1
1911	Health-related Quality of Life of Patients Treated With Different Fractionation Schedules for Early Prostate Cancer Compared to the Age-standardized General Male Population. Clinical Genitourinary Cancer, 2023, 21, 146-154.	1.9	3
1912	Grade group 1 prostate cancer on biopsy: are we still missing aggressive disease in the era of image-directed therapy?. World Journal of Urology, 2022, 40, 2423-2429.	2.2	5
1913	Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression. European Urology Oncology, 2022, 5, 617-627.	5.4	21
1914	Postprostatectomy Radiation Therapy in the Setting of a Rectal Vascular Malformation. Advances in Radiation Oncology, 2022, 7, 101043.	1.2	0
1915	Restorative medicine in the aging genitourinary system. , 2023, , 347-357.		0
1916	Significance of postoperative membranous urethral length and position of vesicourethral anastomosis for short-term continence recovery following robot-assisted laparoscopic radical prostatectomy. BMC Urology, 2022, 22, .	1.4	2
1917	Surgeon volume and patient-reported urinary incontinence after radical prostatectomy. Population-based register study in Sweden. Scandinavian Journal of Urology, 2022, 56, 343-350.	1.0	5
1918	Fully automated segmentation of prostatic urethra for MRâ€guided radiation therapy. Medical Physics, 2023, 50, 354-364.	3.0	3

#	ARTICLE	IF	CITATIONS
1919	Correlation between Quality of Life under Treatment and Current Life Satisfaction among Cancer Survivors Aged 75 Years and Older Receiving Outpatient Chemotherapy in Ishikawa Prefecture, Japan. Healthcare (Switzerland), 2022, 10, 1863.	2.0	1
1920	Prostate Brachytherapy Utilization in the COVID-19 Era: A Cross-Sectional Study of Radiation Oncologists in the United States. Brachytherapy, 2022, , .	0.5	0
1921	Predictors of prostate cancer survivorsâ€™™ engagement in self-management behaviors. Canadian Urological Association Journal, 2022, 17, .	0.6	0
1922	Testosterone replacement in prostate cancer survivors with testosterone deficiency: Study protocol of a randomized controlled trial. Andrology, 2023, 11, 93-102.	3.5	1
1923	Unmet Sexual Health Needs of Patients and Female Partners Following Diagnosis and Treatment for Prostate Cancer. Journal of Sexual Medicine, 2022, 19, 1797-1803.	0.6	5
1924	Association of nerve-sparing grading in robotic radical prostatectomy and trifecta outcome. World Journal of Urology, 2022, 40, 2925-2930.	2.2	1
1925	Comparison of Early Urinary Continence, Oncological Outcomes, and Postoperative Complications in Retzius-Sparing and Standard Approach Robot-Assisted Radical Prostatectomy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2023, 33, 150-154.	1.0	3
1926	A Web-Based Prostate Cancerâ€™“Specific Holistic Needs Assessment (CHAT-P): Multimethod Study From Concept to Clinical Practice. JMIR Cancer, 2022, 8, e32153.	2.4	0
1928	2 Year Functional Outcomes Stratified According to Baseline Erectile Function Following Partial Gland Cryo-Ablation. Urology, 2022, , .	1.0	2
1929	High-Frequency Pulsed Electric Field Ablation in Beagle Model for Treatment of Prostate Cancer. Cancers, 2022, 14, 4987.	3.7	0
1930	Racial Analysis of Clinical & Biochemical Outcomes in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.8	0
1931	The effect of race on treatment patterns and subsequent health-related quality of life outcomes in men undergoing treatment for localized prostate cancer. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	3
1932	Systematic review of self-management programs for prostate cancer patients, a quality of life and self-efficacy meta-analysis. Patient Education and Counseling, 2023, 107, 107583.	2.2	3
1933	Can PROMs improve racial equity in outcomes after prostatectomy?. Nature Reviews Urology, 0, , .	3.8	0
1934	Intermittent Use of Anti-Hormonal Agents for the Endocrine Therapy of Sex-Hormone-Dependent Breast and Prostate Cancer: A Protocol for a Systematic Review. International Journal of Environmental Research and Public Health, 2022, 19, 15486.	2.6	0
1935	Variation in patient reported outcomes following radical prostatectomy: A bi-national registry-based study. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 105.e9-105.e18.	1.6	2
1936	Robot-assisted radical prostatectomy using a novel urethral reconstruction technique vs standard vesicourethral anastomosis. A retrospective cohort study. World Journal of Urology, 2023, 41, 51-58.	2.2	1
1937	Effect of different postures of Pilates combined with Kegel training on pelvic floor muscle strength in post-prostatectomy incontinence. International Urology and Nephrology, 2023, 55, 519-527.	1.4	3

#	ARTICLE	IF	CITATIONS
1938	Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 787-794.	3.9	2
1939	Applications of Hypnosis as an Adjuvant in Oncological Settings: A Systematic Review. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2023, 71, 1-24.	1.8	4
1940	Long-Term Subjective Functional Outcomes of Prostate Cancer: Prostatectomy vs Radiation. <i>American Surgeon</i> , 0, , 000313482211483.	0.8	0
1941	Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 770-778.	0.8	4
1942	Simple and reliable predictive factor for early recovery of urinary continence after non-nerve-sparing robot-assisted laparoscopic radical prostatectomy. <i>Journal of Robotic Surgery</i> , 2023, 17, 1077-1083.	1.8	1
1943	Association between overweight, obesity, and quality of life of patients receiving an anticancer treatment for prostate cancer: a systematic literature review. <i>Health and Quality of Life Outcomes</i> , 2023, 21, .	2.4	1
1944	A Critical Analysis of the Magnetic Resonance Imaging Lesion Diameter Threshold for Adverse Pathology Features. <i>Prague Medical Report</i> , 2023, 124, 40-51.	0.8	1
1945	“Urethral-Sparing” Robotic Radical Prostatectomy: Critical Appraisal of the Safety of the Technique Based on the Histologic Characteristics of the Prostatic Urethra. <i>Current Oncology</i> , 2023, 30, 1065-1076.	2.2	4
1946	Urinary Continence Recovery after Robotic Radical Prostatectomy without Anterior or Posterior Reconstruction: Experience from a Tertiary Referral Center. <i>Journal of Clinical Medicine</i> , 2023, 12, 1358.	2.4	3
1947	Comparison of Outcomes of Active Surveillance in Intermediate-Risk Versus Low-Risk Localised Prostate Cancer Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 2732.	2.4	3
1948	Late, persistent, substantial treatment-related symptoms (LAPERS) following low-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2023, 22, 524-530.	0.5	0
1949	Geriatric assessment in the older adult with genitourinary cancer: A narrative review. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
1950	Prevalence and Morbidity of Local Treatment-Related Side Effects in Metastatic Prostate Cancer Patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 204.e1-204.e6.	1.6	1
1951	The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer. <i>Prostate International</i> , 2023, , .	2.3	0
1952	A Contemporary Report of Low-Dose-Rate Brachytherapy for Prostate Cancer Using MRI for Risk Stratification: Disease Outcomes and Patient-Reported Quality of Life. <i>Cancers</i> , 2023, 15, 1336.	3.7	3
1953	Advanced hydrogels: New expectation for the repair of organic erectile dysfunction. <i>Materials Today Bio</i> , 2023, 19, 100588.	5.5	1
1954	Association between Presurgical Weight Status and Urinary and Sexual Function in Prostate Cancer Patients Treated by Radical Prostatectomy: A Prospective Cohort Study. <i>Urology</i> , 2023, , .	1.0	0
1956	Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 1069-1078.	0.8	2

#	ARTICLE	IF	CITATIONS
1957	Quality of life in patients who underwent robot-assisted radical prostatectomy compared with those who underwent low-dose-rate brachytherapy. <i>Prostate</i> , 2023, 83, 701-712.	2.3	1
1958	Localized Prostate Cancer – Then and Now. <i>New England Journal of Medicine</i> , 2023, 388, 1617-1618.	27.0	2
1959	Surgical approach affecting long-term urinary continence status after robot-assisted laparoscopic prostatectomy prospectively evaluated using self-reported functional status (Expanded Prostate) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 6	0.0	0
1960	Which characteristics are associated with changes in medication status for lower urinary tract symptoms among patients with prostate cancer receiving external beam radiotherapy?. <i>Current Urology</i> , 0, Publish Ahead of Print, .	0.6	0
1961	Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
1963	The Long-term Incidence and Quality of Life Outcomes Associated With Treatment-Related Toxicities of External Beam Radiotherapy for Prostate Cancer. <i>Urology</i> , 2023, 178, 114-119.	1.0	0
1964	Stereotactic Body Radiation Therapy With Integrated Boost to the Dominant Intraprostatic Nodule: Initial Dosimetric and Clinical Outcomes. <i>Applied Radiation Oncology</i> , 0, , .	0.5	0
1965	Patient-reported outcomes after curative treatment for prostate cancer with prostatectomy, primary radiotherapy or salvage radiotherapy. <i>Acta Oncol</i> ³gica, 2023, 62, 657-665.	1.8	0
1966	Reliable Visualization of the Treatment Effect of Transperineal Focal Laser Ablation in Prostate Cancer Patients by Magnetic Resonance Imaging and Contrast-enhanced Ultrasound Imaging. <i>European Urology Open Science</i> , 2023, 54, 72-79.	0.4	0
1967	Psychological recovery and well-being of spouses of patients with prostate cancer 5 years after primary treatment in Finland: a follow-up survey. <i>BMJ Open</i> , 2023, 13, e063435.	1.9	1
1968	The lived experience of prostate cancer: 10-year survivor perspectives following contemporary treatment of localized prostate cancer. <i>Journal of Cancer Survivorship</i> , 0, , .	2.9	1
1969	Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer. <i>Nature Reviews Urology</i> , 2023, 20, 332-355.	3.8	3
1970	Revolutionizing Radiotoxicity Management with Mesenchymal Stem Cells and Their Derivatives: A Focus on Radiation-Induced Cystitis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9068.	4.1	0
1971	“Single Knot” Single Running Suture•Vesicourethral Anastomosis with Posterior Musculofascial Reconstruction during Robot-Assisted Radical Prostatectomy: A Step-by-Step Guide of Surgical Technique. <i>Journal of Personalized Medicine</i> , 2023, 13, 1072.	2.5	1
1972	Is Active Surveillance Too Active?. <i>Current Urology Reports</i> , 2023, 24, 463-469.	2.2	1
1973	Functional recovery of injured cavernous nerves achieved through endogenous nerve growth factor-containing bioactive fibrous membrane. <i>Acta Biomaterialia</i> , 2023, 168, 416-428.	8.3	0
1974	Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs). <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	3.9	1
1975	The association of smoking with urinary and sexual function recovery following radical prostatectomy for localized prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	3.9	0

#	ARTICLE	IF	CITATIONS
1976	Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	1
1979	Physiotherapy in rehabilitation of patients with urinary incontinence after radical prostatectomy. Fizioterapevt, 2023, , 70-78.	0.1	0
1980	The influence of secondary resection using NeuroSAFE-technique on sexual function in unilateral nerve-sparing robot-assisted laparoscopic prostatectomies. Scandinavian Journal of Urology, 0, 58, 60-67.	1.0	0
1982	Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis. Journal of Medical Economics, 0, , 1-13.	2.1	0
1983	Racial differences in patient-reported outcomes among men treated with radical prostatectomy for prostate cancer. Prostate, 2024, 84, 47-55.	2.3	0
1984	Recent advances and future perspectives in the therapeutics of prostate cancer. Experimental Hematology and Oncology, 2023, 12, .	5.0	2
1985	Pelvic floor muscle exercise with or without duloxetine for postprostatectomy urinary incontinence: A retrospective single-center study. Medicine (United States), 2023, 102, e34657.	1.0	0
1986	Robot-assisted radical prostatectomy in Aotearoa New Zealand: equity, quality, and workforce. ANZ Journal of Surgery, 2023, 93, 2789-2791.	0.7	0
1987	Current Pathophysiology, Treatment, and Future Perspective for Prostate Cancer. , 2023, , 1-22.		0
1988	Mental health outcomes in a population-based cohort of patients with prostate cancer. Journal of the National Cancer Institute, 2024, 116, 445-454.	6.3	3
1989	Nerve Visualization using Phenoxazine-Based Near-Infrared Fluorophores to Guide Prostatectomy. Advanced Materials, 0, , .	21.0	1
1990	Comparison of perioperative, oncologic, and functional outcomes between 3D and 2D laparoscopic radical prostatectomy: a systemic review and meta-analysis. Frontiers in Oncology, 0, 13, .	2.8	1
1991	An artificial intelligence method for predicting postoperative urinary incontinence based on multiple anatomic parameters of MRI. Heliyon, 2023, 9, e20337.	3.2	1
1992	AdVance, a male sling for stress urinary incontinence: Long-term follow-up and patient satisfaction. BJUI Compass, 2024, 5, 42-51.	1.3	1
1993	Is it Time to Retire the Term of Low-Grade Ductal Carcinoma in Situ and Replace it With Ductal Neoplasia?. Advances in Anatomic Pathology, 2023, 30, 361-367.	4.3	0
1995	Comparison between the European Randomized Study for Screening of Prostate Cancer (ERSPC) and Prostate Biopsy Collaborative Group (PBCG) risk calculators: Prediction of clinically significant Prostate Cancer risk in a cohort of patients from Argentina. Actas Urológicas Españolas (English) Tj ETQq1 1 0.784314 rgBT /Overlock	0.2	1
1996	A pooled long-term follow-up after radiotherapy for prostate cancer with and without a rectal hydrogel spacer: impact of hydrogel on decline in sexual quality of life. Frontiers in Oncology, 0, 13, .	2.8	1
1997	Sexual health problems of patients with cancer: A bibliometrics study and visualization analysis via CiteSpace. Heliyon, 2023, 9, e20856.	3.2	0

#	ARTICLE	IF	CITATIONS
1999	Quality of life after nonâ€nerveâ€sparing, robotâ€assisted radical prostatectomy. Asia-Pacific Journal of Clinical Oncology, 2024, 20, 93-100.	1.1	0
2000	Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imagingâ€Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2024, 118, 986-997.	0.8	1
2001	Exploring Therapeutic Avenues in Lung Cancer: The Epigenetic Perspective. Cancers, 2023, 15, 5394.	3.7	0
2002	How older men live with stress urinary incontinence: Patient experience and navigation to treatment. Neurourology and Urodynamics, 2024, 43, 11-21.	1.5	0
2003	Impact of multiparametric magnetic resonance imaging targeted biopsy on functional outcomes in patients following robot-assisted laparoscopic radical prostatectomy. Frontiers in Surgery, 0, 10, .	1.4	0
2004	A Literature Review of Racial Disparities in Prostate Cancer Research. Current Oncology, 2023, 30, 9886-9894.	2.2	0
2005	Clinical Efficacy and Openness to New Challenges of Low Dose Rate Brachytherapy for Prostate Cancer. Current Oncology, 2023, 30, 9824-9835.	2.2	0
2006	Focal therapy with <scp>highâ€intensity</scp> focused ultrasound for prostate cancer: 3â€year outcomes from a prospective trial. BJU International, 0, , .	2.5	1
2007	Prostateâ€derived circulating microRNAs add prognostic value to prostate cancer risk calculators. , 2023, 2, .		0
2008	Prostatektomi SonrasÄ± Ä°zeriner Ä°nkontinansÄ± Olan Bireylerde Semptom Åžiddeti ile Fiziksel Aktivite DÄ±4zeyi, YaÅŸam Kalitesi ve Cinsel Ä°ÅŸlev Ä°liÅŸkisi. Journal of Exercise Therapy and Rehabilitation, 0, , .	0.2	0
2009	Development and assessment of a self-management intervention for urinary incontinence among patients with prostate cancer: protocol for a randomized feasibility study. BMC Urology, 2023, 23, .	1.4	0
2010	2023 Update On the Screening and Treatment of Localized Prostate Cancer. , 0, , 4-7.		0
2011	Molecular mechanisms underpinning favourable physiological adaptations to exercise prehabilitation for urological cancer surgery. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	0
2012	A pooled patientâ€reported outcomes analysis of moderately hypofractionated proton beam therapy and photonâ€based intensity modulated radiation therapy for lowâ€or intermediateâ€risk prostate cancer. Prostate, 0, , .	2.3	0
2013	Urethra-Sparing Prostate Cancer Stereotactic Body Radiation Therapy: Sexual Function and Radiation Dose to the Penile Bulb, the Crura, and the Internal Pudendal Arteries From a Randomized Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2023, , .	0.8	0
2014	External validation of predictive models of sexual, urinary, bowel and hormonal function after surgery in prostate cancer subjects. BMC Urology, 2024, 24, .	1.4	0
2015	Post-Prostatectomy Urinary Incontinence. , 0, , .		0
2016	Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: aâ€dose-escalation trial (DESTROY-4).. Strahlentherapie Und Onkologie, 2024, 200, 239-249.	2.0	0

#	ARTICLE	IF	CITATIONS
2017	Does intensityâ€modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity scoreâ€matched analysis. International Journal of Urology, 2024, 31, 379-385.	1.0	1
2018	Patient-reported Side Effects 1 Year After Radical Prostatectomy or Radiotherapy for Prostate Cancer: A Register-based Nationwide Study. European Urology Oncology, 2024, , .	5.4	0
2019	Functional Outcomes After Localized Prostate Cancer Treatment. JAMA - Journal of the American Medical Association, 2024, 331, 302.	7.4	0
2020	Quality of Life Longitudinal Evaluation in Prostate Cancer Patients from Radiotherapy Start to 5 Years after IMRT-IGRT. Current Oncology, 2024, 31, 839-848.	2.2	0
2021	Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10 years. , 2024, 34, 102571.		1
2022	Retzius-sparing vs. posterior urethral suspension: similar early-phase post-robotic radical prostatectomy continence outcomes. Journal of Robotic Surgery, 2024, 18, .	1.8	0
2023	Expanded Prostate Cancer Index Composite (EPIC). , 2023, , 2296-2298.		0
2024	Use of Persuasive Language in Communication of Risk during Prostate Cancer Treatment Consultations. Medical Decision Making, 2024, 44, 320-334.	2.4	0
2026	Ultrasound-Based Prognostic Anatomical Parameters for Post-Prostatectomy Incontinence: A Systematic Review. SociÃ©tÃ© Internationale D'urologie Journal, 2024, 5, 64-75.	0.4	0
2027	Variation in communication of side effects in prostate cancer treatment consultations. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	0
2028	The association between preâ€diagnostic levels of psychological distress and adverse effects after radical prostatectomy. BJUI Compass, 0, , .	1.3	0
2029	Hospitalization and mortality rates of malignant prostatic neoplasms in Brazil: A cross-sectional study from 2008 to 2018. Brazilian Journal of Pharmaceutical Sciences, 0, 60, .	1.2	0
2030	Modified Retzius-sparing robot-assisted radical prostatectomy for cases with anterior tumor: a propensity score-matched analysis. World Journal of Urology, 2024, 42, .	2.2	0